

**Cochrane** Database of Systematic Reviews

# Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults (Review)

Tsujimoto Y, Kumasawa J, Shimizu S, Nakano Y, Kataoka Y, Tsujimoto H, Kono M, Okabayashi S, Imura H, Mizuta T

Tsujimoto Y, Kumasawa J, Shimizu S, Nakano Y, Kataoka Y, Tsujimoto H, Kono M, Okabayashi S, Imura H, Mizuta T. Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults. *Cochrane Database of Systematic Reviews* 2022, Issue 5. Art. No.: CD012809. DOI: 10.1002/14651858.CD012809.pub2.

www.cochranelibrary.com

**Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults (Review)** Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY



# TABLE OF CONTENTS

PLAIN LANGUAGE SUMMARY 2   SUMMARY OF FINDINGS 2   BACKGROUND 6   Figure 1. 0   OBJECTIVES 2   METHODS 2   RESULTS 11   Figure 2. 12   Figure 3. 12   Figure 4. 14   Figure 5. 11   Figure 6. 16   Figure 7. 11   Figure 8. 12   Figure 9. 2   Figure 10. 21   Figure 11. 22   DISCUSSION 22   ACKNOWLEDGEMENTS 22   CHAROCERLISC OF STUDIES 22   CHAROCERLISC OF STUDIES 22   CHAROCERLISC OF STUDIES 24   ACKNOWLEDGEMENTS 24   REFERENCES 22   CHAROERLISC OF STUDIES 24   ADDITIONAL TABLES 36   ADPIDIONAL TABLES 36   MHAT'S NEW 36   HISTORY 36   SOURCES OF SUPPORT 36   SOURCES OF SUPPORT 36	ABSTRACT	1
SUMMARY OF FINDINGS 4   BACKGROUND 6   Figure 1 6   OBJECTIVES 5   METHODS 5   RESULTS 11   Figure 2 12   Figure 3 13   Figure 4 14   Figure 5 15   Figure 6 16   Figure 7 11   Figure 8 12   Figure 9 20   Figure 10 21   Figure 11 22   DISCUSSION 22   ACKNOWLDGEMENTS 22   CHARACTERISTICS OF STUDIES 22   DATA 32   Test 1. Doppler trans-thoracic echocardiography 32   Test 2. Sensitivity analysis 1 36   ADDITIONAL TABLES 36   MHAT'S NEW 35   HISTORY 36   SOURCES OF SUPPORT 39   SOURCES OF SUPPORT 39	PLAIN LANGUAGE SUMMARY	2
BACKGROUND 6   Figure 1. 6   OBJECTIVES 5   METHODS 5   RESULTS 11   Figure 2. 12   Figure 3. 13   Figure 4. 14   Figure 5. 15   Figure 7. 16   Figure 8. 16   Figure 9. 20   Figure 10. 21   Figure 11. 22   Figure 11. 22   Figure 12. 22   Figure 13. 22   Figure 14. 22   Figure 15. 22   Figure 10. 22   Figure 11. 22   DISCUSSION 22   AUTHORS' CONCLUSIONS 22   ACKNOWLEDGEMENTS 24   REFERENCES 25   DATA 36   Test 1. Doppler trans-thoracic echocardiography 36   Test 2. Sensitivity analysis 1 36   ADDITIONAL TABLES 36   APPENDICES 36   WHAT'S NEW 86   HISTOR	SUMMARY OF FINDINGS	4
Figure 1. 6   OBJECTIVES 5   METHODS 5   RESULTS 11   Figure 2. 12   Figure 3. 12   Figure 6. 12   Figure 7. 11   Figure 8. 12   Figure 9. 20   Figure 10. 21   Figure 11. 22   DISCUSSION 22   ACKNOWLEDGEMENTS 22   CHARACTERISTICS OF STUDIES 22   CHARACTERISTICS OF STUDIES 23   DATA 36   DATA 36   ADTHONAL TABLES 36   ADDITIONAL TABLES 36   APPENDICES 36   MONTONAL TABLES 36   MONTONS OF AUTHORS 36   ONTRIBUTIONS OF AUTHORS 36   ONTRIBUTIONS OF AUTHORS 36   MISTORY 36   ONTRIBUTIONS OF AUTHORS 36	BACKGROUND	6
OBJECTIVES 5   METHODS 6   RESULTS 11   Figure 2. 12   Figure 3. 13   Figure 4. 14   Figure 5. 15   Figure 6. 16   Figure 7. 11   Figure 8. 15   Figure 9. 22   Figure 10. 21   Figure 11. 22   DISCUSSION 22   ACKNOWLEDGEMENTS 22   REFERENCES 22   CHARACTERISTICS OF STUDIES 26   DATA 82   Test 1. Doppler trans-thoracic echocardiography 82   Test 2. Sensitivity analysis 1 83   ADDITIONAL TABLES 84   APPENDICES 84   MPENDICES 86   MPENDICES 86   MOSTORY 88   CONTRIBUTIONS OF AUTHORS 99   CONTRIBUTIONS OF AUTHORS 99   SOURCES OF SUPPORT 99	Figure 1	8
METHODS 5   RESUITS 11   Figure 2. 12   Figure 3. 12   Figure 4. 14   Figure 5. 15   Figure 6. 16   Figure 7. 17   Figure 8. 16   Figure 9. 20   Figure 10. 21   Figure 11. 22   DISCUSSION 22   AUTHORS' CONCLUSIONS 22   ACKNOWLEDGEMENTS 22   CHARACTERISTICS OF STUDIES 23   DATA 26   Test 1. Doppler trans-thoracic echocardiography 82   Test 1. Doppler trans-thoracic echocardiography 82   ADDTIONAL TABLES 84   APPENDICES 83   WHAT'S NEW 86   HISTORY 86   ONTRIBUTIONS OF AUTHORS 90   DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90	OBJECTIVES	9
RESULTS 11   Figure 2. 12   Figure 3. 13   Figure 4. 14   Figure 5. 15   Figure 6. 16   Figure 7. 11   Figure 9. 22   Figure 10. 21   Figure 11. 22   DISCUSSION 22   AUTHOR' CONCLUSIONS 22   AUTHOR' CONCLUSIONS 22   CHARACTERISTICS OF STUDIES 22   CHARACTERISTICS OF STUDIES 36   DATA 36   ADTIONAL TABLES 36   ADDITIONAL TABLES 36   MHAT'S NEW 86   HISTORY 86   MISTORY 86   ODECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90   SOURCES OF SUPPORT 90	METHODS	9
Figure 2. 12   Figure 3. 13   Figure 4. 14   Figure 5. 16   Figure 6. 16   Figure 7. 17   Figure 8. 16   Figure 9. 22   Figure 10. 21   Figure 11. 22   DISCUSSION 22   AUTHORS' CONCLUSIONS 22   AUTHORS' CONCLUSIONS 22   ACKNOWLEDGEMENTS 22   CHARACTERISTICS OF STUDIES 22   CHARACTERISTICS OF STUDIES 22   CHARACTERISTICS OF STUDIES 24   ADTA 36   DATA 36   MOTIONAL TABLES 84   ADDITIONAL TABLES 84   APPENDICES 85   WHAT'S NEW 86   HISTORY 86   ODITIONS OF AUTHORS 90   DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90	RESULTS	11
Figure 3. 13   Figure 4. 14   Figure 5. 16   Figure 6. 16   Figure 7. 11   Figure 8. 12   Figure 9. 20   Figure 10. 21   Figure 11. 22   DISCUSSION 22   AUTHORS' CONCLUSIONS 22   ACKNOWLEDGEMENTS 22   CONCLUSIONS 22   ACKNOWLEDGEMENTS 22   ACKNOWLEDGEMENTS 22   ACKNOWLEDGEMENTS 24   ACKNOWLEDGEMENTS 25   ACKNOWLEDGEMENTS 26   DATA	Figure 2	12
Figure 4. 14   Figure 5. 12   Figure 6. 16   Figure 7. 11   Figure 8. 12   Figure 9. 22   Figure 10. 21   Figure 11. 22   DISCUSSION 22   AUTHORS' CONCLUSIONS 22   ACKNOWLEDGEMENTS 22   CHARACTERISTICS OF STUDIES 24   DATA 82   Test 1. Doppler trans-thoracic echocardiography 82   Test 2. Sensitivity analysis 1 82   ADDITIONAL TABLES 84   APPENDICES 84   CONTRIBUTIONS OF AUTHORS 85   OINTRIBUTIONS OF INTEREST 90   SOURCES OF SUPPORT 90	Figure 3	13
Figure 5. 15   Figure 6. 16   Figure 7. 11   Figure 8. 16   Figure 9. 20   Figure 10. 21   Figure 11. 22   DISCUSSION 22   AUTHORS' CONCLUSIONS 22   AUTHORS' CONCLUSIONS 22   ACKNOWLEDGEMENTS 22   CHARACTERISTICS OF STUDIES 26   DATA 36   DATA 36   ADDITIONAL TABLES 36   ADDITIONAL TABLES 36   MHAT'S NEW 36   HISTORY 36   CONTRIBUTIONS OF AUTHORS 90   DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90	Figure 4	14
Figure 6. 16   Figure 7. 11   Figure 8. 12   Figure 9. 20   Figure 10. 21   Figure 11. 22   DISCUSSION 22   AUTHORS' CONCLUSIONS 22   ACKNOWLEDGEMENTS 22   CHARACTERISTICS OF STUDIES 24   DATA 25   Test 1. Doppler trans-thoracic echocardiography 36   Test 2. Sensitivity analysis 1 36   ADDITIONAL TABLES 36   APPENDICES 36   WHAT'S NEW 86   HISTORY 88   CONTRIBUTIONS OF AUTHORS 90   DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90	Figure 5	15
Figure 7. 11   Figure 8. 12   Figure 9. 20   Figure 10. 21   Figure 11. 22   DISCUSSION 22   AUTHORS' CONCLUSIONS 22   AUTHORS' CONCLUSIONS 22   ACKNOWLEDGEMENTS 22   ACKNOWLEDGEMENTS 24   REFERENCES 25   CHARACTERISTICS OF STUDIES 36   DATA 82   Test 1. Doppler trans-thoracic echocardiography 82   Test 2. Sensitivity analysis 1 82   ADDITIONAL TABLES 84   APPENDICES 84   HISTORY 85   UNAT'S NEW	Figure 6	16
Figure 8. 15   Figure 9. 20   Figure 10. 21   Figure 11. 22   DISCUSSION 22   AUTHORS' CONCLUSIONS 22   ACKNOWLEDGEMENTS 24   ACKNOWLEDGEMENTS 24   REFERENCES 25   CHARACTERISTICS OF STUDIES 36   DATA 36   Test 1. Doppler trans-thoracic echocardiography 82   Test 2. Sensitivity analysis 1 83   ADDITIONAL TABLES 84   APPENDICES 85   WHAT'S NEW 85   HISTORY 85   OONTRIBUTIONS OF AUTHORS 96   DECLARATIONS OF INTEREST 96   SOURCES OF SUPPORT 96	Figure 7	17
Figure 9. 20   Figure 10. 21   Figure 11. 22   DISCUSSION 22   AUTHORS' CONCLUSIONS 22   ACKNOWLEDGEMENTS 22   REFERENCES 22   CHARACTERISTICS OF STUDIES 36   DATA 82   Test 1. Doppler trans-thoracic echocardiography 82   Test 2. Sensitivity analysis 1 83   ADDITIONAL TABLES 84   APPENDICES 85   WHAT'S NEW 85   HISTORY 85   OONTRIBUTIONS OF AUTHORS 90   DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90	Figure 8	19
Figure 10.21Figure 11.22DISCUSSION22AUTHORS' CONCLUSIONS24ACKNOWLEDGEMENTS24REFERENCES25CHARACTERISTICS OF STUDIES36DATA82Test 1. Doppler trans-thoracic echocardiography82Test 2. Sensitivity analysis 183ADDITIONAL TABLES84APPENDICES85WHAT'S NEW85HISTORY85CONTRIBUTIONS OF AUTHORS96DECLARATIONS OF INTEREST96SOURCES OF SUPPORT96	Figure 9	20
Figure 11. 22   DISCUSSION 22   AUTHORS' CONCLUSIONS 22   ACKNOWLEDGEMENTS 22   REFERENCES 22   CHARACTERISTICS OF STUDIES 36   DATA 36   Test 1. Doppler trans-thoracic echocardiography 82   Test 2. Sensitivity analysis 1 83   ADDITIONAL TABLES 84   APPENDICES 84   WHAT'S NEW 85   HISTORY 85   CONTRIBUTIONS OF AUTHORS 90   DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90	Figure 10.	21
DISCUSSION22AUTHORS' CONCLUSIONS24ACKNOWLEDGEMENTS24REFERENCES25CHARACTERISTICS OF STUDIES36DATA36Test 1. Doppler trans-thoracic echocardiography82Test 2. Sensitivity analysis 183ADDITIONAL TABLES84APPENDICES85WHAT'S NEW85CONTRIBUTIONS OF AUTHORS90DECLARATIONS OF INTEREST90SOURCES OF SUPPORT90	Figure 11	22
AUTHORS' CONCLUSIONS24ACKNOWLEDGEMENTS24REFERENCES25CHARACTERISTICS OF STUDIES36DATA82Test 1. Doppler trans-thoracic echocardiography82Test 2. Sensitivity analysis 183ADDITIONAL TABLES84APPENDICES87WHAT'S NEW88HISTORY86CONTRIBUTIONS OF AUTHORS90SOURCES OF SUPPORT90	DISCUSSION	22
ACKNOWLEDGEMENTS24REFERENCES25CHARACTERISTICS OF STUDIES36DATA82Test 1. Doppler trans-thoracic echocardiography82Test 2. Sensitivity analysis 183ADDITIONAL TABLES84APPENDICES87WHAT'S NEW88HISTORY86CONTRIBUTIONS OF AUTHORS90DECLARATIONS OF INTEREST90SOURCES OF SUPPORT90	AUTHORS' CONCLUSIONS	24
REFERENCES25CHARACTERISTICS OF STUDIES36DATA82Test 1. Doppler trans-thoracic echocardiography82Test 2. Sensitivity analysis 183ADDITIONAL TABLES84APPENDICES87WHAT'S NEW85HISTORY85CONTRIBUTIONS OF AUTHORS90DECLARATIONS OF INTEREST90SOURCES OF SUPPORT90	ACKNOWLEDGEMENTS	24
CHARACTERISTICS OF STUDIES36DATA82Test 1. Doppler trans-thoracic echocardiography82Test 2. Sensitivity analysis 183ADDITIONAL TABLES84APPENDICES87WHAT'S NEW89HISTORY85CONTRIBUTIONS OF AUTHORS90DECLARATIONS OF INTEREST90SOURCES OF SUPPORT90	REFERENCES	25
DATA82Test 1. Doppler trans-thoracic echocardiography82Test 2. Sensitivity analysis 183ADDITIONAL TABLES84APPENDICES87WHAT'S NEW85HISTORY85CONTRIBUTIONS OF AUTHORS90DECLARATIONS OF INTEREST90SOURCES OF SUPPORT90	CHARACTERISTICS OF STUDIES	36
Test 1. Doppler trans-thoracic echocardiography82Test 2. Sensitivity analysis 183ADDITIONAL TABLES84APPENDICES87WHAT'S NEW85HISTORY85CONTRIBUTIONS OF AUTHORS90DECLARATIONS OF INTEREST90SOURCES OF SUPPORT90	DATA	82
Test 2. Sensitivity analysis 1 83   ADDITIONAL TABLES 84   APPENDICES 87   WHAT'S NEW 85   HISTORY 85   CONTRIBUTIONS OF AUTHORS 90   DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90	Test 1. Doppler trans-thoracic echocardiography	82
ADDITIONAL TABLES	Test 2. Sensitivity analysis 1	83
APPENDICES 87   WHAT'S NEW 85   HISTORY 85   CONTRIBUTIONS OF AUTHORS 90   DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90	ADDITIONAL TABLES	84
WHAT'S NEW 85   HISTORY 85   CONTRIBUTIONS OF AUTHORS 90   DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90	APPENDICES	87
HISTORY 85   CONTRIBUTIONS OF AUTHORS 90   DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90	WHAT'S NEW	89
CONTRIBUTIONS OF AUTHORS 90   DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90   SOURCES OF SUPPORT 90	HISTORY	89
DECLARATIONS OF INTEREST 90   SOURCES OF SUPPORT 90   SOURCES OF SUPPORT 90	CONTRIBUTIONS OF AUTHORS	90
SOURCES OF SUPPORT	DECLARATIONS OF INTEREST	90
	SOURCES OF SUPPORT	90
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	DIFFERENCES BETWEEN PROTOCOL AND REVIEW	90
INDEX TERMS	INDEX TERMS	91

# Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults

Yasushi Tsujimoto<sup>1,2,3</sup>, Junji Kumasawa<sup>4,5</sup>, Sayaka Shimizu<sup>6</sup>, Yoshio Nakano<sup>7</sup>, Yuki Kataoka<sup>3,8,9</sup>, Hiraku Tsujimoto<sup>10</sup>, Michihiko Kono<sup>11</sup>, Shinji Okabayashi<sup>6</sup>, Haruki Imura<sup>12</sup>, Takahiro Mizuta<sup>13</sup>

<sup>1</sup>Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan. <sup>2</sup>Department of Nephrology and Dialysis, Kyoritsu Hospital, Kawanishi, Japan. <sup>3</sup>Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan. <sup>4</sup>Department of Critical Care Medicine, Department of Clinical Research and Epidemiology, Sakai City Medical Center, Sakai City, Japan. <sup>5</sup>Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. <sup>6</sup>Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan. <sup>7</sup>Department of Respiratory Medicine, Sakai City Medical Center, Sakai City, Japan. <sup>8</sup>Department of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Kyoto, Japan. <sup>9</sup>Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan. <sup>10</sup>Hospital Care Research Unit, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan. <sup>11</sup>Department of Critical Care Medicine, Sakai City Medical Center, Osaka, Japan. <sup>12</sup>Department of Health Informatics, School of Public Health in Graduate School of Medicine, Kyoto University, Kyoto, Japan. <sup>13</sup>Department of Dermatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan

Contact: Yasushi Tsujimoto, yssh0108@yahoo.co.jp.

# Editorial group: Cochrane Airways Group.

Publication status and date: Edited (no change to conclusions), published in Issue 5, 2022.

**Citation:** Tsujimoto Y, Kumasawa J, Shimizu S, Nakano Y, Kataoka Y, Tsujimoto H, Kono M, Okabayashi S, Imura H, Mizuta T.Doppler transthoracic echocardiography for detection of pulmonary hypertension in adults. *Cochrane Database of Systematic Reviews* 2022, Issue 5. Art. No.: CD012809. DOI: 10.1002/14651858.CD012809.pub2.

Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

# ABSTRACT

# Background

Pulmonary hypertension (PH) is an important cause of morbidity and mortality, which leads to a substantial loss of exercise capacity. PH ultimately leads to right ventricular overload and subsequent heart failure and early death. Although early detection and treatment of PH are recommended, due to the limited responsiveness to therapy at late disease stages, many patients are diagnosed at a later stage of the disease because symptoms and signs of PH are nonspecific at earlier stages. While direct pressure measurement with right-heart catheterisation is the clinical reference standard for PH, it is not routinely used due to its invasiveness and complications. Trans-thoracic Doppler echocardiography is less invasive, less expensive, and widely available compared to right-heart catheterisation; it is therefore recommended that echocardiography be used as an initial diagnosis method in guidelines. However, several studies have questioned the accuracy of noninvasively measured pulmonary artery pressure. There is substantial uncertainty about the diagnostic accuracy of echocardiography for the diagnosis of PH.

# Objectives

To determine the diagnostic accuracy of trans-thoracic Doppler echocardiography for detecting PH.

# Search methods

We searched MEDLINE, Embase, Web of Science Core Collection, ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform from database inception to August 2021, reference lists of articles, and contacted study authors. We applied no restrictions on language or type of publication.



# **Selection criteria**

We included studies that evaluated the diagnostic accuracy of trans-thoracic Doppler echocardiography for detecting PH, where rightheart catheterisation was the reference standard. We excluded diagnostic case-control studies (two-gate design), studies where right-heart catheterisation was not the reference standard, and those in which the reference standard threshold differed from 25 mmHg. We also excluded studies that did not provide sufficient diagnostic test accuracy data (true-positive [TP], false-positive [FP], true-negative [TN], and false-negative [FN] values, based on the reference standard). We included studies that provided data from which we could extract TP, FP, TN, and FN values, based on the reference standard. Two authors independently screened and assessed the eligibility based on the titles and abstracts of records identified by the search. After the title and abstract screening, the full-text reports of all potentially eligible studies were obtained, and two authors independently assessed the eligibility of the full-text reports.

# Data collection and analysis

Two review authors independently assessed the risk of bias and extracted data from each of the included studies. We contacted the authors of the included studies to obtain missing data. We assessed the methodological quality of studies using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. We estimated a summary receiver operating characteristic (SROC) curve by fitting a hierarchical summary ROC (HSROC) non-linear mixed model. We explored sources of heterogeneity regarding types of PH, methods to estimate the right atrial pressure, and threshold of index test to diagnose PH. All analyses were performed using the Review Manager 5, SAS and STATA statistical software.

# **Main results**

We included 17 studies (comprising 3656 adult patients) assessing the diagnostic accuracy of Doppler trans-thoracic echocardiography for the diagnosis of PH. The included studies were heterogeneous in terms of patient distribution of age, sex, WHO classification, setting, country, positivity threshold, and year of publication. The prevalence of PH reported in the included studies varied widely (from 6% to 88%). The threshold of index test for PH diagnosis varied widely (from 30 mmHg to 47 mmHg) and was not always prespecified. No study was assigned low risk of bias or low concern in each QUADAS-2 domain assessed. Poor reporting, especially in the index test and reference standard domains, hampered conclusive judgement about the risk of bias. There was little consistency in the thresholds used in the included studies; therefore, common thresholds contained very sparse data, which prevented us from calculating summary points of accuracy estimates. With a fixed specificity of 86% (the median specificity), the estimated sensitivity derived from the median value of specificity using HSROC model was 87% (95% confidence interval [CI]: 78% to 96%). Using a prevalence of PH of 68%, which was the median among the included studies conducted mainly in tertiary hospitals, diagnosing a cohort of 1000 adult patients under suspicion of PH would result in 88 patients being undiagnosed with PH (false negatives) and 275 patients would avoid unnecessary referral for a right-heart catheterisation (true negatives). In addition, 592 of 1000 patients would receive an appropriate and timely referral for a right-heart catheterisation (true positives), while 45 patients would be wrongly considered to have PH (false positives). Conversely, when we assumed low prevalence of PH (10%), as in the case of preoperative examinations for liver transplantation, the number of false negatives and false positives would be 13 and 126, respectively.

# **Authors' conclusions**

Our evidence assessment of echocardiography for the diagnosis of PH in adult patients revealed several limitations. We were unable to determine the average sensitivity and specificity at any particular index test threshold and to explain the observed variability in results. The high heterogeneity of the collected data and the poor methodological quality would constrain the implementation of this result into clinical practice. Further studies relative to the accuracy of Doppler trans-thoracic echocardiography for the diagnosis of PH in adults, that apply a rigorous methodology for conducting diagnostic test accuracy studies, are needed.

# PLAIN LANGUAGE SUMMARY

# Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults

# What was studied in this review?

Pulmonary hypertension is high blood pressure in the blood vessels that supply blood from the right half of the heart to the lungs. It is a serious condition that can damage the right side of the heart. The walls in the blood vessels become thick and stiff which makes it harder for the blood to flow. This can lead to heart failure. Symptoms can include shortness of breath, tiredness, chest pain, a racing heartbeat or swelling in the lower limbs and abdomen.

The symptoms can be similar to other heart and lung diseases, so diagnosis can take time. Early diagnosis is beneficial because treatment can start early. Starting treatment early is better because people respond better to treatment in the early stages of the disease. Not being diagnosed early can have severe consequences such as disability in daily life or death.

The most accurate way to diagnose pulmonary hypertension is using a pressure measurement called right-heart catheterisation. However, this is invasive and can cause complications. Another technique, called Doppler echocardiography is noninvasive, cheaper and more widely available in hospitals. Therefore, many guidelines recommend the use of echocardiography as an initial diagnosis method. We wanted to do

**Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults (Review)** Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



this review because several studies have questioned the accuracy of echocardiography. We wanted to find out how good echocardiography is compared to right-heart catheterisation for the diagnosis of pulmonary hypertension.

# What was the aim of this review?

To evaluate evidence on the ability of echocardiography to identify pulmonary hypertension in adults compared to right-heart catheterisation.

# What were the main results of the review?

We found 17 studies involving 3656 people who had suspected pulmonary hypertension.

There was a lot of variation in the studies. We found the characteristics of participants varied in terms of age, sex, cause of pulmonary hypertension, setting and country. The cut-off values for the echocardiography readings chosen to diagnose pulmonary hypertension also varied. We used the available data to estimate how well the echocardiography performed compared to right-heart catheterisation. In tertiary care hospitals, where most of the included studies were conducted, it is assumed that 680 of 1000 patients have pulmonary hypertension. We found that 592 people of 1000 would be correctly diagnosed with pulmonary hypertension using echocardiography. But 45 of 1000 patients would be wrongly considered as having pulmonary hypertension (false positive), while 88 of 1000 patients might be incorrectly considered as not having pulmonary hypertension (false negative) and 275 of 1000 patients would avoid unnecessary referral for a right-heart catheterisation. In a scenario where the preoperative examination for liver transplantation is conducted, 100 of 1000 are assumed to have pulmonary hypertension. We found the number of false negatives and false positives would be 13 and 126, respectively.

# How reliable were the results of the studies?

We judged the included studies to have important limitations in their validity, which means that they were at high risk of providing distorted results. Therefore, we cannot be certain if the number of false negatives is correct (i.e. it could be even higher).

# Who do the results of this review apply to?

These results apply to adults who are suspected of having pulmonary hypertension. However, the diagnostic accuracy of echocardiography varied considerably among studies and it is yet unclear what causes this diversity of test accuracy. Of note, the results are from studies conducted in relatively high prevalence settings. Therefore, care should be taken when applying this result to individual situations.

# How up-to-date was the review?

This review is current to August 2021.

# SUMMARY OF FINDINGS

Summary of findings 1	Summary of Findings: Donnler trans-thoracic	echocardiography for detection c	f nulmonary hypertension in adults
Summary of multigs 1.	Summary of Findings. Doppler trans-thoracte	echocardiography for detection of	putitionally hypertension in adults

Patients/popul	ation	Adults with suspected pulmonary hypertension							
Settings		High-prevalence settings: tertiary care hospitals including university hospitals or cardiopulmonary centres							
Index test		Systolic pulmon equation and ac	nary arterial pressure dding right atrial pres	calculated from t sure by Doppler t	the maximum tricuspid regurgitation jet velocity by using the modified Bernoulli trans-thoracic echocardiography				
Reference stan	dard	Mean of pulmor	nary arterial pressure	of 25 mmHg or gr	eater assessed by rig	nt-heart catheterisati	on		
Study designs		Prospective or r	etrospective cohorts	and cross-sectior	nal studies. We exclud	ed case reports and s	tudies of case-control design.		
.Findings									
Evaluations	No. of participa	nts	Comfirmed PH participants		Median sensitivity (	IQR)	Median specificity (IQR)		
(studies)				[range]			[range]		
17	3656		1342		87% (81 to 92%)		86% (79% to 91%)		
					[40 to 98%]		[33 to 100%]		
Index test	Prevalence <sup>1</sup>	No. of partic- ipants (stud- ies)	Sensitivity (un- der fixed speci- ficity of 86%) <sup>2</sup>	Specificity (fixed) <sup>3</sup>	Numbers of false positives out of 1000 patients	Numbers of false negatives out of 1000 patients	Quality and Comments		
Systolic pul-	10%	3656 (17)	87% (95% CI 78%	86%	126	13	No study was assigned low risk of bias		
rial pressure by echocar- diography	58%		10 90%)		59	75	mains. Poor reporting, especially in		
	68%				45	88	dex test and reference standard do- mains, hampered conclusive judge-		
	77%				32	100	ments about the risk of bias.		
	88%				17	114			

<sup>1</sup>Minimum, 25 percentile, 50 percentile, 75 percentile, maximum of prevalence among included studies

Cochrane Library

Trusted evidence. Informed decisions. Better health. <sup>2</sup>HSROC (hierarchical summary receiver operating characteristic) parameters were used to illustrate sensitivity for a fixed specificity of 86% (median specificity of the included studies)

<sup>3</sup>Median specificity estimated from included studies.

Abbreviations: CI: confidence interval IQR: interquartile range PH: pulmonary hypertension QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies WHO: World Health Organization



# BACKGROUND

# **Target condition being diagnosed**

Pulmonary hypertension (PH) is an important cause of morbidity and mortality. Although the exact prevalence of PH is not known because of various possible aetiologies, a previous study reported that PH affects up to 100 million people worldwide (Schermuly 2011). PH leads to a substantial loss of exercise capacity and can cause right ventricular overload, resulting in heart failure and early mortality. A recently published study reported that three-year survival ranges from 58.2% to 73.3% (Ling 2012). PH is diagnosed when resting mean pulmonary arterial pressure is 25 mmHg or more at right-heart catheterisation. It is a progressive disease that, if left untreated, can be fatal although the rate of progression is highly variable.

PH is divided into five aetiological categories according to the World Health Organization (WHO) criteria (Simonneau 2013).

Group 1 comprises patients with pulmonary arterial hypertension (PAH). This group consists of sporadic idiopathic PH (IPAH), heritable IPAH, and PAH due to diseases that localise to small pulmonary muscular arterioles. These diseases include connective tissue disease, HIV infection, portal hypertension, congenital heart disease, schistosomiasis, chronic haemolytic anaemia, persistent PH of the newborn, pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis. Drug-induced PAH (including anorexigenic) and toxin-induced PAH are also considered to belong to group 1 PAH.

Group 2 PH comprises patients with PH due to left heart disease and is the most common form of PH worldwide. PH due to systolic dysfunction, diastolic dysfunction, or valvular heart disease is included in this group.

Group 3 PH includes patients with PH due to lung disease or hypoxaemia. This includes PH caused by chronic obstructive pulmonary disease (COPD), interstitial lung disease, pulmonary disease with a mixed restrictive and obstructive pattern, sleepdisordered breathing, and alveolar hypoventilation disorders.

Group 4 PH comprises patients with chronic thromboembolic PH due to chronic thromboembolic occlusion of the proximal or distal pulmonary vasculature.

Group 5 PH includes patients with PH with unclear, multifactorial mechanisms.

Although the epidemiology of PH varies among the five groups, most of the available evidence relates to group 1 PAH. The prevalence of group 1 PAH in the general population is estimated to be 5 to 15 cases per 1 million adults (Humbert 2006; Ling 2012). The prevalence of PH in groups 2 to 5 is unknown due to the broad classification and multiple aetiologies. One cohort study reported that the proportion of each group among individuals with PH was 0.18, 0.35, 0.17, 0.09, and 0.21 (Meredith 2014).

The prognosis of PH depends on various factors. The Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) risk score is used to predict disease progression (Benza 2010). Poor prognostic indicators include age at initial presentation > 50 years (Peacock 2007), male sex and  $\geq$  60 years (Marcus 2008), persistent (WHO) functional class III or IV (Appendix 1), pericardial effusion, and elevated right atrial pressure (Paulus 2007; Torbicki 2007). The natural history and prognosis of group 1 PAH are better studied than those of groups 2 through 5. In general, in the absence of therapy, those with group 1 PAH have worse survival than groups 2 through 5. Symptomatic patients with IPAH who do not receive treatment have a median survival of approximately three years. Data from the REVEAL registry reported that, from the time of diagnostic rightheart catheterisation, people with PAH had one-, three-, five-, and seven-year survival rates of 85%, 68%, 57%, and 49%, respectively (Benza 2010).

Early detection and treatment of PH is recommended as advanced disease may be less responsive to therapy (Galie 2013). Primary therapy of PH is directed at the underlying cause of the PH. People with persistent PH with WHO functional class II, III, or IV, despite treatment of the underlying cause of the PH, should be referred to a specialised centre to be evaluated for advanced therapy. Advanced therapy is directed at the PH itself, rather than the underlying cause of the PH. It includes treatment with prostacyclin pathway agonists, endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and soluble guanylate cyclase stimulants. Although PH is divided into five aetiological categories, the first diagnosis test for PH is echocardiography. Therefore, we defined the target condition as PH regardless of the WHO classification group 1 to 5.

# Index test(s)

Estimated systolic pulmonary artery pressure determination by Doppler trans-thoracic echocardiography was the Index test. The Doppler echocardiography is a noninvasive test that can be used to estimate the blood flow through blood vessels or cardiac chamber by using high-frequency sound waves. The tricuspid regurgitation jet velocity, which is the velocity of regurgitated blood flow through tricuspid valve from right ventricular to right atrium, is also estimated by Doppler echocardiography. The systolic pulmonary arterial pressure can be estimated from the maximum tricuspid regurgitation jet velocity by using the modified Bernoulli equation and adding the right atrial pressure (systolic pulmonary arterial pressure = 4  $(v)^2$  + right atrial pressure, where v is the peak velocity of the tricuspid regurgitation jet) (Berger 1985). The majority of people have some degree of tricuspid regurgitation, and the utilisation of tricuspid regurgitation to estimate systolic pulmonary arterial pressure is the most common practice in echocardiography (Kaplan 2010). Right atrial pressure can be estimated by the diameter and collapse of the inferior vena cava (IVC) during spontaneous respiration(Galie 2016; Rudski 2010). An IVC diameter of < 2.1 cm that collapses > 50% with a sniff suggests a normal right atrial pressure of 3 mmHg (range 0-5 mmHg), whereas an IVC diameter of > 2.1 cm that collapses < 50% with a sniff or < 20% on quiet inspiration suggests a high right atrial pressure of 15 mmHg (range 10-20 mmHg) (Galie 2016; Rudski 2010). Several studies have demonstrated an adequate correlation between the estimated systolic pulmonary arterial pressure by Doppler transthoracic echocardiography and the direct measurement of mean pulmonary artery pressure with right-heart catheterisation (Zhang 2010). If the estimated systolic pulmonary arterial pressure is higher than 35 to 40 mmHg or if tricuspid regurgitation velocity is more than 2.8 m/s, further evaluation is recommended by guidelines to determine if PH is present (Galie 2016; Rudski 2010). Although several studies have demonstrated an adequate correlation between the estimated systolic pulmonary arterial pressure by echocardiography and by the direct measurement of right-heart



catheterisation, several studies have reported that the overinflated lung lowered the diagnostic accuracy of echocardiography (Fisher 2007). In patients with overinflated lungs such as in COPD, the heart may rotate toward the right, which makes it difficult to visualise the tricuspid valve and pulmonary artery. In patients with severe tricuspid regurgitation, pulmonary arterial pressure may also be underestimated (Galie 2016). Another problem of Doppler echocardiography is the overestimation of systolic pulmonary arterial pressure mainly due to the overestimation of right atrial pressure (Fisher 2009; Testani 2010). The size of the IVC, and its variation with respiration may affect this overestimation. Due to the risk of underestimation or overestimation, the current European Society of Cardiology guidelines reported that the estimation of pulmonary arterial pressure based solely on Doppler transthoracic echocardiography measurements could not be suitable for triage for mild and asymptomatic PH (Galie 2016).

# **Clinical pathway**

Symptoms and signs of PH are nonspecific, which frequently result in a delay in diagnosis (Brown 2011). The initial symptoms

of PH are exertional dyspnoea, fatigue, chest pain, syncope, palpitations, and peripheral oedema. Many people with PH visit hospitals complaining of these nonspecific symptoms and physicians suspect the presence of PH in the presence of these nonspecific symptoms or following initial evaluation by chest radiograph or electrocardiogram. The classic chest radiograph of an individual with PH shows enlargement of the central pulmonary arteries, right ventricular enlargement, and right atrial dilatation. An electrocardiogram of an individual with PH may show signs of right ventricular disease, which includes right axis deviation, an R wave/S wave ratio greater than one in the lead V1, incomplete or complete right bundle branch block, or increased P wave amplitude in lead II.

When PH is suspected by these signs or initial diagnosis tests, diagnostic evaluation is performed to confirm that PH exists, to determine its severity, and to identify its cause (Figure 1) (Rubin 2016).



Figure 1. Clinical pathway of diagnostic evaluation for pulmonary hypertension among adults, adolescents, and children Abbreviations: PAH: pulmonary arterial hypertension; PH: pulmonary hypertension (Rubin 2016).



**Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults (Review)** Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



# Figure 1. (Continued)

The first step of diagnostic testing is evaluation by echocardiogram. Pulmonary arterial pressure can be estimated by this noninvasive method. When the echocardiogram does not suggest PH, further evaluation depends on clinical suspicion. If clinical suspicion of PH is still high, right-heart catheterisation should be considered. When the echocardiogram is suggestive of PH, clinicians should evaluate whether left heart disease exists to adequately explain the degree of estimated PH. Patients with substantial left heart disease revealed by the echocardiogram to explain the degree of estimated PH do not require further evaluation to determine the aetiology of PH.

Patients who have no left heart disease should undergo additional diagnostic testing to determine the aetiology of PH other than left heart diseases and appropriate treatment. Such additional tests may include a pulmonary function test, ventilation-perfusion scanning, overnight oximetry, polysomnography, or laboratory testing (e.g. autoimmune serologies, HIV serology, and liver function tests) based on the history and physical examination.

Right-heart catheterisation is indicated to confirm PH and its severity. Direct pressure measurement of pulmonary arterial pressure with right-heart catheterisation is the clinical reference standard to confirm PH (Lewis 2016).

#### Alternative test(s)

Some additional tests (e.g. chest radiograph, magnetic resonance, computed tomography) may also be considered to confirm the aetiology of PH, however Doppler echocardiography plays a central role in the diagnosis and management of PH (Freed 2016).

# Rationale

Many patients are diagnosed at a late stage of the disease because symptoms and signs of PH are nonspecific at the beginning of the disease (Brown 2011). Early and accurate detection of PH would therefore be of great benefit. While direct pressure measurement with right-heart catheterisation is the clinical reference standard for PH, it is not routinely used in clinical practice due to its invasiveness and potential complications (Connors 1996).

Trans-thoracic Doppler echocardiography is less invasive, less expensive, and widely available compared with right-heart catheterisation. The guidelines from the European Society of Cardiology and the European Respiratory Society (Galie 2016) and the expert consensus document from the American Heart Association and the American College of Cardiology Foundation (McLaughlin 2009) suggested that echocardiography should be performed as an initial diagnosis method and as a method for monitoring disease progression for both patients suspected with PH and those diagnosed with PH. However, the guidelines also documented the insufficient test accuracy of Doppler echocardiography. Several studies have questioned the accuracy of noninvasively measured pulmonary arterial pressure (Arcasoy 2003; Fisher 2009; Rich 2011). They reported that Doppler echocardiography underestimated pulmonary arterial pressure, which could lead to missed diagnosis of PH. To avoid diagnosis in later stages of the disease, accurate triage of PH is necessary. We will therefore evaluate the diagnostic accuracy of echocardiography to diagnose patients suspected of PH.

We hypothesise that Doppler echocardiography could be a beneficial test to triage PH since ultrasound devices have become more commonly available in a variety of clinical settings.

# OBJECTIVES

To determine the diagnostic accuracy of Doppler trans-thoracic echocardiography for detecting PH in people with suspected pulmonary hypertension.

# Secondary objectives

To investigate several possible sources of heterogeneity as indicated below.

- Types of PH defined by WHO classification (Group 3, not Group 3, or classification not reported).
- Mechanical ventilation (including noninvasive positive pressure ventilation) or not.
- Estimation of right atrial pressure (whether estimated by using the diameter and collapse of the IVC during spontaneous respiration or by any other methods).

# METHODS

# Criteria for considering studies for this review

# **Types of studies**

We included studies that evaluated the diagnostic accuracy of trans-thoracic Doppler echocardiography for detecting PH, where right-heart catheterisation was the reference standard. We excluded diagnostic case-control studies (two-gate design) (Rutjes 2005). We excluded studies where right-heart catheterisation was not the reference standard or the reference standard threshold differed from 25 mmHg. We excluded studies with an interval of more than one week between the index test and the reference standard because interventions may be implemented soon after the initial examination and medical conditions could differ due to different times (e.g. > 1 week apart) (Delcroix 2010; Lewis 2016). We excluded studies that did not provide sufficient diagnostic test accuracy data (true positive [TP], false positive [FP], true negative [TN], and false negative [FN] values, based on the reference

Cochrane Library

standard) such as case series studies. We included studies that provided data from which we could extract TP, FP, TN, and FN values, based on the reference standard. We contacted study authors for missing data. We did not exclude studies based on the publication type (e.g. full articles, letters to the editor, conference abstracts, or unpublished data).

# Participants

We included all adults (16 years of age or older) with suspected PH. We excluded any participant with a prior diagnosis of PH. We did not exclude participants based on sex or cause of PH.

# Index tests

Measurement by Doppler trans-thoracic echocardiography was the index test. We included all studies where systolic pulmonary arterial pressure was calculated from the maximum tricuspid regurgitation jet velocity using the modified Bernoulli equation and adding right atrial pressure (Berger 1985). We included all methods used to measure right atrial pressure (e.g. clinical estimation from jugular venous pressure, using a fixed value from 5 mmHg to 10 mmHg, using the diameter and collapse of the IVC during spontaneous respiration). The threshold of the estimated systolic pulmonary arterial pressure by echocardiography to diagnose PH was defined as the authors defined in the included studies.

# **Target conditions**

The target condition was PH regardless of WHO classification group 1 to 5 (Simonneau 2013).

# **Reference standards**

We included only studies in which PH was defined as a mean pulmonary arterial pressure assessed by right-heart catheterisation of  $\geq$  25 mmHg (Hoeper 2013).

# Search methods for identification of studies

# **Electronic searches**

We systematically searched the following databases on 21 October 2019 and updated the search on 03 August 2021:

- MEDLINE Ovid SP (1946 to 03 August 2021) (Appendix 2);
- Embase Ovid SP (1974 to 03 August 2021) (Appendix 3);
- Web of Science Core Collection (1970 to 03 August 2021) (Appendix 4).

We searched the following trials registries on 21 October 2019 and updated the search on 03 August 2021:

- US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (clinicaltrials.gov/) (Appendix 5).
- World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/) (Appendix 5).

We combined search terms describing the target condition and the index text. We did not use search terms to describe diagnostic study designs as this is not currently recommended in the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy (De Vet 2008). We applied no restrictions on language or type of publication.

# Searching other resources

To identify additional published, unpublished, and ongoing studies, we entered included studies identified from the above sources into the Web of Science database and used the 'Related Articles' feature. We checked the reference lists of all primary studies and relevant systematic reviews. Furthermore, we also searched for conference proceedings through Embase and the Web of Science.

# Data collection and analysis

# **Selection of studies**

We undertook the systematic review using the methods outlined in the Cochrane Handbook for Reviews of Diagnostic Test Accuracy (Deeks 2013). Two authors (from JK and YN, YK, YT, MK, SO, HI, TM) independently reviewed titles and abstracts identified by the search strategy. After the title and abstract screening, the fulltext reports of all potentially eligible studies were obtained and two authors independently assessed the eligibility of the fulltext reports. Differences were resolved by discussion between the review authors. We provided details of both included and excluded studies in the Characteristics of included studies and Characteristics of excluded studies tables.

# **Data extraction and management**

Two authors (from JK and YN, YK, YT, MK, SO, HI, TM) independently extracted data on study characteristics, participant demographics, sample size, test methods, methodological quality, sensitivity, and specificity. Two review authors then extracted data to construct a 2 × 2 contingency table. Disagreements were resolved by consensus.

# Assessment of methodological quality

We used the QUADAS-2 tool to assess the quality of studies (Whiting 2011). The qualities to be assessed are described in detail in (Appendix 6). For each item in the quality assessment form, we included a description of how the study addressed the issue and entered a judgement of 'low', 'high', or 'unclear' for the overall risk of bias for each of the four domains. In addition, we added a judgement of 'low', 'high', or 'unclear' for the overall concern of applicability to the review question for domains 1, 2, and 3. The assessment of methodological quality is reported in Assessment of methodological quality table which lists all judgements made for each included study. Two authors (from JK and YN, YK, YT, MK, SO, HI, TM) independently assessed methodological quality. Disagreements were resolved by discussion among the review authors.

# Statistical analysis and data synthesis

We performed data synthesis using the methods recommended by the Working Group of the Cochrane Collaboration on Systematic Reviews of Diagnostic Test Accuracy (Deeks 2013). We extracted accuracy data for all thresholds used in the primary studies. We represented individual study sensitivities and specificities in forest plots in order to inspect between-study variability. These individual study accuracy estimates were also represented in a Receiver Operating Characteristic (ROC) plot of sensitivity versus 1specificity to visually assess the correlation between both indices. Given the considerable variation of cut-off values in the collected data, we did not use the bivariate model and avoided providing the summary point of sensitivity and specificity (Deeks 2013).



Instead, we estimated a summary ROC (SROC) curve by fitting a hierarchical summary ROC (HSROC) model (Rutter 2001). Using HSROC parameter estimates, we derived sensitivity at the median value of specificity along with corresponding 95% confidence intervals (CI)s. We set the fixed specificity as median specificity among the included studies and calculated the sensitivity with the corresponding 95% CIs or vice versa in a manner similar to a previous Cochrane review (Molano 2019). This is because diagnostic accuracy studies typically contain fewer patients with the target condition than without, and estimates of sensitivities are often made with less certainty than estimates of specificity. (Best 2018; Heazell 2019). Since we observed a large variability in specificity, we added a post hoc analysis to present the summary of specificity and 95% CI at median sensitivity among the included studies. The potential numerical consequences, given a positive and negative index test result using different prevalence, were calculated. We performed all analyses using Review Manager 5 (Review Manager 2014), STATA software, version 13.0 (Stata 2013), or SAS studio (SAS/STAT®, SAS Institute Inc. NC, USA).

#### Investigations of heterogeneity

To test whether sensitivity or specificity, or both, differed in subgroups of studies, we tabulated the median and range of sensitivity and specificity for the following subgroups:

- Types of PH defined by WHO classification (Group 3 (PH due to lung diseases or hypoxaemia), not Group 3, or classification not reported). We expected that measuring tricuspid regurgitation would be more difficult in patients with lung disease, especially COPD, than in patients without lung disease, which could decrease the sensitivity and specificity of echocardiography to detect PH.
- Mechanical ventilation (including non-invasive positive pressure ventilation) or not.
- Estimation of right atrial pressure (using the diameter of IVC, any other methods, or not reported).

Since we observed considerable heterogeneity, we performed a post hoc subgroup analysis using the bivariate model (Macaskill 2021; Reitsma 2005) stratified by the threshold of the index test that was categorised according to the guidelines (Rudski 2010) as follows: < 36 mmHg,  $\geq$  36 and < 40 mmHg, and  $\leq$  40 mmHg for clinical implementation.

# Sensitivity analyses

We examined the robustness of the meta-analysis by conducting the following sensitivity analysis where possible.

- Repeating the analysis excluding studies at high risk of bias in domains 1 or 4 of the QUADAS-2 assessment: We anticipated that studies at high risk of bias in domains 1 and 4 would have a great impact on meta-analysis because these domains would cause selection bias.
- Repeating the analysis for each quartile of prevalence: due to the invasiveness of the reference standard, less severe cases would not be verified by right-heart catheterisation, which would lead to partial verification bias. We therefore performed additional sensitivity analysis by using prevalence as a surrogate of partial verification. We used the quartiles of prevalence among included studies and checked the robustness of the results.
- Repeating the analysis by including uninterpretable results as both test negative and positive: although uninterpretable results would be likely to occur among patients with overinflated lung, which is associated with the severity of pulmonary hypertension and causes a difficulty of visualisation, they are not always considered test positive.

#### Assessment of reporting bias

We did not plan to explore reporting bias due to a lack of suitable statistical methods (Deeks 2013).

# RESULTS

# **Results of the search**

We identified 11,999 references through electronic searches of MEDLINE, Embase, Web of Science, Clinicaltrial.gov, the International Clinical Trials Registry Platform (ICTRP), and additional references through other searches (citation search of previous systematic reviews). The flow of studies through the diagnosis process is shown in Figure 2. After removing 3816 duplicates, 8183 references remained. Of these, we excluded 8012 references by analysis of the title and abstracts. We assessed the full text of the remaining 171 references. We excluded 154 references for reasons listed in the Characteristics of excluded studies table. The remaining 17 references (of 17 studies) met our inclusion criteria.



# Figure 2. Flow diagram



#### **Included studies**

We summarised the characteristics of the 17 included studies in the Characteristics of included studies table and Table 1. The studies included 3656 participants, of which 1342 participants (37%) had PH. The prevalence of PH ranged from 10% to 88% with a median of 68% (interquartile range (IQR): 58% to 77%). The included studies were conducted in various departments from university or tertiary hospitals; three studies were from lung or liver transplantation centres (Balci 2016; Colle 2003; Wainstein 2017), nine studies were from the cardiology or pulmonary department of university or tertiary hospitals (Amsallem 2016; Er 2010; Greiner 2014; Hellenkamp 2018; Lafitte 2013; Nowak 2018; Sawada 2019; Schneider 2017; Venkateshvaran 2021), and the others were from unclear settings (Hsu 2008; Kyranis 2018; Mazhar 2011; Mo 2015; Mo 2015a).

Of the 17 studies, six studies were prospective (Balci 2016; Colle 2003; Er 2010; Hsu 2008; Kyranis 2018; Schneider 2017); 11 studies were retrospective (Amsallem 2016; Greiner 2014; Hellenkamp 2018; Lafitte 2013; Mazhar 2011; Mo 2015; Mo 2015a; Nowak 2018; Sawada 2019; Venkateshvaran 2021; Wainstein 2017). Four studies were published as abstracts only (Mazhar 2011; Mo 2015; Mo 2015a; Wainstein 2017), and the remaining 13 studies were full-text publications. We considered Mo 2015 and Mo 2015a to be separate studies because they had different numbers of participants and a different prevalence of PH. However, there is still a potential overlap among the patients included in the two studies.

Four studies enrolled participants with a single WHO classification of PH, two studies enrolled participants with group 1 PH (Colle 2003; Hsu 2008); two studies enrolled participants with group 3 PH (Balci 2016; Wainstein 2017); two studies enrolled participants with group 1, 2, 3 and 4 PH (Er 2010; Schneider 2017); one study enrolled participants with group 2, 3, and 4 PH (Nowak 2018); and the remaining 10 studies did not report the WHO classification. Four studies reported the proportion of mild or asymptomatic participants (Er 2010; Greiner 2014; Hellenkamp 2018; Nowak 2018), but others did not. The reported proportion ranged from 2% to 16%.

The cut-off value of the index test (systolic pulmonary arterial pressure) ranged from 30 to 47 mmHg with a median of 36 mmHg (IQR: 31 to 40 mmHg). In nine studies, right atrial pressure was measured using the diameter and collapse of the inferior vena cava during spontaneous respiration (Amsallem 2016; Colle 2003; Er 2010; Greiner 2014; Hellenkamp 2018; Kyranis 2018; Lafitte 2013; Sawada 2019; Venkateshvaran 2021); in another study, right atrial pressure was defined as 10 mmHg (Hsu 2008); and the remaining seven studies did not report the methods used to measure right atrial pressure.

The interval between the index test and reference standard was less than one day in seven of the 17 studies (Er 2010; Hellenkamp 2018; Hsu 2008; Kyranis 2018; Sawada 2019; Schneider 2017; Venkateshvaran 2021) and was between two and seven days in the remaining 10 studies.



We contacted trial authors for missing data, but none were provided except for one study (Amsallem 2016).

# **Excluded studies**

We excluded 154 references (154 studies). The reason for exclusion is stated for each study in the Characteristics of excluded studies table and summarised below.

- insufficient diagnostic test accuracy data: 100
- index test and reference standard were not performed within one week: 15
- not a diagnostic test accuracy study: 14
- inappropriate population: 6

- case series: 4
- case-control study: 1
- inappropriate index test: 3
- inappropriate target condition: 4
- inappropriate reference standard: 7

# Methodological quality of included studies

The methodological quality of the included studies is reported in the Characteristics of included studies, Figure 3 and Figure 4. Poor reporting, especially in the index test and reference standard domains, hampered conclusive judgement relative to the risk of bias. Only one study had a low risk of bias in all four domains (Hellenkamp 2018).

# Figure 3. Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies





					Applicability Concerns			
	Patient Selection	Index Test	Reference Standard	Flow and Timing	Patient Selection Index Test Reference Standard			
Amsallem 2016	Ŧ	Ŧ	Ŧ		• • •			
Balci 2016	•	?	?		• ? •			
C <b>olle</b> 2003	Ŧ	Ŧ	Ŧ	•	• • •			
Er 2010	Ŧ	?	?	Ŧ	• • •			
Greiner 2014	•	•	?	•	? 🕂 🛨			
Hellenkamp 2018	Ŧ	Ŧ	Ŧ	Ŧ	? 🛨 🛨			
Hsu 2008	•	•	?	Ŧ				
Kyranis 2018	•	Ŧ	Ŧ	•	? 🛨 🛨			
Lafitte 2013	•	?	?	•	? 🛨 🛨			
Mazhar 2011	•	?	?	•	??			
Mo 2015	?	?	?	•	??			
Mo 2015a	Ŧ	?	?		??			
Nowak 2018	Ŧ	Ŧ	Ŧ		• ? •			
Sawa <b>d</b> a 2019	•	Ŧ	Ŧ	•	? 🛨 🛨			
Schneider 2017	Ŧ	?	?	•	- <b>-</b>			
Venkateshvaran 2021	•	?	Ŧ		? 😑 🕒			
Wainstein 2017	Ŧ	?	?	•	• ? •			
😑 High	?	Uncl	ear		🕂 Low			

Figure 4. Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study



# Patients selection domain

Three studies had a high risk of bias with regard to patient selection due to inappropriate exclusion (Greiner 2014; Sawada 2019; Venkateshvaran 2021). For these studies, patients whose index test results were not explicitly documented were excluded. One study had unclear risk of bias because the inclusion procedures were not reported (Mo 2015). For the remaining 13 studies, we rated patient selection as having low risk of bias. We judged applicability as being of high concern. The prevalence from the included studies was high as the included studies were often conducted in tertiary care settings. The classification of PH in the patients included in our review was mainly unclear.

# Index test domain

Two studies had a high risk of bias because the threshold of index test was not prespecified ((Greiner 2014; Hsu 2008); in Greiner 2014, the threshold that had the highest accuracy was reported and in Hsu 2008, the threshold that had the highest positive likelihood ratio was reported), seven studies had a low risk of bias (Amsallem 2016; Colle 2003; Hellenkamp 2018; Kyranis 2018; Nowak 2018; Sawada 2019; Venkateshvaran 2021), and we rated the remaining eight studies as having an unclear risk of bias because it was unclear whether the index test results were interpreted without the knowledge of the results of the reference standard (Balci 2016; Er 2010; Lafitte 2013; Mazhar 2011; Mo 2015; Mo 2015a; Schneider 2017; Wainstein 2017) and/or it was unclear whether a threshold was prespecified (Balci 2016; Lafitte 2013; Mazhar 2011; Mo 2015; Mo 2015a; Venkateshvaran 2021; Wainstein 2017). Applicability was judged as of high concern in two studies because right atrial pressure was not measured using the diameter and collapse of the inferior vena cava during spontaneous respiration (Hsu 2008; Schneider 2017), of unclear concern in six studies because the methods used to measure right atrial pressure were unclear (Balci 2016; Mazhar 2011; Mo 2015; Mo 2015a; Nowak 2018; Wainstein 2017), and of low concern in the remaining nine studies.

# **Reference standard domain**

Seven studies were at low risk of bias in the reference standard domain (Amsallem 2016; Colle 2003; Hellenkamp 2018; Kyranis

2018; Nowak 2018; Sawada 2019; Venkateshvaran 2021). For the remaining 10 studies, the risk of bias was unclear because it was not specified whether reference standard results were interpreted without knowledge of the results of the index tests (Balci 2016; Er 2010; Greiner 2014; Hsu 2008; Lafitte 2013; Mazhar 2011; Mo 2015; Mo 2015a; Schneider 2017; Wainstein 2017). It was not clear whether a threshold was prespecified in 13 studies (Balci 2016; Colle 2003; Er 2010; Greiner 2014; Hellenkamp 2018; Hsu 2008; Kyranis 2018; Lafitte 2013; Mazhar 2011; Mo 2015; Mo 2015a; Nowak 2018; Wainstein 2017). Applicability was of low concern in all the studies.

# Flow and timing domain

Five studies were at low risk of bias in the flow and timing domain (Er 2010; Hellenkamp 2018; Hsu 2008; Sawada 2019; Schneider 2017). The remaining 12 studies were at high risk of bias. Eight studies excluded some participants from the analysis due to the uninterpretable results of the index test (Amsallem 2016; Greiner 2014; Kyranis 2018; Lafitte 2013; Mazhar 2011; Mo 2015; Mo 2015a; Venkateshvaran 2021) and in 10 studies the interval between the index test and reference standard was not less than one day (Amsallem 2016; Balci 2016; Colle 2003; Greiner 2014; Lafitte 2013; Mazhar 2011; Mo 2015; Mo 2015a; Nowak 2018; Wainstein 2017).

# Findings

The sensitivity of the index test ranged from 40% to 98% with a median of 87% and the specificity of the index test ranged from 33% to 100% with a median of 86%. The range of sensitivity and specificity estimated by the studies, as well as the different thresholds for echocardiography positive findings, the prevalence of PH, and the methods to estimate the right atrial pressure (RAP) are shown in Figure 5. There was a large variability between the studies and uncertainty in the results. The SROC curve under the HSROC model, representing the accuracy of echocardiography thresholds used across studies, as well as individual study accuracy estimates, are shown in Figure 6. Given the considerable variation of cut-off values in the collected data, we refrained from calculating the summary diagnostic accuracy using the bivariate model.

# Figure 5. Forest plots: sensitivity and specificity of Doppler trans-thoracic echocardiography for detecting PH Abbreviations: CI: confidence interval; FN: false negative; FP: false positive; IVC: inferior vena cava; RAP: right atrial pressure; TN: true negative; TP: true positive.

Study	ТР	FP	FN	TN	Prevalence	Prevalence category	Threshold	RAP estimation	Sensitivity (95% CI)	Specificity (95% CI) !	Sensitivity (95% CI)Specificity (95% CI)
Er 2010	42	0	1	7	0.86	4th quartile	38 mmHg	using the diameter of IVC	0.98 [0.88, 1.00]	1.00 [0.59, 1.00]	· · · · · · · · · · · · · · · · · · ·
Mo 2015	20	2	1	1	0.88	4th quartile	35 mmHg	not reported	0.95 [0.76, 1.00]	0.33 [0.01, 0.91]	
Kyranis 2018	60	4	5	27	0.68	2nd quartile	31 mmHg	using the diameter of IVC	0.92 [0.83, 0.97]	0.87 [0.70, 0.96]	
Nowak 2018	24	2	2	9	0.7	3rd quartile	43 mmHg	not reported	0.92 [0.75, 0.99]	0.82 [0.48, 0.98]	
Sawada 2019	45	13	4	127	0.26	1st quartile	40 mmHg	using the diameter of IVC	0.92 [0.80, 0.98]	0.91 [0.85, 0.95]	
Amsallem 2016	140	5	13	41	0.77	3rd quartile	40 mmHg	using the diameter of IVC	0.92 [0.86, 0.95]	0.89 [0.76, 0.96]	• -•
Venkateshvaran 2021	364	4	45	6	0.87	4th quartile	31 mmHg	using the diameter of IVC	0.89 [0.86, 0.92]	0.60 [0.26, 0.88]	· · · · · · · · · · · · · · · · · · ·
Lafitte 2013	91	9	12	43	0.66	2nd quartile	38 mmHg	using the diameter of IVC	0.88 [0.81, 0.94]	0.83 [0.70, 0.92]	
Schneider 2017	47	1	7	10	0.83	4th quartile	34 mmHg	not using the diameter of IVC	0.87 [0.75, 0.95]	0.91 [0.59, 1.00]	
Greiner 2014	86	334	13	1262	0.06	1st quartile	36 mmHg	using the diameter of IVC	0.87 [0.79, 0.93]	0.79 [0.77, 0.81]	
Balci 2016	50	15	9	29	0.57	1st quartile	35 mmHg	not reported	0.85 [0.73, 0.93]	0.66 [0.50, 0.80]	
Mo 2015a	48	4	11	24	0.68	3rd quartile	45 mmHg	not reported	0.81 [0.69, 0.90]	0.86 [0.67, 0.96]	
Hellenkamp 2018	55	10	13	12	0.76	3rd quartile	31 mmHg	using the diameter of IVC	0.81 [0.70, 0.89]	0.55 [0.32, 0.76]	
Colle 2003	13	8	4	140	0.1	1st quartile	30 mmHg	using the diameter of IVC	0.76 [0.50, 0.93]	0.95 [0.90, 0.98]	
Hsu 2008	12	3	4	30	0.33	1st quartile	47 mmHg	not using the diameter of IVC	0.75 [0.48, 0.93]	0.91 [0.76, 0.98]	
Mazhar 2011	38	7	19	35	0.58	2nd quartile	31 mmHg	not reported	0.67 [0.53, 0.79]	0.83 [0.69, 0.93]	
Wainstein 2017	33	6	50	45	0.62	2nd quartile	36 mmHg	not reported	0.40 [0.29, 0.51]	0.88 [0.76, 0.96]	0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1

Figure 6. Main analysis: Summary ROC plot and curve of Doppler trans-thoracic echocardiography for PH under the HSROC model Abbreviations: HSROC: hierarchical summary receiver operating characteristic; PH: pulmonary hypertension; ROC: receiver operating characteristic.



We used the HSROC parameters to calculate the sensitivity under fixed specificity. As shown in Summary of findings 1, using a prevalence of PH of 68% (the median prevalence) and a fixed specificity of 86% (the median specificity) (Best 2018; Heazell 2019), the estimated sensitivity was 87% (95% CI 78% to 96%). Seven out of 17 studies in this analysis reported sensitivities inferior to this estimation. The estimated specificity at median sensitivity was 86% (95% CI 76% to 94%).

Additional estimations with a prevalence of 10%, 58%, 77% and 88% (minimum, 25 percentile, 75% percentile and maximum values

from included studies) showed an increase in the number of false positives or false negatives, respectively (Summary of findings 1).

# Investigation of heterogeneity

We summarised these results in Table 2. There were many potential sources of variation and too few studies to explain the observed variabilities.

**Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults (Review)** Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Types of PH defined by WHO classification (Group 3, not Group 3, or classification not reported)

Due to the limited number of studies in each group, especially for non-reporting of the classification, we could not apply the HSROC

model. Instead, we presented the summary plots of the sensitivity and specificity in each subgroup (Figure 7).

# Figure 7. Subgroup analysis: Summary ROC plot and curve of Doppler trans-thoracic echocardiograph for PH by WHO classifications of pulmonary hypertension Abbreviations: PH: pulmonary hypertension; ROC: receiver operating characteristic; WHO: World Health Organization.



# *Mechanical ventilation (including non-invasive positive pressure ventilation) or not*

Since all the included studies did not recruit patients undergoing mechanical ventilation, we could not perform this analysis.

# Estimation of right atrial pressure (using the diameter of IVC, any other methods, or not reported)

In 10 studies, right atrial pressure was measured using the diameter and collapse of the inferior vena cava during spontaneous

respiration, in two studies, the diameter of the inferior vena cava was not used to measure right atrial pressure, and in the remaining six studies, the method of measuring right atrial pressure was not reported. Due to the limited number of studies in the group using other methods than IVC, we could not apply the HSROC model. Instead, we presented the summary plots of the sensitivity and specificity in each subgroup (Figure 8).

# Figure 8. Subgroup analysis: Summary ROC plot and curve of Doppler trans-thoracic echocardiograph for PH by methods used to estimate RAP Abbreviations: RAP: right atrial pressure; ROC: receiver operating characteristic.



# Threshold of index test (< 36 mmHg, $\geq$ 36 and < 40 mmHg, and $\leq$ 40 mmHg)

The pooled sensitivity and specificity of each threshold category are shown in Table 2 and Figure 9. Although we could not observe

a clear threshold effect between the categories, there was a large overlap of 95% Cls.

Figure 9. Subgroup analysis: Summary ROC plot of Doppler trans-thoracic echocardiograph for PH by thresholds under the bivariate model Abbreviations: RAP: right atrial pressure; ROC: receiver operating characteristic.



# Sensitivity analyses

Table 3 summarised the results from sensitivity analyses. We presented the pooled sensitivity under the fixed specificity of 86% (median of the included studies).

The results were similar to the main results when we excluded studies at high risk of bias in domains 1 and 4 of QUADAS-2 (Figure 10). The sensitivity varied with the prevalence, but we could not find a clear dose-response relationship between the accuracy and prevalence (Figure 11).

Figure 10. Sensitivity analysis: Summary ROC plot and curve of Doppler trans-thoracic echocardiograph for PH, excluding studies at high risk of bias in domain 1 or 4 in QUADAS-2 assessment under the HSROC model Abbreviations: HSROC: hierarchical summary receiver operating characteristic; PH: pulmonary hypertension; QUADAS: Quality Assessment of Diagnostic Accuracy Studies; ROC: receiver operating characteristic.



Figure 11. Sensitivity analysis: Summary ROC plot and curve of Doppler trans-thoracic echocardiograph for PH, repeating the analysis for each quartile of prevalence under the HSROC model Abbreviations: PH: pulmonary hypertension; ROC: receiver operating characteristic.



We could not perform sensitivity analysis on uninterpretable results it because such patients were excluded from the analysis and the data on whether they had PH was not available (Table 1).

# DISCUSSION

# Summary of main results

We included 17 studies (3656 adult patients) assessing the diagnostic accuracy of Doppler trans-thoracic echocardiography for the diagnosis of PH. The included studies enrolled patients suspected of PH. The samples were heterogeneous in terms of

Cochrane

their distribution of age, sex, WHO classification, setting, country, positivity threshold, and year of publication. In addition, the prevalence of PH reported in the included studies varied widely (from 6% to 88%). Epidemiological and clinical characteristics of participants are presented in Table 1 and key results in Summary of findings 1.

The estimated sensitivity was 87% (95% CI 78 to 96%) when we applied the median specificity of 86% among the included studies. When applying a cohort assuming a 68% prevalence of PH which was the median of the included studies, the result suggested that 275 out of 1000 patients would avoid unnecessary referral for a right-heart catheterisation but 88 would miss PH diagnosis. The intended role of Doppler echocardiography is as a triage which is used before the reference standard to avoid unnecessary referrals and to minimise false negatives. Given the number of false negatives, the poor prognosis of PH, and the results of our review, a single echocardiography may not be acceptable as a triage test for PH in such a hypothetical cohort. The results of applying the test in other settings with the prevalence of 10%, 58%, 77%, and 88% (minimum, 25% percentile, 75% percentile, and maximum values from included studies) are summarised in the Summary of findings 1.

Previous reviews reported that Doppler echocardiography was useful for triage to undergo right-heart catheterisation (Janda 2011; Taleb 2013; Zhang 2010). However, as shown in Summary of findings 1, the diagnostic accuracy of Doppler echocardiography is not likely to be sufficient for clinical use in patients suspected of having PH in settings where the prevalence of PH is high. Such settings include patients with heart failure treated in tertiary care hospitals or patients with end-stage lung disease who need lung transplantation (Andersen 2012; Bursi 2012; Dzudie 2014). This inaccuracy is likely to partly be due to the problem of overestimation or underestimation of pulmonary arterial pressure, as reported previously (Fisher 2009; Galie 2016; Lang 2015). When the prevalence is low (10%), as is the case for preoperative examinations for liver transplantation (Colle 2003) in the present review, the number of true negatives and false negatives would be 808 and 8 of 1000, respectively. Such low prevalence scenarios can also be apparent in patients with systemic sclerosis or older patients with chronic obstructive pulmonary disease (Avouac 2010; Moreira 2015). In these settings, Doppler echocardiography might be considered as a triage test.

The consequences of applying the test to the hypothetical cohort above used the estimated sensitivity at a fixed specificity. Of note, the reporting sensitivity at a fixed specificity does not indicate how the test would likely perform in practice but represents a point on the HSROC curve that is ideally somewhere near the centre of the observed data. Overall, the methodological quality was low; no study was assigned a low risk of bias or low concern in each QUADAS-2 domain assessed. Further, there was a high concern regarding applicability due to a variety of settings, characteristics of participants, and prevalence. Poor reporting, especially in the index test and reference standard domains, also raises unclear concerns. Due to the limited amount of data, it was not possible to estimate the cause of heterogeneity in the results of each study. Therefore, the uncertainty of the present results should be noted.

Our meta-analysis yielded better diagnostic values of Doppler echocardiography as compared with several systematic reviews on the same topic (Janda 2011; Taleb 2013; Zhang 2010). The

difference might be due to the discrepancy in reference standards between the previous and current reviews. We used a strict reference standard that is likely to diagnose the target condition with a high degree of accuracy. On the other hand, the three reviews included studies where the interval between the index test and the reference standard was more than one week. Both echocardiography and right-heart catheterisation are subject to disagreement when performed at different times (e.g. days or weeks apart), which is a major limitation of the studies that compare their accuracy in the diagnosis of PH. For example, any treatment would be performed if the results of echocardiography suggested pulmonary hypertension (Delcroix 2010). This could lead to negative results for a reference standard performed a few weeks or months later, which means that the false positive rate increases and specificity decreases. We therefore excluded studies with an interval of more than a week to obtain unbiased estimates.

The included studies adopted a variety of thresholds to diagnose PH (30 to 47 mmHg). Therefore, we used the HSROC model to take the variation into account. We also performed the post hoc subgroup analysis by the threshold categories. The analysis did not show a clear threshold effect in the range of thresholds. However, higher thresholds  $\geq$  40 mmHg might be avoided based on the role as a triage test.

# Strengths and weaknesses of the review

We conducted a thorough literature search and included full-text publications and abstracts without any language restrictions. There are currently no reliable search strategies to identify diagnostic test accuracy studies (Beynon 2013). The major strengths of the review are as follows: we did not use any diagnostic filters in our search strategy, which ensured that all studies on the topic were identified. PH was defined when the mean pulmonary arterial pressure assessed by right-heart catheterisation was  $\geq$  25 mmHg (Simonneau 2013). This strict reference standard was used as it likely could diagnose the target condition with a high degree of accuracy.

This review has several limitations. First, many studies were excluded due to insufficient diagnostic test accuracy data. Of the 131 studies excluded at full-text screening, 85 studies were excluded because of lack of diagnostic accuracy data, which matched the inclusion criteria of our review. If some of these studies could have been included in our review, the results of our review might have changed. Second, we attempted to obtain detailed data by contacting the authors of included studies, but most of them were not available, especially for studies that were published as conference abstracts. The space limitations for the publication of a conference abstract would yield unclear risk of bias judgements rather than low or high judgements during the QUADAS-2 assessment. Furthermore, due to the lack of information, there might be potential patient overlap between Mo 2015 and Mo 2015a. Third, there was a high proportion of studies that were judged at high risk of bias on the flow and timing domain and with high concern regarding applicability in the patient selection domain of the QUADAS-2 tool.

# Applicability of findings to the review question

Although our review collated all available evidence on the diagnostic accuracy of Doppler echocardiography for PH, the applicability of our findings to the review question was limited.



PH was highly prevalent among the participants in the included studies. For example, the mean systolic pulmonary arterial pressure was 62.3 mmHg and the prevalence of PH was 86% in Er 2010. It is questionable if the triage test is needed in such a high-prevalence setting. The care settings were mostly hospitals such as university hospitals, cardiovascular centres, and lung and liver transplant centres. Findings from such settings may be difficult to apply to other settings that play a triage role for assessment of PH. Our sensitivity analysis did not show a doseresponse relationship between prevalence and diagnostic accuracy of Doppler echocardiography; however, it was not conclusive as the CIs were substantially wide due to the limited data. We could not investigate the potential reason for the variety of prevalence due to the poor reporting of patient characteristics including WHO classification of PH. Additionally, there was limited information on the symptoms that the participants had. In the four studies that reported the information on symptoms, the proportion of mild or asymptomatic patients was small.

# AUTHORS' CONCLUSIONS

# **Implications for practice**

Our evidence assessment of echocardiography for the diagnosis of PH in adult patients revealed several limitations.

Current available data indicate generally poor methodological and reporting quality of the evidence. Due to their heterogeneity, we were unable to determine average sensitivity and specificity at any particular index test threshold and could not explain the observed variability in results.

# **Implications for research**

To determine if the Doppler echocardiography is a useful triage test, we need more studies with transparent reporting and high methodological quality. There is room for further study on the optimal threshold to diagnose PH by trans-thoracic Doppler echocardiography. The influence of different types of PH, methods of estimating right atrial pressure, and the use of ventilation on the accuracy of diagnosis needs to be investigated.

# ACKNOWLEDGEMENTS

We thank Elizabeth Stovold, Information Specialist of the Cochrane Airway Group, for designing our search strategy. We thank Dr. Amsallem for correspondence and sending us unpublished data.

We thank the following translators for data extraction and QUADAS-2 assessment of various articles:

Anja Lieder, Katja Boehm, Liliya Eugenevna Ziganshina, Pascale Hess and Rachael Kelly.

The Cochrane Diagnostic Test Accuracy Editorial Team helped to edit this manuscript and commented critically on the protocol.

The authors and Cochrane Airways Editorial Team are grateful to the following peer reviewers for their time and comments:

Tim Donovan, University of Cumbria, UK;

Alan L Hinderliter, University of North Carolina, USA; and

Prof Dr Tim Seidler, University of Göttingen, Germany.

This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Airways Group. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health and Social Care.

# REFERENCES

# **References to studies included in this review**

#### Amsallem 2016 {published and unpublished data}

Amsallem M, Sternbach JM, Adigopula S, Kobayashi Y, Vu TA, Zamanian R, et al.Addressing the controversy of estimating pulmonary arterial pressure by echocardiography. *Journal of the American Society of Echocardiography* 2016;**29**(2):93-102.

# Balci 2016 {published data only}

Balci MK, Ari E, Vayvada M, Salturk C, Asicioglu E, Kahveci G, et al.Assessment of pulmonary hypertension in lung transplantation candidates: correlation of Doppler echocardiography with right heart catheterization. *Transplantation Proceedings* 2016;**48**(8):2797-802.

#### Colle 2003 {published data only}

Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al.Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. *Hepatology* 2003;**37**(2):401-9.

#### Er 2010 {published data only}

Er F, Ederer S, Nia AM, Caglayan E, Dahlem KM, Semmo N, et al.Accuracy of doppler-echocardiographic mean pulmonary artery pressure for diagnosis of pulmonary hypertension. *PLOS One* 2010;**5**(12):e15670.

#### Greiner 2014 {published data only}

Greiner S, Jud A, Aurich M, Hess A, Hilbel T, Hardt S, et al.Reliability of noninvasive assessment of systolic pulmonary artery pressure by doppler echocardiography compared to right heart catheterization: analysis in a large patient population. *Journal of the American Heart Association* 2014;**3**(4):pii: e001103. [DOI: 10.1161/JAHA.114.001103]

#### Hellenkamp 2018 {published data only}

Hellenkamp K, Unsold B, Mushemi-Blake S, Shah AM, Friede T, Hasenfuss G, et al.Echocardiographic estimation of mean pulmonary artery pressure: a comparison of different approaches to assign the likelihood of pulmonary hypertension. *Journal of the American Society of Echocardiography* 2018;**31**(1):89-98.

#### Hsu 2008 {published data only}

Hsu VM, Moreyra AE, Wilson AC, Shinnar M, Shindler DM, Wilson JE, et al.Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization. *Journal of Rheumatology* 2008;**35**(3):458-65.

#### Kyranis 2018 {published data only}

Kyranis SJ, Latona J, Platts D, Kelly N, Savage M, Brown M, et al.Improving the echocardiographic assessment of pulmonary pressure using the tricuspid regurgitant signal -The "chin" vs the "beard". *Echocardiography* 2018;**35**(8):1085-96.

# Lafitte 2013 {published data only}

Lafitte S, Pillois X, Reant P, Picard F, Arsac F, Dijos M, et al.Estimation of pulmonary pressures and diagnosis of

pulmonary hypertension by Doppler echocardiography: a retrospective comparison of routine echocardiography and invasive hemodynamics. *Journal of the American Society of Echocardiography* 2013;**26**(5):457-63.

# Mazhar 2011 {published data only}

Mazhar J, Pera V, Liang M, Lee E, Tamuno P, Jayabal J, et al.How good is tricuspid regurgitation velocity in excluding pulmonary hypertension in patients with left heart disease. *Heart Lung and Circulation* 2011;**20**:S176.

# Mo 2015 {published data only}

Mo V, Bellucci B, Fisher J, Balekian A.PAAT and RVET versus RVSP to predict pulmonary hypertension. *European Respiratory Journal* 2015;**46**:PA3784. [DOI: 10.1183/13993003.congress-2015.PA3784]

# Mo 2015a {published data only}

Mo VY, Bellucci BM, Fisher JM, Balekian AA.PAAT, RVET, and Vmax versus RVSP to predict pulmonary hypertension. *European Heart Journal Cardiovascular Imaging* 2015;**16**:ii154.

# Nowak 2018 {published data only}

Nowak J, Hudzik B, Jastrzebski D, Niedziela JT, Rozentryt P, Wojarski J, et al.Pulmonary hypertension in advanced lung diseases: echocardiography as an important part of patient evaluation for lung transplantation. *Clinical Respiratory Journal* 2018;**12**(3):930-8.

# Sawada 2019 {published data only}

Sawada N, Kawata T, Daimon M, Nakao T, Hatano M, Maki H, et al.Detection of pulmonary hypertension with systolic pressure estimated by doppler echocardiography. *International Heart Journal* 2019;**60**(4):836-44. [DOI: doi: 10.1536/ihj.18-453]

# Schneider 2017 {published data only}

Schneider M, Pistritto AM, Gerges C, Gerges M, Binder C, Lang I, et al.Multi-view approach for the diagnosis of pulmonary hypertension using transthoracic echocardiography. In: Annual Meeting of the OKG-Austrian Cardiology Society; 2017 Jun 7-10; Salzburg. 2017:S73-4.

# Venkateshvaran 2021 {published data only}

Venkateshvaran A, Seidova N, Tureli HO, Kjellstrom B, Lund LH, Tossavainen E, et al.Accuracy of echocardiographic estimates of pulmonary artery pressures in pulmonary hypertension: insights from the KARUM hemodynamic database. *International Journal of Cardiovascular Imaging* 2021;**37**(9):2637-45.

#### Wainstein 2017 {published data only}

Wainstein EJ, Castro HM, Orazi ML, Svetliza GN, Maritano Furcada J, Precerutti JA, et al.Accuracy of ecocardiographic assessment of pulmonary pressure in lung transplant candidates. *Journal of Heart and Lung Transplantation* 2017;**36**(4 Suppl 1):S406.

# References to studies excluded from this review

# Aashish 2020 {published data only}

Aashish A, Giridharan S, Karthikeyan S, Ganesh BA, Prasath PA.Assessment of pulmonary artery pressures by various doppler echocardiographic parameters and its correlation with cardiac catheterization in patients with pulmonary hypertension. *Heart Views* 2020;**21**(4):263-8.

# Abaci 1998 {published data only}

Abaci A, Kabukcu M, Ovünç K, Tokgözoğlu L, Tarrach M, Batur MK, et al.Comparison of the three different formulas for Doppler estimation of pulmonary artery systolic pressure. *Angiology* 1998;**49**:463e70.

#### Abbas 2003 {published data only}

Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno CA, Lester SJ.Echocardiographic determination of mean pulmonary artery pressure. *American Journal of Cardiology* 2003;**92**(11):1373-6.

# Abreu 1990 {published data only}

Abreu J, Bernardes L, Soares R, Ramos JM, Quininha J, Salomao S.Non-invasive evaluation of systolic pressure of the pulmonary artery in patients with tricuspid regurgitation, using Doppler echocardiography. *Revista Portuguesa de Cardiologia* 1990;**9**(3):199-203.

#### Adrian 2016 {published data only}

Adrian Lescano A, Lavalle Cobo A, Santa Maria H, Damianich G, Ferro A, Gonzalez N, et al.Accuracy and precision of systolic pulmonary pressure assessed by echocardiography among patients with pulmonary hypertension. *European Journal of Heart Failure* 2016;**18**:416.

# Aduen 2009 {published data only}

Aduen JF, Castello R, Lozano MM, Hepler GN, Keller CA, Alvarez F, et al.An alternative echocardiographic method to estimate mean pulmonary artery pressure: diagnostic and clinical Implications. *Journal of the American Society of Echocardiography* 2009;**7**:814-9.

# Aduen 2011 {published data only}

Aduen JE, Castello R, Daniels JT, Diaz JA, Safford RE, Heckman MG, et al.Accuracy and precision of three echocardiographic methods for estimating mean pulmonary artery pressure. *Chest* 2011;**2**:347-52.

# Agrawal 2019 {published data only}

Agrawal V, D'Alto M, Naeije R, Romeo E, Xu M, Assad TR, et al.Echocardiographic detection of occult diastolic dysfunction in pulmonary hypertension after fluid challenge. *Journal of the American Heart Association* 2019;**8**(17):e012504.

# Ahmed 2016 {published data only}

Ahmed I, Hassan Nuri MM, Zakariyya AN, Ahmad SM, Ahmed M.Correlation between doppler echocardiography and right heart catheterization derived pulmonary artery pressures: impact of right atrial pressures. *Journal of the College of Physicians and Surgeons* 2016;**26**(4):255-9.

# Albani 2020 {published data only}

Albani S, Pinamonti B, Giovinazzo T, De Scordilli M, Fabris E, Stolfo D, et al.Accuracy of right atrial pressure estimation using a multi-parameter approach derived from inferior vena cava semi-automated edge-tracking echocardiography: a pilot study in patients with cardiovascular disorders. *International Journal* of Cardiovascular Imaging 2020;**36**(7):1213-25.

# Ali 1987 {published data only}

Ali AS, Sergakova LM, At'kov OLU.Diagnosis of pulmonary hypertension using Doppler-echocardiography. *Terapevticheskii Arkhiv* 1987;**59**(3):138-41.

#### Ali 1988 {published data only}

Ali SA, Sergakova LM.Quantitative assessment of pulmonary hypertension by doppler echocardiography. *Kardiologiya* 1988;**7**:112-5.

# Alonso 1988 {published data only}

Alonso F, Garcia Fernandez MA, Moreno M, Martinez Romero P, Rabgo R.Doppler ultrasound imaging of the heart in the assessment of pulmonary hypertension. *Ultrasonidos* 1988;**7**(4):149-59.

# Althammer 1994 {published data only}

Althammer G, Barnickel H, Siemon G.Doppler echocardiography in pulmonary hypertension. *Atemwegs - Und Lungenkrankheiten* 1994;**20**(9):520-4.

# Antoun 2009 {published data only}

Antoun P, Breall J, Kwo P, Sadanandan S, Shoemaker T, Singh I, et al.Pre-operative pulmonary hypertension and mortality in patients undergoing liver transplantation. *Catheterization and Cardiovascular Interventions* 2009;**73**:S68.

# Arcasoy 2003 {published data only}

Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al.Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *American Journal of Respiratory and Critical Care Medicine* 2003;**167**(5):735-40. [DOI: 10.1164/ rccm.200210-1130OC]

# Arellano 2017 {published data only}

Arellano Serrano C, Garcia-Izquierdo Jaen E, Monivas Palomero V, Vilches Soria S, Oteo Dominguez JF, Segovia Cubero J, et al.Is the assessment of pulmonary arterial hypertension by echocardiography reliable in patients with severe tricuspid regurgitation? In: 21st Annual Meeting of the European Association of Echocardiography, EUROECHO; 2017 Dec 6-9; Lisbon. 2017:iii272.

# Artaud-Macari 2010 {published data only}

Artaud-Macari E, Muir JF, Cuvelier A, Molano LC, Viacroze C, Mouton-Schleiffer D, et al.How accurate is trans-thoracic Doppler echocardiography for the hemodynamic assessment of pulmonary hypertension? In: American Thoracic Society International Conference; 2010 May 14-19; New Orleans. 2010.



# Ashrith 2015 {published data only}

Ashrith G, Fida N, Cordero-Reyes A, Amione-Guerra J, Khan Z, Bhimaraj A, et al.Echocardiographic predictors of combined pre and post capillary pulmonary hypertension (PH) in a population of systolic heart failure with who group II. *Journal of the American College of Cardiology* 2015;**65**(10 Suppl 1):A1564.

# Attaran 2009 {published data only}

Attaran RR, Ramaraj R, Sorrell VL, Movahed MR.Poor correlation of estimated pulmonary artery systolic pressure between echocardiography and right heart catheterization inpatients awaiting cardiac transplantation: results from the clinical arena. *Transplantation Proceedings* 2009;**41**:3827e30.

# Barbier 2020 {published data only}

Barbier P, Cucco C, Guglielmo M, Simioniuc A, Fabiani I, Pugliese NR, et al.Estimation of increased pulmonary wedge pressure by an algorithm based on noninvasively measured pulmonary diastolic pressure in cardiac patients independent of left ventricular ejection fraction. *Echocardiography (Mount Kisco, NY)* 2020;**37**(2):215-22.

# Bech-Hanssen 2009 {published data only}

Bech-Hanssen O, Selimovic N, Rundqvist B, Wallentin J.Doppler echocardiography can provide a comprehensive assessment of right ventricular afterload. *Journal of the American Society of Echocardiography* 2009;**22**(12):1360-7.

# Bech-Hanssen 2013 {published data only}

Bech-Hanssen O, Karason K, Rundqvist B, Bollano E, Lindgren F, Selimovic N.Can pulmonary hypertension and increased pulmonary vascular resistance be ruled in and ruled out by echocardiography? *Journal of the American Society of Echocardiography* 2013;**26**(5):469-78.

# Belfort 1994 {published data only}

Belfort MA, Rokey R, Saade GR, Moise KJ.Rapid echocardiographic assessment of left and right heart hemodynamics in critically ill obstetric patients. *American Journal of Obstetrics and Gynecology* 1994;**4**:884-92.

# Bloch 1989 {published data only}

Bloch A, Mayor C, Guillaume-Gentil M, Vuille C, Suard J.Doppler ultrasound diagnosis of pulmonary hypertension. *Revue Medicale de la Suisse Romande* 1989;**109**(11):907-10.

# Boley 2013 {published data only}

Boley T, Manning B, Nallamothu N, Markwell S, Henkle J, Vassileva C, et al.Utility of echocardiography and right heart catheterization in pulmonary artery pressure evaluation for lung volume reduction surgery. *American Journal of Respiratory and Critical Care Medicine* 2013;**187**:A4328.

# Bournia 2020 {published data only}

Bournia VK, Tsangaris I, Rallidis L, Konstantonis D, Frantzeskaki F, Anthi A, et al.Cardiac catheterization versus echocardiography for monitoring pulmonary pressure: a prospective study in patients with connective tissue diseaseassociated pulmonary arterial hypertension. *Diagnostics* 2020;**10**(1):49.

# Calvin 2011 {published data only}

Calvin JE, Holoshitz N, Liebson P.Echo estimates of pulmonary artery pressure correlates poorly with right heart catheterization. *Journal of the American College of Cardiology* 2011;**57**(14 Suppl 1):E1572.

# Caravita 2019 {published data only}

Caravita S, Yerly P, Baratto C, Dewachter C, Rimouche A, Faini A, et al.Validation of noninvasive pulmonary artery pressure/flow relationship: echocardiography vs right heart catheterization. *European Heart Journal* 2019;**40**(Suppl 1):ehz745.1066.

# Castria 2012 {published data only}

Castria D, Refini RM, Mezzasalma F, Di Sipio P, Bargagli E, Filippi R, et al.Precocious detection of pulmonary hypertension in idiopathic pulmonary fibrosis. *European Respiratory Journal* 2012;**40**:P3636.

# Cebrian 2010 {published data only}

Cebrian J, Balerdi B, Bonastre J, Lopez C.Correlation between systolic pulmonary artery values estimated with Doppler echocardiography and measured with pulmonary artery catheter in patients with suspected pulmonary artery hypertension. *Intensive Care Medicine* 2010;**36**:S333.

# Chan 1987 {published data only}

Chan KL, Currie PJ, Seward JB, Hagler DJ, Mair DD, Tajik AJ.Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. *Journal of the American College of Cardiology* 1987;**9**:549-54.

# ChiCtr65129 {published data only}

ChiCtr65129.Analysis of reliability of noninvasive assessment of pulmonary artery pressure by Doppler echocardiography compared to right heart catheterization: a prospective clinical study. www.chictr.org.cn/showproj.aspx?proj=65129 (first received 26 Jan 2021).

# Correale 2019 {published data only}

Correale M, Tricarico L, Padovano G, Ferraretti A, Monaco I, Musci RL, et al.Echocardiographic score for prediction of pulmonary hypertension at catheterization: the Daunia Heart Failure Registry. *Journal of Cardiovascular Medicine* 2019;**20**(12):809-15.

# Cottini 2017 {published data only}

Cottini S, Benden C, Huber LC, Arrigo M.Echocardiography accurately predicts pulmonary hypertension in patients with advanced lung disease. *Critical Care* 2017;**21**:115. [DOI: 10.1186/s13054-017-1697-y]

# Cotton 2002 {published data only}

Cotton CL, Ghandi S, Vaitkus PT, Massad VG, Benedetto E, Mrtek RG, et al.Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates. *Liver Transplantation* 2002;**8**(11):1051-4.

# D'Alto 2013 {published data only}

D'Alto M, Romeo E, Argiento P, D'Andrea A, Vanderpool R, Correra A, et al.Accuracy and precision of echocardiography versus right heart catheterization for the assessment of



pulmonary hypertension. *International Journal of Cardiology* 2013;**168**(4):4058-62.

# D'Alto 2018 {published data only}

D'Alto M, Di Marco GM, D'Andrea A, Argiento P, Romeo E, Ferrara F, et al.Invasive and noninvasive evaluation for the diagnosis of pulmonary hypertension how to use and how to combine them. *Heart Failure Clinics* 2018;**14**(3):353-60.

# Denton 1997 {published data only}

Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM.Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. *British Journal of Rheumatology* 1997;**36**(2):239-43.

# **De Scordilli 2019** {published data only}

De Scordilli M, Pinamonti B, Albani S, Gregorio C, Barbati G, Daneluzzi C, et al.Reliability and challenges in non-invasive hemodynamic assessment with Doppler echocardiography: comparison with the invasive evaluation. *European Heart Journal Cardiovascular Imaging* 2019;**20**(Suppl 1):i167.

# Dina 2020 {published data only}

Dina A, Kennington A, Garrahy P, Chong A, Wahi S.311 Contrast enhancement of the Tricuspid Regurgitant (TR) spectral Doppler signal in pulmonary hypertension (PHTN) - waste of bubbles or truth be told? *Heart Lung and Circulation* 2020;**29**:S173.

# Doutreleau 2016 {published data only}

Doutreleau S, Canuet M, Enache I, Di Marco P, Lonsdorfer E, Oswald-Mammoser M, et al.Right heart hemodynamics in pulmonary hypertension - an echocardiography and catheterization study. *Circulation Journal* 2016;**80**(9):2019-25.

# Etxebeste 1989 {published data only}

Etxebeste J, Martinez J, Ruiz de Azua E, Urrengoetxea J, Arrillaga M, Ormaetxe J, et al.Diagnosis of pulmonary hypertension by means of continuous, pulsed and color Doppler, and its correlation with hemodynamics. *Revista Espanola de Cardiologia* 1989;**42**(2):90-7.

# Fauvel 2020 {published data only}

Fauvel C, Raitiere O, Burdeau J, Si Belkacem N, Bauer F.Impact of the new PH guidelines on echocardiographic definition leading to double demand of right heart catheterization. *European Heart Journal Cardiovascular Imaging* 2020;**21**(Suppl 1):jez319.951.

# Fei 2017 {published data only}

Fei BN, Fan T, Zhao L, Pei XL, Shu XH, Fang XY, et al.Impact of severe tricuspid regurgitation on accuracy of systolic pulmonary arterial pressure measured by Doppler echocardiography: analysis in an unselected patient population. *Echocardiography* 2017;**34**(7):1082-8.

# Finkelhor 2014 {published data only}

Finkelhor RS, Scrocco JD, Madmani M, Rovner A, Pillai D.Discordant doppler right heart catheterization pulmonary artery systolic pressures: importance of pulmonary capillary wedge pressure. *Echocardiography* 2014;**31**(3):279-84.

# Fisher 2004 {published data only}

Fisher MR, Forfia PR, Chamera E, Housten T, Champion HC, Resar J, et al.Accuracy of Doppler echocardiography in the hemodynamic evaluation of pulmonary hypertension. *Chest* 2004;**126**(4):883S.

# Fisher 2007 {published data only}

Fisher MR, Criner GJ, Fishman AP, Hassoun PM, Minai OA, Scharf SM, et al.Estimating pulmonary artery pressures by echocardiography in patients with emphysema. *European Respiratory Journal* 2007;**30**(5):914-21. [DOI: 10.1183/09031936.00033007]

# Fisher 2009 {published data only}

Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al.Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine* 2009;**179**(7):615-21. [DOI: 10.1164/ rccm.200811-1691OC]

# Fitzgerald 2012 {published data only}

Fitzgerald M, Fagan K, Herbert DE, Al-Ali M, Mugal M, Haynes J Jr.Misclassification of pulmonary hypertension in adults with sickle hemoglobinopathies using Doppler echocardiography. *Southern Medical Journal* 2012;**105**(6):300-5.

# Fontana 2013 {published data only}

Fontana A, Vincenzi A, Paciocco G, De Vito G, Marinari A, Trocino G, et al.Doppler echocardiography pulmonary artery flow acceleration time: an adjunctive parameter to select candidates with suspected pulmonary hypertension to proceed to right heart catheterization. *European Heart Journal* 2013;**34**:48.

# Gallet 1989 {published data only}

Gallet B, Saudemont JP, Bourdon D, Bayet G, Babo P, Thenault D, et al.Evaluation of pulmonary arterial hypertension by Doppler echocardiography in chronic respiratory insufficiency. *Archives des Maladies du Coeur et des Vaisseaux* 1989;**82**(9):1575-83.

# Ge 1993 {published data only}

Ge Z, Zhang Y, Fan D, Kang W, Hatle L, Duran C.Simultaneous measurement of pulmonary artery diastolic pressure by Doppler echocardiography and catheterization in patients with patent ductus arteriosus. *American Heart Journal* 1993;**125**(1):263-6.

# Gelape 2011 {published data only}

Gelape CL, Nunes Mdo C, Braulio R, Nogueira PH, Andrade SA, Machado PA, et al.Pulmonary pressure checked by echocardiography in chagasic patients on the heart transplant waiting list. *Revista Brasileira de Cirurgia Cardiovascular* 2011;**26**(1):54-60.

# **Glinel 2015** {*published data only*}

Glinel B, Bauer F.Pulmonary hypertension and transcatheter aortic valve implantation: prevalence, prognosis impact and evolution. *Archives of Cardiovascular Diseases Supplements* 2015;**7**(2):201.



# Gopal 2014 {published data only}

Gopal DM, Doldt B, Finch K, Simms RW, Farber HW, Gokce N.Relation of novel echocardiographic measures to invasive hemodynamic assessment in scleroderma-associated pulmonary arterial hypertension. *Arthritis Care and Research* 2014;**66**(9):1386-94.

# Granstam 2013 {published data only}

Granstam SO, Bjorklund E, Wikstrom G, Roos MW.Use of echocardiographic pulmonary acceleration time and estimated vascular resistance for the evaluation of possible pulmonary hypertension. *Cardiovascular Ultrasound* 2013;**11**:7. [DOI: 10.1186/1476-7120-11-7]

# Guvenc 2020 {published data only}

Guvenc TS, Poyraz E, Cetin Guvenc R, Can F.Contemporary usefulness of pulmonary venous flow parameters to estimate left ventricular end-diastolic pressure on transthoracic echocardiography. *International Journal of Cardiovascular Imaging* 2020;**36**(9):1699-709.

# Habash 2017 {published data only}

Habash F, Gurram P, Almomani A, Duarte-Rojo A, Hakeem A, Vallurupalli S, et al.Correlation between echocardiographic pulmonary artery pressure estimates and right heart catheterization measurements in patients undergoing liver transplant evaluation: a single center study. *Journal of the American College of Cardiology* 2017;**11**(Suppl 1):1888.

# Habash 2018 {published data only}

Habash F, Gurram P, Almomani A, Duarte A, Hakeem A, Vallurupalli S, et al.Correlation between echocardiographic pulmonary artery pressure estimates and right heart catheterization measurement in liver transplant candidates. *Journal of Cardiovascular Imaging* 2018;**26**(2):75-84.

# Hachulla 2004 {published data only}

Hachulla E, Gressin V, Guillevin L, De Groote P, Cabane J, Carpentier P, et al.Pulmonary arterial hypertension in systemic sclerosis: definition of a screening algorithm for early detection (the ItinerAIR-Sclerodermie Study). *Revue de Medecine Interne* 2004;**25**(5):340-7.

# Hachulla 2005 {published data only}

Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al.Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. *Arthritis and Rheumatism* 2005;**52**(12):3792-800.

# Held 2014 {published data only}

Held M, Linke M, Jany B.Echocardiography and right heart catheterization in pulmonal hypertension. *Deutsche Medizinische Wochenschrift* (1946) 2014;**139**(30):1511-7.

# Hilde 2012 {published data only}

Hilde JM, Skjoerten IS, Melsom MNM, Humerfelt SH, Hansteen VH, Hisdal JH, et al.Noninvasive assessment of pulmonary arterial compliance and its impact on right ventricular function in COPD patients. *European Heart Journal. Cardiovascular Imaging* 2012;**13**:i118.

# Hsu 2004 {published data only}

Hsu VM, Shinnar M, Moreyra A, Shindler D, Wilson A, Wilson JE, et al.Assessment of pulmonary hypertension (PH) in systemic sclerosis (SSc): a comparison of Doppler echocardiography, cardiac MRI and right heart catheterization. *Arthritis and Rheumatism* 2004;(9):S424.

# Hua 2009 {published data only}

Hua R, Sun YW, Wu ZY, Cheng W, Xu Q, Cao H, et al.Role of 2-dimensional Doppler echo-cardiography in screening portopulmonary hypertension in portal hypertension patients. *Hepatobiliary & Pancreatic Diseases International* 2009;**8**(2):157-61.

# Jiang 2017 {published data only}

Jiang R, Wu C, Pudasaini B, Wang L, Zhao QH, Zhang R, et al.A novel scoring index by Doppler echocardiography for predicting severe pulmonary hypertension due to chronic lung diseases: a cross-sectional diagnostic accuracy study. *International Journal* of Chronic Obstructive Pulmonary Disease 2017;**12**:1741-51.

# Julien 2015 {published data only}

Julien HM, Fields A, Siu H, Scharf M, Mehrotra P.Right ventricular fractional area change predicts invasivelydetermined hemodynamics in patients with pulmonary arterial hypertension. *Journal of the American College of Cardiology* 2015;**65**(10 Suppl 1):A1566.

# Junsirimongkol 2019 {published data only}

Junsirimongkol B, Cheewatanakornkul S, Jamulitrat S.Comparison of performances among five prediction formulae using echocardiography in estimation of mean pulmonary arterial pressure. *European Heart Journal Cardiovascular Imaging* 2019;**20**(Suppl 1):i363.

# Khanduja 2012 {published data only}

Khanduja K, Lakshmanan RV, Roscoe A, Srinivas C, Therapondos G, McCluskey SA.Does the severity of tricuspid regurgitation affect the correlation and agreement between pulmonary systolic artery pressures estimated transthoracic echocardiography and intra-operative right heart catherization? *Canadian Journal of Anesthesia* 2012;**59**(Suppl 1):188.

# Kim 2000 {published data only}

Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, et al.Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. *Liver Transplantation* 2000;**6**(4):453-8.

# Kim 2013 {published data only}

Kim SM, Faulkner M, Booth D, Campbell C, Hundley J, Charnigo R, et al.Can we rule out significant pulmonary hypertension in liver transplant candidates noninvasively? *Journal of the American College of Cardiology* 2013;**61**(10):E1289.

# Kooranifar 2021 {published data only}

Kooranifar S, Naghshin R, Sezavar SH, Hajsadeghi S, Talebzadeh SM.Diagnostic value of chest spiral CT scan and Doppler echocardiography compared to right heart catheterization to predict pulmonary arterial



hypertension in patients with scleroderma. *Acta Bio-Medica* 2021;**92**(1):e2021074.

# Kovacs 2014 {published data only}

Kovacs G, Avian A, Foris V, Tscherner M, Kqiku X, Douschan P, et al.Role of simple non-invasive tools to assess pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine* 2014;**189**::A4750.

# Krowka 1999 {published data only}

Krowka MJ, Kim WR, Wiesner RH, McGoon MD, Frantz RP.Screening Doppler echocardiography to detect pulmonary hypertension in liver transplant candidates. *American Journal of Respiratory and Critical Care Medicine* 1999;**3**:A155.

# Laaban 1989 {published data only}

Laaban JP, Diebold B, Lafay M, Rochemaure J, Peronneau P.Detection of pulmonary hypertension by Doppler echocardiography of the inferior vena cava in chronic airflow obstruction. *Thorax* 1989;**44**(5):396-401.

# Laaban 1989a {published data only}

Laaban JP, Diebold B, Zelinski R, Lafay M, Raffoul H, Rochemaure J.Noninvasive estimation of systolic pulmonary artery pressure using Doppler echocardiography in patients with chronic obstructive pulmonary disease. *Chest* 1989;**96**(6):1258-62.

# Lamia 2014 {published data only}

Lamia B, Molano LC, Viacroze C, Gounane C, Cuvelier A, Muir JF.Relevance of echocardiographic composite index to improve the detection of pulmonary hypertension. In: European Respiratory Society 24th Annual Congress; 2014 Sep 6-10; Munich. 2014.

# Lange 2013 {published data only}

Lange TJ, Baumgartner S, Arzt M, Pfeifer M.Qualitative echocardiography parameters for prediction of pulmonary hypertension. *International Journal of Clinical Practice* 2013;**67**(Suppl 179):5-12.

# Lanzarini 2005 {published data only}

Lanzarini L, Fontana A, Campana C, Klersy C.Two simple echo-Doppler measurements can accurately identify pulmonary hypertension in the large majority of patients with chronic heart failure. *Journal of Heart and Lung Transplantation* 2005;**24**(6):745-54.

# Li 1988 {published data only}

Li LG.Pulmonary hypertension measured by Doppler echocardiography. *Chung-hua Hsin Hsueh Kuan Ping Tsa Chih* [*Chinese Journal of Cardiology*] 1988;**16**(1):39-40.

# Lindgren 2009 {published data only}

Lindgren F, Rundqvist B, Petersson S, Selimovic N, Bech-Hanssen O.Pressure increase after peak velocity in the pulmonary artery: a novel echocardiography method to identify patients with increased pulmonary vascular resistance. *European Heart Journal* 2009;**30**:897.

# Lindqvist 2011 {published data only}

Lindqvist P, Soderberg S, Gonzalez M, Tossavainen E, Henein MY.Doppler echocardiography based estimation of pulmonary vascular resistance in patients with pulmonary hypertension: a simultaneous echocardiographic and cardiac catheterization study. *European Heart Journal. Cardiovascular Imaging* 2011;**12**:ii51.

# Lindqvist 2012 {published data only}

Lindqvist P, Henein M, Soderberg S, Tossavainen E, Gonzalez M, Henein MY.Echo-based estimation of pulmonary vascular resistance and pulmonary capillary wedge pressure correlate closely with catheter-based measurements. *European Heart Journal. Cardiovascular Imaging* 2012;**13**:i167-8.

# Lindqvist 2013 {published data only}

Lindqvist P, Tossavainen E, Gonzalez M, Henein M, Soderberg S.Echo-based estimation of pulmonary vascular resistance and pulmonary capillary wedge pressure correlate closely with catheter-based measurements. *Scandinavian Cardiovascular Journal* 2013;**47**:1-2.

# Maeder 2010 {published data only}

Maeder MT, Htun NM, Karapanagiotidis S, Dewar L, Kaye DM.Accuracy of non-invasive right heart catheterisation to predict haemodynamics in subjects with normal left ventricular ejection fraction. *European Heart Journal* 2010;**31**:725.

# Maeder 2011 {published data only}

Maeder MT, Karapanagiotidis S, Dewar EM, Gamboni SE, Htun N, Kaye DM.Accuracy of Doppler echocardiography to estimate key hemodynamic variables in subjects with normal left ventricular ejection fraction. *Journal of Cardiac Failure* 2011;**17**(5):405-12.

# Marangoni 1988 {published data only}

Marangoni S, Quadri A, Dotti A, Scalvini S, Volterrani M, Schena M, et al.Noninvasive assessment of pulmonary hypertension: a simultaneous echo-Doppler hemodynamic study. *Cardiology* 1988;**75**(6):401-8.

# Matos 1988 {published data only}

Matos P, Pereira A, De Oliveira LM, Ramos JS, Quininha J, Ferreira T, et al.Pulsed 2D Doppler echocardiography in pulmonary arterial hypertension. *Revista Portuguesa de Cardiologia* 1988;**7**(5):479-84.

# McClanahan 2011 {published data only}

McClanahan A, Guglin M.Right ventricular dysfunction compromises accuracy of echocardiographic diagnosis of pulmonary hypertension in heart failure. *Journal of Cardiac Failure* 2011;**17**(12):1023-7.

# Mercado 2019 {published data only}

Mercado P, Maizel J, Beyls C, Kontar L, Orde S, Huang S, et al.Reassessment of the accuracy of cardiac Doppler pulmonary artery pressure measurements in ventilated ICU patients: a simultaneous doppler-catheterization study. *Critical Care Medicine* 2019;**47**(1):41-8.



# Metz 1987 {published data only}

Metz D, Laudinat JM, Beruben E, Marchal E, Blaise C, Deschildre A, et al.Evaluation of pulmonary systolic arterial pressures by continuous Doppler in tricuspid regurgitation in adults. Apropos of 43 cases. *Archives des Maladies du Coeur et des Vaisseaux* 1987;**80**(11):1605-9.

# Metz 1991 {published data only}

Metz D, Chapoutot L, Ouzan J, Chabert JP, Pollet E, Elaerts J, et al.Doppler echocardiographic assessment of the severity of acute pulmonary embolism. A correlative angiographic study in forty-eight adult patients. *American Journal of Noninvasive Cardiology* 1991;**5**(4):223-8.

# Minai 2010 {published data only}

Minai OA, Criner GJ, Scharf SM, Fessler H, Meli Y, Nutter B, et al.Pulmonary hemodynamics in moderate to severe emphysema: characteristics and predictors. In: American Thoracic Society International Conference; 2010 May 14-19; New Orleans. 2010:181.

# Miyamoto 1993 {published data only}

Miyamoto K, Aida A, Kawakami Y.Diagnosis of cor pulmonale by echocardiography. *Nippon Naika Gakkai Zasshi (Journal of Japanese Society of Internal Medicine)* 1993;**82**(6):818-23.

# Mo 2015b {published data only}

Mo VY, Fisher JM, Balekian AA.Pulmonary artery acceleration time and right ventricular ejection time for the echocardiographic screening of elevated pulmonary vascular resistance in patients with right ventricular systolic failure. *American Journal of Respiratory and Critical Care Medicine* 2015;**191**:A4856.

# Modrykamien 2010 {published data only}

Modrykamien AM, Gudavalli R, McCarthy K, Parambil J.Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. *Respiratory Care* 2010;**55**(5):584-8.

# Mogollon 2008 {published data only}

Mogollón Jiménez MV, Escoresca Ortega AM, Cabeza Letrán ML, Hinojosa Pérez R, Lage Gallé E, Sobrino Márquez JM.Correlation of echocardiographic and haemodynamic parameters in pulmonary hypertension assessment prior to heart transplantation. *Transplant Proceedings* 2008;**40**:3023e4.

# Mukerjee 2004 {published data only}

Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM.Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. *Rheumatology* 2004;**43**:461e6.

# Naeije 1995 {published data only}

Naeije R, Torbicki A.More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. *European Respiratory Journal* 1995;**8**(9):1445-9.

# Nathan 2008 {published data only}

Nathan SD, Shlobin OA, Barnett SD, Saggar R, Belperio JA, Ross DJ, et al.Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. *Respiratory Medicine* 2008;**102**:1305–10.

# Niederle 1988 {published data only}

Niederle P, Starek A, Jezek V, Hes I.Doppler echocardiography in the diagnosis of pulmonary hypertension. *Vnitrni Lekarstvi* 1988;**34**(10):950-6.

#### Niederle 1990 {published data only}

Niederle P, Jezek V, Jezkova J.Estimation of systolic pressure in the right ventricle (pulmonary artery) using Doppler and its importance in the detection of pulmonary hypertension. *Casopis Lekaru Ceskych* 1990;**129**(49):1553-6.

# Nishimaki 1991 {published data only}

Nishimaki T, Aotsuka S, Kunieda T, Yokohari R.Preliminary criteria for the diagnosis of pulmonary hypertension in mixed connective tissue disease. *Ryumachi* [*Rheumatism*] 1991;**31**(2):159-66.

# Nogami 2009 {published data only}

Nogami M, Ohno Y, Koyama H, Kono A, Takenaka D, Kataoka T, et al.Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography. *Journal of Magnetic Resonance Imaging* 2009;**30**(5):973e80.

# O'Leary 2018 {published data only}

O'Leary JM, Assad TR, Xu M, Farber-Eger E, Wells QS, Hemnes AR, et al.Lack of a tricuspid regurgitation doppler signal and pulmonary hypertension by invasive measurement. *Journal of the American Heart Association* 2018;**7**(13):e009362. [DOI: 10.1161/JAHA.118.009362]

# Okubo 1988 {published data only}

Okubo S, Nakayama R.Modern Doppler echocardiography as a diagnostic aid for cor pulmonale. *Rinsho Byori (Japanese Journal of Clinical Pathology)* 1988;**36**(5):573-7.

#### Okubo 1989 {published data only}

Okubo S, Miyatake K, Nagata S, Nakanishi N, Yoshioka T, Kunieda T.Role of echocardiography in acute pulmonary embolism. *Japanese Heart Journal* 1989;**30**(5):655-64.

#### Oudiz 2003 {published data only}

Oudiz RJ, Ginzton L.Pulmonary artery systolic pressure estimated by echocardiogram vs catheterization in patients awaiting lung transplantation. *Journal of Heart and Lung Transplantation* 2003;**22**(7):832-3; author reply 833.

#### Pande 2014 {published data only}

Pande A, Sarkar A, Ahmed I, Naveen Chandra G, Patil SK, Kundu CK, et al.Non-invasive estimation of pulmonary vascular resistance in patients of pulmonary hypertension in congenital heart disease with unobstructed pulmonary flow. *Annals of Pediatric Cardiology* 2014;**7**(2):92-7.



# Parsaee 2016 {published data only}

Parsaee M, Ghaderi F, Alizadehasl A, Bakhshandeh H.Time from the beginning of the right ventricle isovolumetric contraction to the peak of the S wave: a new TDI indicator for the noninvasive estimation of pulmonary hypertension. *Research in Cardiovascular Medicine* 2016;**5**(3):e26494.

# Pasierski 1993 {published data only}

Pasierski TJ, Starling RC, Binkley PF, Pearson AC.Echocardiographic evaluation of pulmonary artery distensibility. *Chest* 1993;**103**(4):1080-3.

# Penning 2001 {published data only}

Penning S, Robinson KD, Major CA, Garite TJ.A comparison of echocardiography and pulmonary artery catheterization for evaluation of pulmonary artery pressures in pregnant patients with suspected pulmonary hypertension. *American Journal of Obstetrics and Gynecology* 2001;**184**:1568e70.

# Phetcharat 2019 {published data only}

Phetcharat S, Kavouras C, Ilagan L, Roxy S, Wort J, Gatzoulis M, et al.Echocardiographic assessment of pulmonary pressures: the value of pulmonary regurgitation and pulmonary acceleration time. *European Heart Journal Cardiovascular Imaging* 2019;**20**(Suppl 1):i35.

# Philip 2013 {published data only}

Philip RT, Balekian A.Utility of trans-thoracic Doppler echocardiography in avoiding invasive right heart catheterization in end-stage liver disease patients undergoing evaluation for liver transplantation. *American Journal of Respiratory and Critical Care Medicine* 2013;**187**:A2542.

# Polak-Slaboszewska 1989 {published data only}

Polak-Slaboszewska D, Bolinska H, Moczak R, Kowalewski J, Radominski S, Kaczmarek A.Usefulness of Doppler echocardiography for evaluation of pulmonary hypertension based on the analysis of blood flow through the pulmonary artery. *Kardiologia Polska* 1989;**32**(5):248-54.

# Prasanna 2009 {published data only}

Prasanna V, Opotowsky A, Ojeda J, Arkles J, Palevsky H, Taichman D, et al.Echo-Doppler scoring system provides simple noninvasive assessment of the pathophysiology of pulmonary hypertension in a mixed pulmonary hypertension cohort. *Chest* 2009;**136**(4):32S.

# Raevens 2013 {published data only}

Raevens S, Colle I, Geerts A, Reyntjens K, Troisi R, Berrevoet F, et al.Detection of portopulmonary hypertension in liver transplant candidates with echocardiography. In: 32nd Annual Scientific Meeting of the Belgian Society of Cardiology; 2013 Jan 31-1 Feb; Brussels. 2013:118.

# Raevens 2013a {published data only}

Raevens S, Colle I, Reyntjens K, Geerts A, Berrevoet F, Rogiers X, et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values. *Liver Transplantation* 2013;**19**(6):602-10.

# Rajagopalan 2009 {published data only}

Rajagopalan N, Simon MA, Suffoletto MS, Shah H, Edelman K, Mathier MA, et al.Noninvasive estimation of pulmonary vascular resistance in pulmonary hypertension. *Echocardiography* 2009;**26**(5):489-94.

# Rallidis 2020 {published data only}

Rallidis L, Papangelopoulou K, Anthi A, Makavos G, Konstantonis D, Tsangaris I, et al.Is there any role of exercise Doppler echocardiography to unmask pulmonary hypertension (PH) in patients with systemic sclerosis and baseline echocardiographic measurements for PH in the gray zone? *European Heart Journal Cardiovascular Imaging* 2020;**21**(Suppl 1):jez319.1146.

# Rallidis 2021 {published data only}

Rallidis LS, Papangelopoulou K, Anthi A, Tsangaris I, Varounis C, Makavos G, et al.The role of exercise Doppler echocardiography to unmask pulmonary arterial hypertension in selected patients with systemic sclerosis and equivocal baseline echocardiographic values for pulmonary hypertension. *Diagnostics* 2021;**11**(7):1200.

# Refini 2021 {published data only}

Refini RM, Bettini G, Kacerja E, Cameli P, D'Alessandro M, Bergantini L, et al.The role of the combination of echo-HRCT score as a tool to evaluate the presence of pulmonary hypertension in idiopathic pulmonary fibrosis. *Internal and Emergency Medicine* 2021;**16**(4):941-7.

# Rich 2010 {published data only}

Rich J, Shah S, Swamy R, Kamp A, Rich S.Doppler echocardiographic estimates of pulmonary artery systolic pressure in patients with pulmonary hypertension are inaccurate. In: American Thoracic Society International Conference; 2010 May 14-19; New Orleans. 2010:181.

#### Rich 2011 {published data only}

Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S.Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. *CHEST* 2011;**139**(5):988-93. [DOI: 10.1378/chest.10-1269]

# Roodpeyma 2015 {published data only}

Roodpeyma S, Mojtahedzadeh S, Rafieyian S, Behbahani SR.Accuracy of electrocardiography and echocardiography in the assessment of pulmonary arterial hypertension in patients with congenital heart disease. *Iranian Heart Journal* 2015;**15**(4):20-5.

# **Saner 2006** {*published data only*}

Saner FH, Nadalin S, Pavlakovic G, Gu Y, Olde Damink SW, Gensicke J, et al.Portopulmonary hypertension in the early phase following liver transplantation. *Transplantation* 2006;**82**(7):887-91.

#### Schewel 2020 {published data only}

Schewel J, Schluter M, Schmidt T, Kuck KH, Frerker C, Schewel D.Correlation between Doppler echocardiography and right heart catheterization assessment of systolic pulmonary



artery pressure in patients with severe aortic stenosis. *Echocardiography* 2020;**37**(3):380-7.

# Schiopu 2010 {published data only}

Schiopu E, Impens AJ, Rubenfire M, Mahmood F, Phillips K.Comparison of estimated pulmonary artery systolic pressure by echocardiography (PASPECHO) and right heart catheterization (PASPRHC) in patients with systemic sclerosis (scleroderma, SSc). *Arthritis and Rheumatism* 2010;**62**:567.

# Seidova 2020 {published data only}

Seidova N, Manouras A, Lund LH, Venkateshvaran A.Comparison between echocardiographic right ventricular-pulmonary arterial coupling and right ventricular longitudinal strain to identify pulmonary hypertension in heart failure. *European Heart Journal Cardiovascular Imaging* 2020;**21**(Suppl 1):i988.

# Selby 2012 {published data only}

Selby VN, Scherzer R, Barnett CF, MacGregor JS, Morelli J, Donovan C, et al.Doppler echocardiography does not accurately estimate pulmonary artery systolic pressure in HIV-infected patients. *AIDS* 2012;**26**(15):1967-9.

# Shen 1989 {published data only}

Shen XD, Jiang L, He J.A quantitative study of pulmonary artery systolic pressure in patients with tricuspid regurgitation using continuous wave Doppler. *Chung-hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]* 1989;**17**(6):347-9, 382.

# Shim 2018 {published data only}

Shim CY.Issues on estimated pulmonary artery pressure in liver transplant candidates. *Journal of Cardiovascular Imaging* 2018;**26**(2):61-2.

# Skjaerpe 1986 {published data only}

Skjaerpe T, Hatle L.Noninvasive estimation of systolic pressure in the right ventricle in patients with tricuspid regurgitation. *European Heart Journal* 1986;**7**:704-10.

# Slegg 2021 {published data only}

Slegg O, Willis J, Gibson C, Kendler-Rhodes A, Wilkinson F, Rossdale J, et al.Audit of echocardiographic probability of pulmonary hypertension in a real world population referred to a specialist centre. *Heart (British Cardiac Society)* 2021;**107**:A62-4.

# Sohrabi 2016 {published data only}

Sohrabi B, Kazemi B, Mehryar A, Teimouri-Dereshki A, Toufan M, Aslanabadi N.Correlation between pulmonary artery pressure measured by echocardiography and right heart catheterization in patients with rheumatic mitral valve stenosis (a prospective study). *Echocardiography* 2016;**33**(1):7-13.

# Solik 2013 {published data only}

Solik P, Lesny P, Luknar M, Varga I, Wimmerova S, Goncalvesova E.Pulmonary artery systolic pressure - direct measurement versus echocardiographic estimation in patients with pulmonary arterial hypertension and pulmonary venous hypertension. *Cardiology Letters* 2013;**22**(6):459-65.

# Sonaglioni 2021 {published data only}

Sonaglioni A, Cassandro R, Luisi F, Ferrante D, Nicolosi GL, Lombardo M, et al.Correlation between Doppler echocardiography and right heart catheterisation-derived systolic and mean pulmonary artery pressures: determinants of discrepancies between the two methods. *Heart, Lung & Circulation* 2021;**30**(5):656-64.

# Torbicki 1987 {published data only}

Torbicki A, Pasierski T, Miskiewicz Z.Noninvasive evaluation of blood pressure in the pulmonary artery using a Doppler method. *Kardiologia Polska* 1987;**30**(12):783-90.

# Torbicki 1989 {published data only}

Torbicki A, Skwarski K, Hawrylkiewicz I, Pasierski T, Miskiewicz Z, Zielinski J.Attempts at measuring pulmonary arterial pressure by means of Doppler echocardiography in patients with chronic lung disease. *European Respiratory Journal* 1989;**2**(9):856-60.

# Torregrosa 2001 {published data only}

Torregrosa M, Genesca J, Gonzalez A, Evangelista A, Mora A, Margarit C, et al.Role of Doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. *Transplantation* 2001;**71**(4):572-4.

# Tramarin 1991 {published data only}

Tramarin R, Torbicki A, Marchandise B, Laaban JP, Morpurgo M.Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. A European multicentre study. *European Heart Journal* 1991;**12**:103–11.

# Wahi 2015 {published data only}

Wahi S, Chong A.Direct comparison of non-invasive estimation of mean pulmonary artery pressure with right heart catheter measurements - which echocardiographic technique is best? *European Heart Journal Cardiovascular Imaging* 2015;**16**:ii154.

# Wang 2016 {published data only}

Wang B, Zhou HX, Yang J, Liang BM, Feng YL.Accuracy of doppler echocardiography in the assessment of pulmonary arterial hypertension in patients with congenital heart disease. *Chest* 2016;**149**(4 Suppl 1):509A.

# Wilansky 1998 {published data only}

Wilansky S.Two-dimensional and Doppler echocardiography for the assessment of congestive heart failure. *Texas Heart Institute Journal* 1998;**25**(4):260-4.

# Wurtemberger 1992 {published data only}

Wurtemberger G, Tiede N, Wencker M, Mathys H.Pulmonary hypertension in patients with chronic lung disease. Validity of Doppler echocardiography. *Atemwegs - und Lungenkrankheiten* 1992;**18**(11):489-95.

# Wylie 2007 {published data only}

Wylie BJ, Epps KC, Gaddipati S, Waksmonski CA.Correlation of transthoracic echocardiography and right heart catheterization in pregnancy. *Journal of Perinatal Medicine* 2007;**35**(6):497-502.



# Yagi 1988 {published data only}

Yagi H, Yamada H, Ookubo S, Koyama S, Kawashima A, Fukushima M, et al.Noninvasive prediction of pulmonaryhypertension induced by hypoxic breathing in subjects susceptible to high-altitude pulmonary-edema by Doppler echocardiography and the role of prostanoids. *Japanese Circulation Journal* 1988;**9**:1023.

# Yamamoto 2013 {published data only}

Yamamoto S, Matsumoto Y, Nochioka K, Miura M, Tatebe S, Sugimura K, et al.Potential involvement of functional tricuspid regurgitation in the diagnostic error to assess pulmonary arterial pressure by Doppler echocardiography. *Life Sciences* 2013;**93**(25-6):e44.

# Yamamoto 2013a {published data only}

Yamamoto S, Matsumoto Y, Nochioka K, Miura M, Tatebe S, Sugimura K, et al.Potential involvement of functional tricuspid regurgitation in the diagnostic error to assess pulmonary arterial pressure by Doppler echocardiography. *European Heart Journal* 2013;**34**:37.

#### Yock 1984 {published data only}

Yock P, Popp R.Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. *Circulation* 1984;**70**:657–62.

# Zenker 1987 {published data only}

Zenker G, Metzler H, Stenzl W, Rehak F, Gombotz H, Forche G, et al.Quantifying pulmonary artery hypertension by Doppler echocardiography measurement of tricuspid valve insufficiency. *Wiener Medizinische Wochenschrift* 1987;**103**:42-3.

# Zhuravlev 2004 {published data only}

Zhuravlev VF, Zhuravleva NV.A new technique for evaluation of the functional state of the cardiovascular system. *Biomedical Engineering* 2004;**38**(4):187-92.

# Zompatori 1993 {published data only}

Zompatori M, Rimondi MR, Canini R, Battaglia M.Chronic cor pulmonale in obstructive lung disease. Diagnostic evaluation with Doppler echography and other non-invasive imaging techniques. *Radiologia Medica* 1993;**85**(3):247-53.

# **Additional references**

# Andersen 2012

Andersen KH, Iversen M, Kjaergaard J, Mortensen J, Nielsen-Kudsk JE, Bendstrup E, et al.Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. *Journal of Heart Lung Transplantation* 2012;**31**(4):373-80.

# Avouac 2010

Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and meta-analysis of 5 studies. *Journal of Rheumatology* 2010;**37**(11):2290-8.

# Benza 2010

Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al.Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). *Circulation* 2010;**122**(2):164-72.

# Berger 1985

Berger M, Haimowitz A, Van A, Berdoff RL, Goldberg E.Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. *Journal of the American College of Cardiology* 1985;**6**(2):359-65. [DOI: 10.1016/ S0735-1097(85)80172-8]

# Best 2018

Best LM, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B, et al.Non-invasive diagnostic tests for Helicobacter pylori infection. *Cochrane Database of Systematic Reviews* 2018, Issue 3. Art. No: CD012080. [DOI: 10.1002/14651858.CD012080.pub2]

#### Beynon 2013

Beynon R, Leeflang MM, McDonald S, Eisinga A, Mitchell RL, Whiting P, et al.Search strategies to identify diagnostic accuracy studies in MEDLINE and EMBASE. *Cochrane Database of Systematic Reviews* 2013, Issue 9. Art. No: MR000022. [DOI: 10.1002/14651858.MR000022.pub3]

# Brown 2011

Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, et al.Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry. *Chest* 2011;**140**(1):19-26. [DOI: 10.1378/chest.10-1166]

# Bursi 2012

Bursi F, McNallan SM, Redfield MM, Nkomo VT, Lam CS, Weston SA, et al.Pulmonary pressures and death in heart failure: a community study. *Journal of the American College of Cardiology* 2012;**59**(3):222-31.

#### Connors 1996

Connors AF, Speroff T, Dawson NV, Thomas C, Harrell FE, Wagner D, et al, SUPPORT Investigators. The effectiveness of right heart catheterization in the initial care of critically ill patients. *JAMA* 1996;**276**(11):889-97. [DOI: 10.1001/ jama.1996.03540110043030]

# De Vet 2008

De Vet HCW, Eisinga A, Riphagen II, Aertgeerts B, Pewsner D, editor(s).Chapter 7: Searching for studies. In: Deeks JJ, Bossuyt PM, Gatsonis C, editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2013. Available from methods.cochrane.org/sdt/ handbook-dta-reviews.

# Deeks 2013

Deeks JJ, Bossuyt PM, Gatsonis C (editors).Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2013. Available from srdta.cochrane.org.
#### Delcroix 2010

Delcroix M, Naeije R.Optimising the management of pulmonary arterial hypertension patients: emergency treatments. *European Respiratory Review* 2010;**19**(117):204-11.

#### Dzudie 2014

Dzudie A, Kengne AP, Thienemann F, Sliwa K.Predictors of hospitalisations for heart failure and mortality in patients with pulmonary hypertension associated with left heart disease: a systematic review. *BMJ Open* 2014;**4**(7):e004843.

#### Freed 2016

Freed BH, Collins JD, Francois CJ, Barker AJ, Cuttica MJ, Chesler NC, et al.MR and CT imaging for the evaluation of pulmonary hypertension. *Journal of the American College of Cardiology: Cardiovascular Imaging* 2016;**9**(6):715-32. [DOI: 10.1016/j.jcmg.2015.12.015]

#### Galie 2013

Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al.Updated treatment algorithm of pulmonary arterial hypertension. *Journal of the American College of Cardiology* 2013;**62**(25 Suppl):D60-72. [DOI: 10.1016/j.jacc.2013.10.031]

#### Galie 2016

Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). *European Heart Journal* 2016;**37**(1):67-119. [DOI: 10.1093/eurheartj/ehv317]

#### Heazell 2019

Heazell AEP, Hayes DJL, Whitworth M, Takwoingi Y, Bayliss SE, Davenport C.Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants. *Cochrane Database of Systematic Reviews* 2019, Issue 5. Art. No: CD012245. [DOI: 10.1002/14651858.CD012245.pub2]

#### Hoeper 2013

Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al.Definitions and diagnosis of pulmonary hypertension. *Journal of the American College of Cardiology* 2013;**62**(25 Suppl):D42-50. [DOI: 10.1016/j.jacc.2013.10.032]

#### Humbert 2006

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al.Pulmonary arterial hypertension in France: results from a national registry. *American Journal of Respiratory Care Medicine* 2006;**173**(9):1023.

#### Janda 2011

Janda S, Shahidi N, Gin K, Swiston J.Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis. *Heart* 2011;**97**:612-22.

#### Kaplan 2010

Kaplan A, Mc Lean A, Vieillard-Baron A.Hemodynamic Monitoring Using Echocardiography in the Critically Ill. Berlin, Heidelberg: Springer, 2010. [DOI: 10.1007/978-3-540-87956-5\_13]

#### Lang 2015

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al.Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Journal of the American Society of Echocardiography* 2015;**28**(1):1-39.e14.

#### Lewis 2016

Lewis R, William H.Clinical features and diagnosis of pulmonary hypertension in adults. www.uptodate.com/contents/clinicalfeatures-and-diagnosis-of-pulmonary-hypertension-in-adults (accessed 6 December 2016).

## Ling 2012

Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS.Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine* 2012;**186**(8):790-6.

# Macaskill 2021

Macaskill P, Takwoingi Y, Deeks JJ, Gatsonis C.Chapter 10: Understanding meta-analysis draft version (17 June 2021). In: Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y, editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 2. Cochrane, 2021. Available from srdta.cochrane.org.

#### Marcus 2008

Marcus JT, Gan CT, Zwanenburg JJ, Boonstra A, Allaart CP, Gotte MJW.Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. *Journal of the American College of Cardiology* 2008;**51**:750-7.

#### McLaughlin 2009

McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J.ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. *Journal of the American College of Cardiology* 2009;**53**(17):1573-619.

#### Meredith 2014

Meredith EP, Lakshmi S, Li W, Ivan MR, John HN, Anna RH.Causes of pulmonary hypertension in the elderly. *CHEST* 2014;**146**(1):159-66. [DOI: 10.1378/chest.13-1900]

#### Molano 2019

Molano Franco D, Arevalo-Rodriguez I, Roque I Figuls M, Montero Oleas NG, Nuvials X, Zamora J.Plasma interleukin-6 concentration for the diagnosis of sepsis in critically ill adults. *Cochrane Database of Systematic Reviews* 2019, Issue 4. Art. No: CD011811. [DOI: 10.1002/14651858.CD011811.pub2]



#### Moreira 2015

Moreira EM, Gall H, Leening MJ, Lahousse L, Loth DW, Krijthe BP, et al.Prevalence of pulmonary hypertension in the general population: the Rotterdam study. *PLOS One* 2015;**10**(6):e0130072.

#### Paulus 2007

Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the heart failure and echocardiography. *European Heart Journal* 2007;**28**:2539-50.

#### Peacock 2007

Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S.An epidemiological study of pulmonary arterial hypertension. *European Respiratory Journal* 2007;**30**:104-9.

#### Reitsma 2005

Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH.Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. *Journal of Clinical Epidemiology* 2005;**58**(10):982-90.

#### Review Manager 2014 [Computer program]

Review Manager.Version 5.3. Copenhagen: Nordic Cochrane Center, The Cochrane Collaboration, 2014.

#### Rubin 2016

Rubin LJ, Hopkins W.Clinical features and diagnosis of pulmonary hypertension in adults. www.uptodate.com/ contents/clinical-features-and-diagnosis-of-pulmonaryhypertension-in-adults (accessed 24 Jan 2017).

#### Rudski 2010

Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al.Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *Journal of the American Society of Echocardiography* 2010;**23**(7):685-713. [DOI: 10.1016/ j.echo.2010.05.010]

#### Rutjes 2005

Rutjes AWS, Reitsma JB, Vandenbrouke JP, Glas AS, Bossuyt PMM.Case-control and two-gate designs in diagnostic

#### CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

#### Amsallem 2016

Study characteristics

accuracy studies. *Clinical Chemistry* 2005;**51**(8):1335-41. [DOI: 10.1373/clinchem.2005.048595]

#### Rutter 2001

Rutter CM, Gatsonis CA.A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. *Statistics in Medicine* 2001;**20**(19):2865-84.

#### Schermuly 2011

Schermuly RT, Janssen W, Weissmann N, Stasch JP, Grimminger F, Ghofrani HA.Riociguat for the treatment of pulmonary hypertension. *Expert Opinion on Investigational Drugs* 2011;**20**(4):567-76.

#### Simonneau 2013

Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al.Updated clinical classification of pulmonary hypertension. *Journal of the American College of Cardiology* 2013;**62**(25 Suppl):D34-41. [DOI: 10.1016/j.jacc.2013.10.029]

#### Stata 2013 [Computer program]

Stata.Version 13.0. College Station (TX): Stata Corporation, 2013.

#### Taleb 2013

Taleb M, Khuder S, Tinkel J, Khouri SJ.The diagnostic accuracy of Doppler echocardiography in assessment of pulmonary artery systolic pressure: a meta-analysis. *Echocardiography* 2013;**30**(3):258-65.

#### Testani 2010

Testani JM, St John Sutton MG, Wiegers SE, Khera AV, Shannon RP, Kirkpatrick JN.Accuracy of noninvasively determined pulmonary artery systolic pressure. *American Journal of Cardiology* 2010;**105**(8):1192-7.

#### Torbicki 2007

Torbicki A.Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction. *European Heart Journal* 2007;**28**:1187-9.

#### Whiting 2011

Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Annals of Internal Medicine* 2011;**155**(8):529-36. [PMID: 22007046]

#### Zhang 2010

Zhang RF, Zhou L, Ma GF, Shao FC, Wu XH, Ying KJ.Diagnostic value of transthoracic Doppler echocardiography in pulmonary hypertension: a meta-analysis. *American Journal of Hypertension* 2010;**23**:1261-4. [DOI: 10.1038/ajh.2010.188]



Amsallem 2016 (Continued)		
Patient Sampling	Retrospective	
Patient characteristics and setting	Study location: USA	
	Study periods: between 2001 and 2012	
	<b>Care setting:</b> the Stanford University Advanced Lung Disease centre, Kosuyolu Training Hospital	
	Participants enrolled: 307: 125 males and 182 females	
	Participants included in analysis: 199: gender not reported	
	<b>Age:</b> mean age 50 ± 13 years	
	BMI: not reported	
	Classification of PH defined by WHO (diagnosis from right-heart catheterisation): not re- ported	
	Number of patients with asymptomatic or mild symptom: not reported	
	Number of participants with COPD: not reported	
	Number of intubated participants: 0	
	<b>Inclusion criteria:</b> All participants aged ≥ 18 years referred to the Stanford University Ad- vanced lung disease centre for right-heart catheterisation and with right-heart catheterisa- tion and complete echocardiography within 5 days	
	Exclusion criteria: not reported	
Index tests	<b>Description of index test:</b> Resting trans-thoracic echocardiography was performed using the Philips 7500 or iE33 system (Philips Medical Systems, Andover, MA) with 5-MHz trans- ducers by experienced, credentialed cardiac sonographers. Right ventricular systolic pres- sure was estimated from the maximal right ventricular-right atrial pressure gradient, using the modified Bernoulli equation 5: right ventricular systolic pressure = 4 (maximal tricuspid regurgitation velocity) <sup>2</sup> + right atrial pressure, where maximal tricuspid regurgitation ve- locity was measured using continuous wave Doppler	
	<b>Description of method to estimate right atrial pressure:</b> Right atrial pressure was esti- mated in the subcostal view according to the inferior vena cava size and collapsibility fol- lowing a normal sniff: 3 mmHg if IVC < 15 mm and collapse ≥ 50%, 5 mmHg if IVC between 15 and 21 mm and collapse ≥ 50%, 15 mmHg if IVC ≥ 21 mm and collapse between 10% and 50%, 20 mmHg if IVC ≥ 21 mm and collapse < 10%, and 10 mmHg in all other cases.	
	Cut-off value to declare PH: 40 mmHg	
	Estimated systolic pulmonary arterial pressure: not reported	
	Sonographer qualification: performed by experienced, credentialed cardiac sonogra- phers	
	How to handle the uninterpretable results: excluded from analysis	
Target condition and reference stan- dard(s)	Target condition: pulmonary hypertension	
	<b>Description of reference standard:</b> A balloon catheter was introduced through the right femoral vein or internal jugular vein after local anaesthesia. Patients could be premedicated with 1 to 3 mg of diazepam 30 min before the procedure.	
	Mean pulmonary arterial pressure: mean 36.5 $\pm$ 17.8 mmHg	
Flow and timing	The interval between the index test and reference standard: within 48 hours	



Amsa	llem	2016	(Continued)
------	------	------	-------------

Number of indeterminates for whom the results of reference standard was available: 0 (0%)

Number of patients who were excluded from the analysis: not stated

Comparative			
Notes			
Methodological quality			
Item	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sample of patients enrolled?	Yes		
Did the study avoid inappropriate ex- clusions?	Yes		
Could the selection of patients have introduced bias?		Low risk	
Are there concerns that the includ- ed patients and setting do not match the review question?			High
DOMAIN 2: Index Test (All tests)			
Were the index test results interpret- ed without knowledge of the results of the reference standard?	Yes		
If a threshold was used, was it pre- specified?	Yes		
Could the conduct or interpretation of the index test have introduced bias?		Low risk	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?			Low concern
DOMAIN 3: Reference Standard			
Were the reference standard results in- terpreted without knowledge of the re- sults of the index tests?	Yes		
Were the criteria of reference standard for target condition prespecified?	Yes		
Could the reference standard, its conduct, or its interpretation have introduced bias?		Low risk	



Low concern

#### Amsallem 2016 (Continued)

Are there concerns that the target condition as defined by the reference standard does not match the question?

# Question? DOMAIN 4: Flow and Timing Was the interval between the index test and reference standard less than one day? No Did all patients receive the same reference standard? Yes Were all patients included in the analy-sis? No

Could the patient flow have introduced bias? High risk

#### Balci 2016

Study characteristics	
Patient Sampling	Prospective
Patient characteristics and setting	Study location: Turkey
	Study periods: between January 2012 and September 2015
	Care setting: the lung transplantation unit of Kartal Kosuyolu Training Hospital
	Participants enrolled: 103: 67 males and 36 females
	Participants included in analysis: 103: 67 males and 36 females
	Age: median age 48 years (range: 18-70 years)
	BMI: mean BMI 24
	Classification of PH defined by WHO (diagnosis from right-heart catheterisation): Class I: 0, Class II: 0, Class III: 59, Class IV: 0, Class V: 0
	Number of patients with asymptomatic or mild symptom: not reported
	Number of participants with COPD: 54
	Number of intubated participants: 0
	<b>Inclusion criteria:</b> We included patients with the diagnosis of end-stage lung disease who were referred as lung transplantation candidates to the lung transplantation unit of Kartal Kosuyolu Training Hospital
	Exclusion criteria: not reported
Index tests	<b>Description of index test:</b> Doppler echocardiography was implemented with the use of conventional clinical echocardiographic equipment (Philips iE33 xMATRIX ultra-

sound system, Andover, Mass, United States). Transthoracic Doppler and 2-dimension-



al images were gained from parasternal long- and short-axis, apical 4-chamber, and subcostal 4-chamber views.			
Description of method to estimate right atrial pressure: not reported			
Cut-off value to declare PH: 35 mmHg			
<b>Estimated systolic pulmonary arterial pressure:</b> median 45 mmHg (range: 20-144 mmHg)			
Sonographer qualificatio	<b>n:</b> not reported		
How to handle the uninte	erpretable results: not	applicable	
Target condition: pulmonary hypertension			
<b>Description of reference standard:</b> Right-heart catheterisation was performed with the use of a balloon-tipped, flow directed pulmonary artery catheter. The catheter was introduced via the right femoral vein or right internal jugular vein, using the Seldinger technique under local anaesthesia. The following measurements were obtained in duplicate: right atrial pressures, pulmonary artery systolic and diastolic pressures, pulmonary artery artery catheter.			
Mean pulmonary arterial	pressure: median 26 m	nmHg (IQR: 20-35 mmHg)	
The interval between the i	ndex test and reference	standard: within 72 hours	
Number of indeterminates (0%)	s for whom the results o	f reference standard was available: 0	
Number of patients who w	vere excluded from the a	analysis: 0 (0%)	
Authors' judgement	Risk of bias	Applicability concerns	
Yes			
Yes			
	Low risk		
		Low concern	
Unclear			
	al images were gained from subcostal 4-chamber view Description of method to Cut-off value to declare P Estimated systolic pulmor mmHg) Sonographer qualification How to handle the uninter Target condition: pulmor Description of reference the use of a balloon-tipped introduced via the right fe technique under local and plicate: right atrial pressur monary artery occlusion p Mean pulmonary arterial The interval between the i Number of indeterminates (0%) Number of patients who w Yes Yes	al images were gained from parasternal long- and subcostal 4-chamber views. Description of method to estimate right atrial pressure mmHg Estimated systolic pulmonary arterial pressure mmHg) Sonographer qualification: not reported How to handle the uninterpretable results: not Target condition: pulmonary hypertension Description of reference standard: Right-heart of the use of a balloon-tipped, flow directed pulmon introduced via the right femoral vein or right interpretechnique under local anaesthesia. The following plicate: right atrial pressures, pulmonary artery acrdiac ou Mean pulmonary arterial pressure: median 26 m The interval between the index test and reference Number of indeterminates for whom the results of (0%) Number of patients who were excluded from the atriat of the set of platents who were excluded from the atriat of the set of platents who were excluded from the atriat of the set of platents who were excluded from the atriat of the set of (0%) Number of platents who were excluded from the atriat of the set of platents who were excluded from the atriat of the set of (0%) Yes Yes Unclear Unclear	



Balci 2016 (Continued)			
If a threshold was used, was it pre-speci- fied?	Unclear		
Could the conduct or interpretation of the index test have introduced bias?		Unclear risk	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?			Unclear
DOMAIN 3: Reference Standard			
Were the reference standard results inter- preted without knowledge of the results of the index tests?	Unclear		
Were the criteria of reference standard for target condition prespecified?	Unclear		
Could the reference standard, its con- duct, or its interpretation have intro- duced bias?		Unclear risk	
Are there concerns that the target con- dition as defined by the reference stan- dard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			
Was the interval between the index test and reference standard less than one day?	No		
Did all patients receive the same reference standard?	Yes		
Were all patients included in the analysis?	Yes		
Could the patient flow have introduced bias?		High risk	

# Study characteristics Patient Sampling Prospective Patient characteristics and setting Study location: France Study periods: between April 1993 and August 2001 Care setting: Service d'H'epatologie and INSERM Participants enrolled: 165: 116 males and 49 females Participants included in analysis: 165: 116 males and 49 females Age: mean age 48 ± 8 years Age: mean age 48 ± 8 years

Colle 2003 (Continued)	BMI: not reported
	<b>Classification of PH defined by WHO (diagnosis from</b> right-heart catheterisation <b>):</b> Class I: 17, Class II: 0, Class III: 0, Class IV: 0, Class V: 0
	Number of patients with asymptomatic or mild symptom: not reported
	Number of participants with COPD: not reported
	Number of intubated participants: 0
	<b>Inclusion criteria:</b> consecutive patients who were evaluated for liver transplantation and for whom transvenous liver biopsy was needed were prospectively included in this study
	Exclusion criteria: none
Index tests	<b>Description of index test:</b> All patients were evaluated with a 2-dimensional Doppler echocardiography on a Sonos 1500 Hewlett-Packard or a Supervision 800 Vingmed machine. Continuous wave Doppler of tricuspid regurgitant jet, when present, was used to calculate right ventricular systolic pulmonary artery pressure with the formula: systolic pulmonary artery pressure (4 maximum velocity of the tricuspid regurgitant jet2) mean right atrial pres- sure.
	<b>Description of method to estimate right atrial pressure:</b> setting mean right atrial pressure at 5 mmHg, except when the inferior vena cava was collapsed (0 mmHg) or clearly enlarged with no collapse during inspiration (10 mmHg)
	Cut-off value to declare PH: 30 mmHg
	Estimated systolic pulmonary arterial pressure: not reported
	Sonographer qualification: not reported
	How to handle the uninterpretable results: not applicable
Target condition and reference stan-	Target condition: pulmonary hypertension
uaru(s)	<b>Description of reference standard:</b> a catheter was inserted into the right or left jugular vein under local anaesthesia. Haemodynamic measurements including pulmonary artery pres- sure, right atrial pressure, and pulmonary capillary wedge pressure were performed using a Swan-Ganz catheter. Cardiac output was measured by the thermodilution method (Bax- ter Healthcare Corporation, Santa Ana, CA). Cardiac output was obtained by the average of 3 consecutive measurements. Arterial pressure was measured using a noninvasive ex- ternal sphygmomanometer (Dinamap; Critikon, Tampa, FL). Systemic vascular resistance was calculated as follows: systemic vascular resistance (dynes.s.cm 5) (mean arterial pres- sure-mean right atrial pressure) 80/cardiac output. Pulmonary vascular resistance (PVR) was calculated as follows: pulmonary vascular resistance (dynes.s.cm 5) (mean pulmonary arter- ial pressure-pulmonary capillary wedged pressure) 80/cardiac output.
	Mean pulmonary arterial pressure: mean 18.8 ± 7.6 mmHg
Flow and timing	The interval between the index test and reference standard: within the same week
	Number of indeterminates for whom the results of reference standard was available: 0 (0%)
	Number of patients who were excluded from the analysis: 0 (0%)
Comparative	
Notes	
Methodological quality	



Colle 2003 (Continued)			
Item	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sample of patients enrolled?	Yes		
Did the study avoid inappropriate ex- clusions?	Yes		
Could the selection of patients have introduced bias?		Low risk	
Are there concerns that the in- cluded patients and setting do not match the review question?			High
DOMAIN 2: Index Test (All tests)			
Were the index test results interpret- ed without knowledge of the results of the reference standard?	Yes		
If a threshold was used, was it pre- specified?	Unclear		
Could the conduct or interpretation of the index test have introduced bias?		Low risk	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?			Low concern
DOMAIN 3: Reference Standard			
Were the reference standard results interpreted without knowledge of the results of the index tests?	Yes		
Were the criteria of reference stan- dard for target condition prespeci- fied?	Unclear		
Could the reference standard, its conduct, or its interpretation have introduced bias?		Low risk	
Are there concerns that the target condition as defined by the refer- ence standard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			



#### Colle 2003 (Continued)

Could the patient flow have intro- duced bias?	High risk
Were all patients included in the analysis?	Yes
Did all patients receive the same ref- erence standard?	Yes
Was the interval between the index test and reference standard less than one day?	No

#### Er 2010

Study characteristics	
Patient Sampling	Prospective
Patient characteristics and setting	Study location: Germany
	Study periods: from December 2008 to June 2010
	Care setting: the Cardiology Department of the University of Cologne
	Participants enrolled: 50
	Participants included in analysis: 50: 14 males and 36 females
	<b>Age:</b> mean age 66.9 ± 14.5 years
	<b>BMI:</b> mean 27.1 ± 5.1
	Classification of PH defined by WHO (diagnosis from right-heart catheterisation): not re- ported
	Number of patients with asymptomatic or mild symptom: 6 (8%)
	Number of participants with COPD: not reported
	Number of intubated participants: 0
	Inclusion criteria: Consecutive patients referred to the Cardiology Department of the University of Cologne were included.
	<b>Exclusion criteria:</b> Patients were excluded when tricuspid regurgitation jet was not available.
Index tests	<b>Description of index test:</b> using a Phillips iE33 ultrasound device equipped with a stan- dard transducer operating at 1–5 MHz without using saline contrast. The echocardiography was performed by three different cardiologists. In each patient only one cardiologist per- formed the examination, randomly. Multiple views were recorded to identify optimal view for analysis as recommended in actual guidelines.
	<b>Description of method to estimate right atrial pressure:</b> The right atrial pressure was estimated by evaluating IVC diameter and change with respiration: when IVC diameter was less than 20 mm and the collapsibility greater than 50%, right atrial pressure was estimated to be 5 mmHg versus 10 mmHg when the collapsibility was less than 50%. When the IVC diameter was greater than 20 mm, right atrial pressure was estimated to be 15 mmHg

	when the collapsibility wa was less than 50%.	s greater than 50% and to	be 20 mmHg when the collapsibility
	Cut-off value to declare PH: 38 mmHg		
	Estimated systolic pulmo	onary arterial pressure: n	nean 62.3 ± 25.7 mmHg
	Sonographer qualification	<b>n:</b> performed by cardiolog	gists
	How to handle the uninte	erpretable results: not ap	plicable
Target condition and reference stan-	an- Target condition: pulmonary hypertension		
dard(s)	<b>Description of reference</b> sedation at rest in the carc versity of Cologne. End-ex um, right ventricle, pulmo	<b>standard:</b> Right-heart cat liac catheter laboratory of piratory pressure measure nary artery and pulmonary	heterisation was performed without the Cardiology Department of the Uni- ements were taken from the right atri- y capillary.
	Mean pulmonary arterial	<b>pressure:</b> mean 39.5 ± 14	.9 mmHg
Flow and timing	The interval between the i	ndex test and reference st	andard: within 120 minutes
	Number of indeterminates (0%)	s for whom the results of re	eference standard was available: 0
	Number of patients who were excluded from the analysis: 0 (0%)		
Comparative			
Notes			
Methodological quality			
Item	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sample			
of patients enrolled?	Yes		
of patients enrolled? Did the study avoid inappropriate ex- clusions?	Yes Yes		
of patients enrolled? Did the study avoid inappropriate ex- clusions? Could the selection of patients have introduced bias?	Yes	Low risk	
of patients enrolled? Did the study avoid inappropriate ex- clusions? Could the selection of patients have introduced bias? Are there concerns that the includ- ed patients and setting do not match the review question?	Yes	Low risk	High
of patients enrolled? Did the study avoid inappropriate ex- clusions? Could the selection of patients have introduced bias? Are there concerns that the includ- ed patients and setting do not match the review question? DOMAIN 2: Index Test (All tests)	Yes	Low risk	High
of patients enrolled? Did the study avoid inappropriate ex- clusions? Could the selection of patients have introduced bias? Are there concerns that the includ- ed patients and setting do not match the review question? DOMAIN 2: Index Test (All tests) Were the index test results interpret- ed without knowledge of the results of the reference standard?	Yes Yes Unclear	Low risk	High



Er 2010 (Continued)			
Could the conduct or interpretation of the index test have introduced bias?		Unclear risk	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?			Low concern
DOMAIN 3: Reference Standard			
Were the reference standard results in- terpreted without knowledge of the re- sults of the index tests?	Unclear		
Were the criteria of reference standard for target condition prespecified?	Unclear		
Could the reference standard, its conduct, or its interpretation have introduced bias?		Unclear risk	
Are there concerns that the target condition as defined by the refer- ence standard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			
Was the interval between the index test and reference standard less than one day?	Yes		
Did all patients receive the same refer- ence standard?	Yes		
Were all patients included in the analy- sis?	Yes		
Could the patient flow have intro- duced bias?		Low risk	

# Greiner 2014

Study characteristics			
Patient Sampling	Retrospective		
Patient characteristics and setting	Study location: Germany		
	Study periods: from July 1, 2007 through June 30, 2013		
	Care setting: Cardiology Department of the University Hospital of Heidelberg, Germany		
	Participants enrolled: 3920: gender not reported		
	Participants included in analysis: 1695: 1136 males and 559 females		



Greiner 2014 (Continued)	<b>Age:</b> mean age 63 ± 15		
	<b>BMI:</b> mean 26 ± 5		
	Classification of PH defin reported	ed by WHO (diagnosis fro	<b>m</b> right-heart catheterisation <b>):</b> not
	Number of patients with	asymptomatic or mild sy	<b>mptom:</b> 85 (5%)
	Number of participants w	<b>ith COPD:</b> not reported	
	Number of intubated par	ticipants: 0	
	<b>Inclusion criteria:</b> All pation within 5 days before or after	ents who had a cardiac ult er invasive examination	rasound examination performed
	Exclusion criteria: Patien plicitly documented	ts whose pulmonary arteri	al pressure documents were not ex-
Index tests	<b>Description of index test:</b> sure was achieved by meas right atrial pressure. Right tolic velocity of the tricusp ing the modified Bernoulli	Noninvasive assessment of surement of right ventricu ventricular systolic pressu id regurgitation obtained equation: pressure gradie	of systolic pulmonary arterial pres- lar systolic pressure and adding ire was derived from the peak sys- with continuous-wave Doppler us- nt = 49Vmax2.
	<b>Description of method to</b> timated by the diameter of	estimate right atrial pres the inferior vena cava and	<b>ssure:</b> Right atrial pressure was es- d its variability during inspiration.
	Cut-off value to declare P	<b>H:</b> 36 mmHg	
	Estimated systolic pulmo	nary arterial pressure: m	nean 45.3 ± 15.5 mmHg
	Sonographer qualificatio	<b>n:</b> performed by two indep	pendent, experienced examiners
	How to handle the uninte	rpretable results: exclud	ed from analysis
Target condition and reference stan-	Target condition: pulmon	ary hypertension	
uaru(s)	<b>Description of reference</b> right-heart catheterisation uration measurement acco monary capillary wedge pr measured during breath he artery pressure was calcula (Metek GmbH, Roetgen, Ge	standard: A femoral or jug . Cardiac output and cardi ording to Fick's method. Pu ressure, and right ventricul old in baseline over at leas ated by integration of the p ermany).	ular venous approach was used for ac index were calculated by sat- ulmonary arterial pressure, pul- lar and right atrial pressures were t 3 heart cycles. Mean pulmonary pressure curve by Metek software
	Mean pulmonary arterial	<b>pressure:</b> mean 31.6 ± 10.	.9 mmHg
Flow and timing	The interval between the i	ndex test and reference sta	andard: within five days
	Number of indeterminates (0%)	for whom the results of re	ference standard was available: 0
	Number of patients who w	ere excluded from the ana	lysis: not stated
Comparative			
Notes			
Methodological quality			
lteres	Authorstindgement	Dick of bias	Applicability concerns

Copyright @ 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Greiner 2014 (Continued)			
<b>DOMAIN 1: Patient Selection</b>			
Was a consecutive or random sample of patients enrolled?	Yes		
Did the study avoid inappropriate exclu- sions?	No		
Could the selection of patients have in- troduced bias?		High risk	
Are there concerns that the included patients and setting do not match the review question?			Unclear
DOMAIN 2: Index Test (All tests)			
Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear		
If a threshold was used, was it pre-speci- fied?	No		
Could the conduct or interpretation of the index test have introduced bias?		High risk	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?			Low concern
DOMAIN 3: Reference Standard			
Were the reference standard results inter- preted without knowledge of the results of the index tests?	Unclear		
Were the criteria of reference standard for target condition prespecified?	Unclear		
Could the reference standard, its con- duct, or its interpretation have intro- duced bias?		Unclear risk	
Are there concerns that the target con- dition as defined by the reference stan- dard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			
Was the interval between the index test and reference standard less than one day?	No		
Did all patients receive the same refer- ence standard?	Yes		



# Greiner 2014 (Continued)

Were all patients included in the analysis? No

#### Could the patient flow have introduced bias?

High risk

Study characteristics	
Patient Sampling	Retrospective
Patient characteristics and setting	Study location: UK and Germany
	Study periods: between 2011 and 2016
	<b>Care setting:</b> the Clinic for Cardiology and Pneumology, University Medical Center Göttingen; King's College Hospital, London; and the Department of Internal Medicine II, University of Regensburg
	Participants enrolled: 90: 43 males and 47 females
	Participants included in analysis: 90: 43 males and 47 females
	Age: mean age 64.8 years (IQR: 55-79 years)
	BMI: not reported
	Classification of PH defined by WHO (diagnosis from right-heart catheterisation): not reported
	Number of patients with asymptomatic or mild symptom: 24 (16%)
	Number of participants with COPD: not reported
	Number of intubated participants: 0
	<b>Inclusion criteria:</b> patients who underwent echocardiography and right-heart catheterisation within 24 hours
	Exclusion criteria: not reported
Index tests	<b>Description of index test:</b> continuous-wave Doppler ultrasonography of tricuspid re- gurgitation in apical four-chamber and parasternal short-axis views was applied, and the tricuspid regurgitation time-velocity tracing was determined to obtain the time-ve- locity integral, tricuspid regurgitation max velocity, mean tricuspid regurgitation ve- locity, maximal right atrial-right ventricular gradient, and TRP mean.
	<b>Description of method to estimate right atrial pressure:</b> Right atrial pressure was estimated by measuring the diameter of the IVC at end expiration and the inspiratory collapsibility in the subcostal view as follows: when the IVC diameter was #21 mm and the collapsibility with a sniff was > 50%, right atrial pressure was estimated to be 3 mmHg; when the IVC diameter was > 21 mm and the collapsibility was < 50%, right atrial pressure was estimated to be 15 mmHg. In all other cases (either IVC diameter > 21 mm and collapse > 50% or IVC diameter #21 mm and collapse < 50%), right atrial pressure was estimated to be 8 mmHg.
	Cut-off value to declare PH: 31 mmHg
	Estimated systolic pulmonary arterial pressure: not reported
	Sonographer qualification: not reported

Copyright @ 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Hellenkamp 2018 (Continued)	How to handle the uninter	pretable results: not applicab	le
Target condition and reference standard(s)	Target condition: pulmonary hypertension		
	Description of reference st	andard: not reported	
	Mean pulmonary arterial p	ressure: median 35 mmHg (IQ	R: 24.7-46.2 mmHg)
Flow and timing	The interval between the ine	dex test and reference standard	d: within 24 hours
	Number of indeterminates for whom the results of reference standard was available: 0 (0%)		
	Number of patients who we	re excluded from the analysis:	0 (0%)
Comparative			
Notes			
Methodological quality			
Item	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sample of patients enrolled?	Yes		
Did the study avoid inappropriate exclu- sions?	Yes		
Could the selection of patients have in- troduced bias?		Low risk	
Are there concerns that the included pa- tients and setting do not match the re- view question?			Unclear
DOMAIN 2: Index Test (All tests)			
Were the index test results interpreted without knowledge of the results of the ref- erence standard?	Yes		
If a threshold was used, was it pre-speci- fied?	Unclear		
Could the conduct or interpretation of the index test have introduced bias?		Low risk	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?			Low concern
DOMAIN 3: Reference Standard			
Were the reference standard results inter- preted without knowledge of the results of the index tests?	Yes		



Hellenkamp 2018 (Continued)			
Were the criteria of reference standard for target condition prespecified?	Unclear		
Could the reference standard, its con- duct, or its interpretation have intro- duced bias?		Low risk	
Are there concerns that the target con- dition as defined by the reference stan- dard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			
Was the interval between the index test and reference standard less than one day?	Yes		
Did all patients receive the same reference standard?	Yes		
Were all patients included in the analysis?	Yes		
Could the patient flow have introduced bias?		Low risk	

#### Hsu 2008

Study characteristics	
Patient Sampling	Prospective
Patient characteristics and setting	Study location: USA
	Study periods: between 2002 and 2004
	Care setting: not reported
	Participants enrolled: 55: gender not reported
	Participants included in analysis: 49: 9 males and 40 females
	Age: mean age 55 years (range 20-80 years)
	BMI: not reported
	Classification of PH defined by WHO (diagnosis from right-heart catheterisation): Class I: 16, Class II: 0, Class III: 0, Class IV: 0, Class V: 0
	Number of patients with asymptomatic or mild symptom: not reported
	Number of participants with COPD: not reported
	Number of intubated participants: 0
	<b>Inclusion criteria:</b> We performed a prospective review of established or new patients who presented consecutively to the University of Medicine and Dentistry of New Jersey-Sclero-derma Program between 2002 and 2004 with progressive dyspnoea and/or had clinical features suspicious of PH.

Hsu 2008 (Continued)				
	<b>Exclusion criteria:</b> Patients were excluded if they had left ventricle dysfunction by echo or right-heart catheterisation, airway obstruction by pulmonary function tests, thromboembolic pulmonary hypertension (excluded by ventilation/perfusion scan), congenital heart disease, porto-pulmonary PH, or HIV, and those who refused right-heart catheterisation or cardiac magnetic resonance imaging.			
Index tests	<b>Description of index test:</b> Echo images were obtained using a Philips Sonos 7500 model. Tricuspid regurgitant flow velocity was measured by continuous-wave echo with both an imaging probe and a non-imaging Pedoff pencil probe. No contrast enhancement was giv- en. RVSP was estimated from the peak tricuspid regurgitant flow velocity (v, in m/s) using a modified Bernoulli equation, $P = 4v2 + 10$ , where P represents the pressure in mmHg. All echo-Doppler studies were read by a single reader.			
	Description of method to es	timate right atrial press	<b>ure:</b> 10 mmHg	
	Cut-off value to declare PH:	47 mmHg		
	Estimated systolic pulmona	ry arterial pressure: not	reported	
	Sonographer qualification:	not reported		
	How to handle the uninterp	retable results: excluded	l from analysis	
Target condition and reference stan-	Target condition: pulmonary	/ hypertension		
uaru(s)	<b>Description of reference standard:</b> Right-heart catheterisation was performed by per- cutaneous approach via the femoral vein using a 7-French Swan-Ganz catheter (Edwards Lifesciences). Baseline pressures were recorded in the right atrium, right ventricle, PA, and PCW position			
	.Mean pulmonary arterial pressure: mean 25.3 mmHg (range: 11-58 mmHg)			
Flow and timing	The interval between the index test and reference standard: within 4 hours			
	Number of indeterminates for whom the results of reference standard was available: 0 (0%)			
	Number of patients who were	excluded from the analy	sis: not stated	
Comparative				
Notes				
Methodological quality				
Item	Authors' judgement	Risk of bias	Applicability concerns	
DOMAIN 1: Patient Selection				
Was a consecutive or random sample of patients enrolled?	Yes			
Did the study avoid inappropriate ex- clusions?	Yes			
Could the selection of patients have introduced bias?		Low risk		



		High
Unclear		
No		
	High risk	
		High
Unclear		
Unclear		
	Unclear risk	
		Low concern
Yes		
Yes		
No		
	Low risk	
	Unclear No Unclear Unclear Unclear Yes Yes	Unclear No High risk Unclear Unclear Unclear Ves Yes Yes Yes No



# Kyranis 2018

Study characteristics			
Patient Sampling	Prospective		
Patient characteristics and setting	Study location: Australia		
	Study periods: not reported		
	Care setting: quaternary cardiopulmonary specialist hospital		
	Participants enrolled: 100: 43 males and 57 females		
	Participants included in analysis: 96: gender not reported		
	<b>Age:</b> mean age $58 \pm 14$ years		
	<b>BMI:</b> mean 28 ± 6		
	Classification of PH defined by WHO (diagnosis from right-heart catheterisation): not reported		
	Number of patients with asymptomatic or mild symptom: not reported		
	Number of participants with COPD: not reported		
	Number of intubated participants: 0		
	<b>Inclusion criteria:</b> patients undergoing clinically indicated right-heart catheterisation were prospectively enrolled.		
	Exclusion criteria: not reported		
Index tests	<b>Description of index test:</b> Both sonographers and reporting cardiologists were blinded to the invasive data. Echocardiographic examinations were performed by experienced sonographers using commercially available ultrasound systems (Vivid I, Vivid 7, and Vivid E9, GE Healthcare, Vingmed, Trondheim Norway and iE33, Philips, Eindhoven, The Netherlands) using 1.5–4.0 MHz matrix-array and phase array transducers according to the guidelines of the American Society of Echocardiography.		
	<b>Description of method to estimate right atrial pressure:</b> Right atrial pressure was estimated to be 3 mmHg when the IVC diameter was < 21 mm with > 50% collapsibility, 8 mmHg when the IVC diameter was < 21 mm with < 50% collapsibility, and 15 mmHg when the IVC diameter was > 21 mm with < 50% collapsibility, as per current American Society of Echocardiography guidelines.		
	Cut-off value to declare PH: 31 mmHg		
	Estimated systolic pulmonary arterial pressure: mean 54.7±22.7 mmHg		
	Sonographer qualification: performed by experienced sonographer		
	How to handle the uninterpretable results: excluded from analysis		
Target condition and reference standard(s)	Target condition: pulmonary hypertension		
	<b>Description of reference standard:</b> Right-heart catheterisation via the jugular or femoral venous approach was performed by experienced accredited cardiologists with established skills in right-heart catheterisation.		
	Mean pulmonary arterial pressure: mean 43.2±15 mmHg		
Flow and timing	The interval between the index test and reference standard: within 24 hours		



# Kyranis 2018 (Continued)

Number of indeterminates for whom the results of reference standard was available: 0 (0%)

Number of patients who were excluded from the analysis: not stated

Comparative			
Notes			
Methodological quality			
ltem	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sample of patients enrolled?	Yes		
Did the study avoid inappropriate exclu- sions?	Yes		
Could the selection of patients have in- troduced bias?		Low risk	
Are there concerns that the included pa- tients and setting do not match the re- view question?			Unclear
DOMAIN 2: Index Test (All tests)			
Were the index test results interpreted without knowledge of the results of the ref- erence standard?	Yes		
If a threshold was used, was it pre-speci- fied?	Unclear		
Could the conduct or interpretation of the index test have introduced bias?		Low risk	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?			Low concern
DOMAIN 3: Reference Standard			
Were the reference standard results inter- preted without knowledge of the results of the index tests?	Yes		
Were the criteria of reference standard for target condition prespecified?	Unclear		
Could the reference standard, its con- duct, or its interpretation have intro- duced bias?		Low risk	



Low concern

# Kyranis 2018 (Continued)

Are there concerns that the target condition as defined by the reference standard does not match the question?

Yes	
Yes	
No	
High risk	
	Yes Yes No High risk

# Lafitte 2013

Study characteristics	
Patient Sampling	Retrospective
Patient characteristics and setting	Study location: France
	Study periods: between June 2011 and March 2012
	<b>Care setting:</b> the cardiac catheterisation department, which performs approximately 4500 right-heart catheterisation procedures every year, and from the echocardiography department, which conducts > 15,000 trans-thoracic Doppler echocardiographic studies every year
	Participants enrolled: 310: 162 males and 148 females
	Participants included in analysis: 155: gender not reported
	<b>Age:</b> mean age 64.8 ± 15.9 years
	<b>BMI:</b> mean 26.3± 5.7
	Classification of PH defined by WHO (diagnosis from right-heart catheterisation): not report- ed
	Number of patients with asymptomatic or mild symptom: not reported
	Number of participants with COPD: not reported
	Number of intubated participants: 0
	<b>Inclusion criteria:</b> The inclusion criterion for patient enrolment was having undergone both haemodynamic and echocardiographic investigations (with estimation of pulmonary pressures by Doppler on tricuspid regurgitant flow) between June 2011 and March 2012, irrespective of the causal disease, during a single hospitalisation period.
	<b>Exclusion criteria:</b> a lack of pulmonary pressures estimation on the basis of tricuspid regurgi- tant flow using Doppler echocardiography
Index tests	<b>Description of index test:</b> All echocardiographic measurements were performed according to American Society of Echocardiography and European Association of Echocardiography recommendations in line with UERD standard operating procedure. Accordingly, tricuspid regurgi-



Lafitte 2013 (Continued)				
	tant maximum velocities we systolic pulmonary arterial p tion when tricuspid regurgits estimation of right atrial pre	re measured on the basis of pressure levels were determ ant jets were analysable, in ssure.	adequate acquisitions, and estimated ined using the modified Bernoulli equa- conjunction with echocardiographic	
	<b>Description of method to estimate right atrial pressure:</b> Echocardiographic right atrial pressure sure estimation was performed on the basis of IVC size and collapsibility. Right atrial pressure was estimated to be 3 mmHg when the IVC diameter was < 21 mm with > 50% collapsibility, 8 mmHg when the IVC diameter was < 21 mm with < 50% collapsibility, and 15 mmHg when the IVC diameter was > 21 mm with < 50% collapsibility.			
	Cut-off value to declare PH: 38 mmHg			
	Estimated systolic pulmonary arterial pressure: mean 49.6 $\pm$ 21.7 mmHg			
	Sonographer qualification: gists	underwent systematic vali	dation by one of the senior cardiolo-	
	How to handle the uninter	pretable results: excluded	from analysis	
Target condition and reference	Target condition: pulmona	ry hypertension		
standard(s)	<b>Description of reference standard:</b> Senior physicians specialising in invasive techniques per- formed the catheterisations according to standard procedures. Fluid-filled catheters were used for patients not sedated. Systolic, diastolic, and mean PPs were averaged and calculated over five beats.			
	Mean pulmonary arterial p	<b>ressure:</b> mean 32.7 ± 15.3 n	nmHg	
Flow and timing	The interval between the index test and reference standard: mean interval 2 days $\pm$ 2.9 days			
	Number of indeterminates for whom the results of reference standard was available: 0 (0%)			
	Number of patients who wer	e excluded from the analys	is: not stated	
Comparative				
Notes				
Methodological quality				
Item	Authors' judgement	Risk of bias	Applicability concerns	
DOMAIN 1: Patient Selection				
Was a consecutive or random sam- ple of patients enrolled?	Yes			
Did the study avoid inappropriate exclusions?	Yes			
Could the selection of patients have introduced bias?		Low risk		
Are there concerns that the in- cluded patients and setting do not match the review question?			Unclear	
DOMAIN 2: Index Test (All tests)				

Library		Cochrane Library
---------	--	---------------------

Lafitte 2013 (Continued)			
Were the index test results inter- preted without knowledge of the results of the reference standard?	Unclear		
If a threshold was used, was it pre- specified?	Unclear		
Could the conduct or interpreta- tion of the index test have intro- duced bias?		Unclear risk	
Are there concerns that the in- dex test, its conduct, or inter- pretation differ from the review question?			Low concern
DOMAIN 3: Reference Standard			
Were the reference standard re- sults interpreted without knowl- edge of the results of the index tests?	Unclear		
Were the criteria of reference stan- dard for target condition prespeci- fied?	Unclear		
Could the reference standard, its conduct, or its interpretation have introduced bias?		Unclear risk	
Are there concerns that the tar- get condition as defined by the reference standard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			
Was the interval between the index test and reference standard less than one day?	No		
Did all patients receive the same reference standard?	Yes		
Were all patients included in the analysis?	No		
Could the patient flow have in- troduced bias?		High risk	

Mazhar 2011

Study characteristics



Mazhar 2011 (Continued)		
Patient Sampling	Retrospective	
Patient characteristics and setting	Study location: New Zealand	
	Study periods: between January 2004 and February 2011	
	Care setting: not reported	
	Participants enrolled: 159: gender not reported	
	Participants included in analysis: 99: gender not reported	
	Age: not reported	
	BMI: not reported	
	Classification of PH defined by WHO (diagnosis from right-heart catheterisation): not reported	
	Number of patients with asymptomatic or mild symptom: not re- ported	
	Number of participants with COPD: not reported	
	Number of intubated participants: not reported	
	<b>Inclusion criteria:</b> Patients having a trans-thoracic echocardiography and right-heart catheterisation within three days of each other	
	Exclusion criteria: not reported	
Index tests	Description of index test: not reported	
	Description of method to estimate right atrial pressure: not report- ed	
	Cut-off value to declare PH: 31 mmHg	
	Estimated systolic pulmonary arterial pressure: not reported	
	Sonographer qualification: not reported	
	How to handle the uninterpretable results: excluded from analysis	
Target condition and reference standard(s)	Target condition: pulmonary hypertension	
	Description of reference standard: not reported	
	Mean pulmonary arterial pressure: not reported	
Flow and timing	The interval between the index test and reference standard: within 3 days	
	Number of indeterminates for whom the results of reference standard was available: 0 (0%)	
	Number of patients who were excluded from the analysis: not stated	
Comparative		
Notes		
Methodological quality		



#### Mazhar 2011 (Continued)

Item	Authors' judgement	Risk of bias	Applicability con- cerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sample of patients enrolled?	Yes		
Did the study avoid inappropriate exclusions?	Yes		
Could the selection of patients have introduced bias?		Low risk	
Are there concerns that the included patients and set- ting do not match the review question?			Unclear
DOMAIN 2: Index Test (All tests)			
Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear		
If a threshold was used, was it pre-specified?	Unclear		
Could the conduct or interpretation of the index test have introduced bias?		Unclear risk	
Are there concerns that the index test, its conduct, or in- terpretation differ from the review question?			Unclear
DOMAIN 3: Reference Standard			
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear		
Were the criteria of reference standard for target condition prespecified?	Unclear		
Could the reference standard, its conduct, or its inter- pretation have introduced bias?		Unclear risk	
Are there concerns that the target condition as defined by the reference standard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			
Was the interval between the index test and reference stan- dard less than one day?	No		
Did all patients receive the same reference standard?	Yes		
Were all patients included in the analysis?	No		
Could the patient flow have introduced bias?		High risk	



#### Mo 2015

Study characteristics		
Patient Sampling	Retrospective	
Patient characteristics and setting	Study location: USA	
	Study periods: not reported	
	Care setting: not reported	
	Participants enrolled: 30: gender not reported	
	Participants included in analysis: 24: gender not reported	
	Age: not reported	
	BMI: not reported	
	Classification of PH defined by WHO (diagnosis from right-heart catheterisation): not reported	
	Number of patients with asymptomatic or mild symptom: not re- ported	
	Number of participants with COPD: not reported	
	Number of intubated participants: not reported	
	<b>Inclusion criteria:</b> Adults with echo and right-heart catheterisation within one week	
	Exclusion criteria: not reported	
Index tests	<b>Description of index test:</b> estimable right ventricular systolic pres- sure by echocardiography	
	Description of method to estimate right atrial pressure: not report- ed	
	Cut-off value to declare PH: 35 mmHg	
	Estimated systolic pulmonary arterial pressure: not reported	
	Sonographer qualification: not reported	
	How to handle the uninterpretable results: excluded from analysis	
Target condition and reference standard(s)	Target condition: pulmonary hypertension	
	Description of reference standard: right-heart catheterisation	
	Mean pulmonary arterial pressure: not reported	
Flow and timing	The interval between the index test and reference standard: within one week	
	Number of indeterminates for whom the results of reference standard was available: 0 (0%)	
	Number of patients who were excluded from the analysis: not stated	
Comparative		



# Mo 2015 (Continued)

Notes

Methodological quality			
Item	Authors' judgement	Risk of bias	Applicability con- cerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sample of patients enrolled?	Unclear		
Did the study avoid inappropriate exclusions?	Unclear		
Could the selection of patients have introduced bias?		Unclear risk	
Are there concerns that the included patients and set- ting do not match the review question?			Unclear
DOMAIN 2: Index Test (All tests)			
Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear		
If a threshold was used, was it pre-specified?	Unclear		
Could the conduct or interpretation of the index test have introduced bias?		Unclear risk	
Are there concerns that the index test, its conduct, or in- terpretation differ from the review question?			Unclear
DOMAIN 3: Reference Standard			
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear		
Were the criteria of reference standard for target condition prespecified?	Unclear		
Could the reference standard, its conduct, or its inter- pretation have introduced bias?		Unclear risk	
Are there concerns that the target condition as defined by the reference standard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			
Was the interval between the index test and reference stan- dard less than one day?	No		
Did all patients receive the same reference standard?	Yes		
Were all patients included in the analysis?	No		
Could the patient flow have introduced bias?		High risk	



#### Mo 2015a

Retrospective	
Study location: USA	
Study periods: not reported	
Care setting: not reported	
Participants enrolled: 87: gender not reported	
Participants included in analysis: 87: gender not reported	
Age: not reported	
BMI: not reported	
Classification of PH defined by WHO (diagnosis from right-heart catheterisation): not reported	
Number of patients with asymptomatic or mild symptom: not re- ported	
Number of participants with COPD: not reported	
Number of intubated participants: not reported	
<b>Inclusion criteria:</b> We selected adults who underwent echo and right- heart catheterisation within one week.	
Exclusion criteria: not reported	
Description of index test: not reported	
Description of method to estimate right atrial pressure: not report ed	
Cut-off value to declare PH: 45 mmHg	
Estimated systolic pulmonary arterial pressure: not reported	
Sonographer qualification: not reported	
How to handle the uninterpretable results: excluded from analysis	
Target condition: pulmonary hypertension	
Description of reference standard: right-heart catheterisation	
Mean pulmonary arterial pressure: not reported	
The interval between the index test and reference standard: within one week	
Number of indeterminates for whom the results of reference standa was available: 0 (0%)	
Number of patients who were excluded from the analysis: 0 (0%)	



#### Mo 2015a (Continued)

Notes

Methodological quality			
Item	Authors' judgement	Risk of bias	Applicability con- cerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sample of patients enrolled?	Yes		
Did the study avoid inappropriate exclusions?	Yes		
Could the selection of patients have introduced bias?		Low risk	
Are there concerns that the included patients and set- ting do not match the review question?			Unclear
DOMAIN 2: Index Test (All tests)			
Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear		
If a threshold was used, was it pre-specified?	Unclear		
Could the conduct or interpretation of the index test have introduced bias?		Unclear risk	
Are there concerns that the index test, its conduct, or in- terpretation differ from the review question?			Unclear
DOMAIN 3: Reference Standard			
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear		
Were the criteria of reference standard for target condition prespecified?	Unclear		
Could the reference standard, its conduct, or its inter- pretation have introduced bias?		Unclear risk	
Are there concerns that the target condition as defined by the reference standard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			
Was the interval between the index test and reference stan- dard less than one day?	No		
Did all patients receive the same reference standard?	Yes		
Were all patients included in the analysis?	Yes		
Could the patient flow have introduced bias?		High risk	



#### Nowak 2018

Study characteristics		
Patient Sampling	Retrospective	
Patient characteristics and setting	Study location: Poland	
	Study periods: between April 2007 and December 2011	
	Care setting: the Silesian Center of Heart Disease	
	Participants enrolled: 65: 49 males and 16 females	
	Participants included in analysis: 37: males and females	
	<b>Age:</b> mean age 53.3 ± 9.5 years	
	<b>BMI:</b> mean 24.1 ± 4.3	
	Classification of PH defined by WHO (diagnosis from right-heart catheterisa- tion): not reported	
	Number of patients with asymptomatic or mild symptom: 2 (3%)	
	Number of participants with COPD: 31	
	Number of intubated participants: 0	
	<b>Inclusion criteria:</b> patients with advanced lung disease who underwent right- heart catheterisation	
	Exclusion criteria: patients with IPH were excluded.	
Index tests	<b>Description of index test:</b> All patients underwent transthoracic echocardio- graphy, including M-mode, 2-dimensional, pulsed, continuous-wave, and colour-flow Doppler imaging using the GE VIVID 5 system and a transducer ar- ray of 2.5 MHz, according to the guidelines of the American Society of Cardiolo- gy.	
	Description of method to estimate right atrial pressure: not reported	
	Cut-off value to declare PH: 43 mmHg	
	Estimated systolic pulmonary arterial pressure: mean $54.2\pm21.5$ mmHg	
	Sonographer qualification: not reported	
	How to handle the uninterpretable results: excluded from analysis	
Target condition and reference standard(s)	Target condition: pulmonary hypertension	
	<b>Description of reference standard:</b> All patients were clinically stable with no changes in medical therapy. This procedure was performed at rest in supine position, using a Swan-ganz catheter. Measurements were performed using supplemental oxygen, if needed, to achieve saturation over 90%.	
	Mean pulmonary arterial pressure: mean $28.8 \pm 11.5 \text{ mmHg}$	
Flow and timing	The interval between the index test and reference standard: mean interval 3 days $\pm1.7$ days	
	Number of indeterminates for whom the results of reference standard was available: 0 (0%)	



# Nowak 2018 (Continued)

Number of patients who were excluded from the analysis: not stated

Comparative			
Notes			
Methodological quality			
Item	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sample of patients enrolled?	Yes		
Did the study avoid inappropriate exclusions?	Yes		
Could the selection of patients have introduced bias?		Low risk	
Are there concerns that the included patients and setting do not match the review question?			Low concern
DOMAIN 2: Index Test (All tests)			
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes		
If a threshold was used, was it pre-specified?	Unclear		
Could the conduct or interpretation of the index test have introduced bias?		Low risk	
Are there concerns that the index test, its con- duct, or interpretation differ from the review question?			Unclear
DOMAIN 3: Reference Standard			
Were the reference standard results interpreted without knowledge of the results of the index tests?	Yes		
Were the criteria of reference standard for target condition prespecified?	Unclear		
Could the reference standard, its conduct, or its interpretation have introduced bias?		Low risk	
Are there concerns that the target condition as defined by the reference standard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			
Was the interval between the index test and refer- ence standard less than one day?	No		



No

# Nowak 2018 (Continued)

Did all patients receive the same reference stan- Yes dard?

Were all patients included in the analysis?

Could the patient flow have introduced bias?

High risk

#### Sawada 2019

Study characteristics					
Patient Sampling	Retrospective				
Patient characteristics and setting	Study location: Japan				
	Study periods: between July 2005 and December 2012				
	Care setting: the University of Tokyo				
	Participants enrolled: 189: 106 males and 83 females				
	Participants included in analysis: 189: 106 males and 83 females				
	<b>Age:</b> mean age 58 ± 17 years				
	<b>BMI:</b> 22 ± 3				
	Classification of PH defined by WHO (diagnosis from right-heart catheterisa- tion): not reported				
	Number of patients with asymptomatic or mild symptom: not reported				
	Number of participants with COPD: not reported				
	Number of intubated participants: not reported				
	Inclusion criteria: Patients with heart disease who underwent right-heart catheterisation were included.				
	<b>Exclusion criteria:</b> Participants whose images of tricuspid regurgitation could not be documented				
Index tests	<b>Description of index test:</b> The continuous wave Doppler measurement of peak tricuspid regurgitation velocity was recorded according to the guidelines.				
	<b>Description of method to estimate right atrial pressure:</b> The right atrial pressure was categorised into three levels (3, 8, and 15 mmHg) on the basis of inferior vena cava diameter, together with its respiratory variation.				
	Cut-off value to declare PH: 41 mmHg				
	<b>Estimated systolic pulmonary arterial pressure:</b> median 27 mmHg (IQR: 21-37.5 mmHg)				
	Sonographer qualification: not reported				
	How to handle the uninterpretable results: not applicable				
Target condition and reference standard(s)	Target condition: pulmonary hypertension				

Cochrane Library

Sawada 2019 (Continued)	(Continued) Description of reference standard: The systolic, diastolic, and mean puln arterial pressure were measured in all participants during the end expirato riod by using a 7F Swan-Ganz catheter inserted via the femoral or internal j vein in the catheter laboratory.				
	Mean pulmonary arterial pressure: median 16 (IQR: 12-26 mmHg)				
Flow and timing	The interval between the	The interval between the index test and reference standard: within 24 hours			
	Number of indeterminates for whom the results of reference standard was avail- able: 0 (0%)				
	Number of patients who were excluded from the analysis: 0 (0%)				
Comparative					
Notes					
Methodological quality					
Item	Authors' judgement	Risk of bias	Applicability concerns		
DOMAIN 1: Patient Selection					
Was a consecutive or random sample of patients enrolled?	Yes				
Did the study avoid inappropriate exclusions?	No				
Could the selection of patients have intro- duced bias?		High risk			
Are there concerns that the included patients and setting do not match the review ques- tion?			Unclear		
DOMAIN 2: Index Test (All tests)					
Were the index test results interpreted without knowledge of the results of the reference stan- dard?	Yes				
If a threshold was used, was it pre-specified?	Unclear				
Could the conduct or interpretation of the in- dex test have introduced bias?		Low risk			
Are there concerns that the index test, its con- duct, or interpretation differ from the review question?			Low concern		
DOMAIN 3: Reference Standard					
Were the reference standard results interpret- ed without knowledge of the results of the index tests?	Yes				



Sawada 2019 (Continued)		
Were the criteria of reference standard for target condition prespecified?	Yes	
Could the reference standard, its conduct, or its interpretation have introduced bias?		Low risk
Are there concerns that the target condition as defined by the reference standard does not match the question?		Low concern
DOMAIN 4: Flow and Timing		
Was the interval between the index test and reference standard less than one day?	Yes	
Did all patients receive the same reference stan- dard?	Yes	
Were all patients included in the analysis?	Yes	
Could the patient flow have introduced bias?		Low risk

# Schneider 2017

Study characteristics			
Patient Sampling	Prospective		
Patient characteristics and setting	Study location: Austria		
	Study periods: between July 2015 and July 2016		
	Care setting: Medical University of Vienna		
	Participants enrolled: 65: 28 males and 37 females		
	Participants included in analysis: 65: 28 males and 37 females		
	Age: mean age 67.2 years (range: 19-89 years)		
	BMI: not reported		
	Classification of PH defined by WHO (diagnosis from right-heart catheterisation): Class I: 8, Class II: 23, Class III: 10, Class IV: 13, Class V: 0		
	Number of patients with asymptomatic or mild symptom: not reported		
	Number of participants with COPD: not reported		
	Number of intubated participants: 0		
	<b>Inclusion criteria:</b> We prospectively included all adult patients with clinically indicated right-heart catheterisation between July 2015 and July 2016.		
	Exclusion criteria: Patients less than 18 years old were excluded.		
Index tests	<b>Description of index test:</b> Transthoracic echocardiograms (2D, Doppler) were performed with echocardiography systems equipped with 3.5 MHz transducers (Vivid E9, Vivid S70; General Electric Healthcare) according to the recommendations and guide-		

Lines by the American Society of Cchocardiography and the European Association of         Cardiovascular imagin; hall platines, peak continuous wave Doppler velocity of the tricuspid regungitation jet was systematically measured in the parasternal Hong-axis view of the right ventricular inflow, and the subcostal four chamber view. the apical long axis is view of right ventricular inflow, and the subcostal four chamber view.         Description of method to estimate right atrial pressure: none         Cut-off value to declare PH: 34 mmHg         Estimated systolic pulmonary arterial pressure: none rout ported         Sonographer qualification: performed by experienced physician         How to handle the uninterpretable results: not applicable         Target condition and reference standard(s)         Description of method to estimate as average of eight measurements were performed pulmonary arterial pressure: mean 37.6 ± 14.9 mmHg         Flow and timing       The interval between the index test and reference standard: within 1 day         Number of indeterminates for whom the results of reference standard was available: 0 (0%).         Comparative       Ves         Number of indeterminates for whom the results of reference standard was available: 0 (0%).         DodAlN 1: Patient Selection       Yes         Nationary judgement       Risk of bias       A	Schneider 2017 (Continued)						
Periodian of method to estimater right atrial pressure: none         Cut off value to declare PH: 34 mmHg         Estimated systolic pulmomary terial pressure: not reported         Boographer qualification: performed by experienced physician         Target condition and reference standard(s)         Target condition: pulmomary terial pressure: not reported         Boographer qualification: performed by experienced physician         Target condition: pulmonary terial pressure: not applicable         Description of reference standard(s)         Target condition: pulmonary terial pressure: mean 37.6 ± 14.9 mmHg         Pressures were documented as average of eight measurements were performed by experiences (bMH, Austrial) via a formoral pair of indeterminates (control (Siemens AG, Berlin and Munich, Germany)).         Pressures were documented as average of eight measurements were register on indeterminates (control (Siemens AG, Berlin and Munich, Germany).         Pressures were documented as average of eight measurements were register on indeterminates (control (Siemens AG, Berlin and Munich, Germany).         Pressures were excluded from the analysis.0 (Ow)         Number of patients who were excluded from the analysis.0 (Ow)         Pressures were excluded from the analysis.0 (Ow)         Pressure some ender one patients were excluded from the analysis.0 (Ow)         Pressure some ender one patient solution (Control (Siemens AG, Berlin and Munich, Germany).         Pressure Some ender one patient solution (Control (Sieme		lines by the American Society of Echocardiography and the European Association of Cardiovascular Imaging. In all patients, peak continuous wave Doppler velocity of the tricuspid regurgitation jet was systematically measured in the parasternal long-axis view of the right ventricular inflow, the parasternal short axis view of the basal right ventricular, the right ventricular modified apical four chamber view, the apical long ax- is view of right ventricular inflow, and the subcostal four chamber view.					
Cut-off value to declare PH: 34 mmHg         Estimated systolic pulmonary arterial pressure: not reported         Songrapher qualification: performed by experienced physician:         How to handle the uninterpretable results: not applicable         Target condition and reference standards         Bescription of reference standards         Target condition and reference standards         Bescription of indeterminates for whom the results of reference standard was available: 0 (0%)         Number of indeterminates for whom the results of reference standards         Bescription of patients who were setladed finat thesingly         Buthotdologica		Description of method to estimate right atrial pressure: none					
Estimated systolic pulmonary arterial pressure: not reported         Songrapher qualification: performed by experienced physician:         How to handle the uninterpretable results: not applicable         Target condition and reference standard(s)       Target condition: pulmonary hypertension         Description of reference standard(s)       Memoral accessore eight measurements were performed using a 7F Swan-Ganz catheter (Edwards Lifesciences GmbH, Austria) via a femoral accessore eight measurements were performed using a 7F Swan-Ganz catheter (Edwards Lifesciences GmbH, Austria) via a femoral accessore eight measurements were performed using a 7F Swan-Ganz catheter (Edwards Lifesciences GmbH, Austria) via a femoral accessore eight measurements were performed using a 7F Swan-Ganz catheter (Edwards Lifesciences GmbH, Austria) via a femoral accessore eight measurements were performed using a 7F Swan-Ganz catheter (Edwards Lifesciences GmbH, Austria) via a femoral accessore eight measurements were performed using a 7F Swan-Ganz catheter (Edwards Lifesciences GmbH, Austria) via a femoral accessore eight measurements were performed using a 7F Swan-Ganz catheter (Edwards Lifesciences GmbH, Austria) via a femoral accessore eight measurements were performed using a 7F Swan-Ganz catheter (Edwards Lifesciences GmbH, Austria) via a femoral accessore eight measurements were performed using a 7F Swan-Ganz catheter (Edwards Lifesciences Standard: within 1 day         Mumbe		Cut-off value to declare PH: 34 mmHg					
Songrapher qualification: performed by experienced physician         How to handle the uninterpretable results: not applicable         Target condition and reference standard(s)       Target condition: pulmonary hypertension         Bescription of reference stardard(s)       Target condition: pulmonary actatheter (Edwards Lifesciences GMBH, Austria) via a femoral accase sere sere of eight measurements were performed using a 7F Swan-Canz catheter (Edwards Lifesciences GMBH, Austria) via a femoral accase sere sere documented as average of eight measurements over eight consuments over eight cons		Estimated systolic pulmonary arterial pressure: not reported					
How to handle the uninterpretable results: not applicable         Target condition and reference standard()       Target condition: pulmonary typertension         Bescription of reference standard()       Bescription of reference standard()         Bescription of reference standard()       Haemodynamic measurements were eperformed using a 75 Swan-Ganz catheler (Edwards Lifesciences of mbH, Austria) via a femoral access. Pressures were documented as average of eight measurements were eperformed scenarios.         Main pulmonary arterial pressure: mean 37.6 ±14.9 mm//       Munich Germany).         Marpendin and the index test and reference standard was available: 0 (%).       Number of indeterminates for whom the results of reference standard was available: 0 (%).         Comparative       Number of patients who were excluded from the analysis: 0 (%).         Mathodological quality       Immer of patients who were excluded from the analysis: 0 (%).         Mathodological quality       Immer of patients who were excluded from the analysis: 0 (%).         Mathodological quality       Immer of patients who were excluded from the analysis: 0 (%).         Mathodological quality       Immer of patients who were excluded from the analysis: 0 (%).         Mathodological quality       Immer of patients who were excluded from the analysis: 0 (%).         Mathodological quality       Immer of patients who were excluded from the analysis: 0 (%).         Mathodological quality       Immer of patients who were excluded from the analysis: 0 (%).		Sonographer qualification: performed by experienced physician					
Target condition: pulmonary hypertension         Description of reference standard: Haemodynamic measurements over eperformed using a 7F. Swan-Ganz catheter (Edwards Lifesciences GmbH, Austria) via a femoral access. Pressures were do cumented as a vareage of eight measurements over eight consecutive heart cycles using CathCorLX (Siemens AG, Berlin and Munich, Germany).         Mean pulmonary arterial pressure: mean 37.6 ± 14.9 mmHz         Flow and timing       The interval between the index test and reference standard: within 1 day         Number of indeterminates for whom the results of reference standard as available: 0 (0%)       Number of patients who were excluded from the analysis: 0 (0%)         Comparative       Ves         Methodological quality       Yes         Mag a consecutive or random sample of patients whore standard: Vess       Yes         Did the study avoid inappropriate exclu-       Yes         Conduct be selection of patients have in-       Low risk         Are there concerns that the included pa-tients and setting do not match there-       Low risk         DOMAIN 2: Index Test (All tests)       Low concern		How to handle the uninterpretable results: not applicable					
Description of reference standard: Haemodynamic measurements were performed using a 7F Swan-Ganz catheter (Edwards Lifescinces GmbH, Austria) via a femoral access. Pressures were documented as avarage of eight measurements over eight consecutive heart cycles using CathCorLX (Siemens AG, Berlin and Munich, Germany). Mean pulmonary arterial pressure: mean 37.6 ± 14.9 mmH         Flow and timing       The interval between the index test and reference standard: within 1 day Number of indeterminates for whom the results of reference standard was available: 0 (0%)         Comparative       Vumber of patients who were excluded from the analysis: 0 (0%)         Number of patients who were excluded from the analysis: 0 (0%)       Number of patients who were excluded from the analysis: 0 (0%)         Methodological quality       Ves       Ves         DOMAIN 1: Patient Selection       Ves       Ves         Vas a consecutive or random sample of patients have inite encluded bias?       Yes       Low risk         Could the selection of patients have inite encluded bias?       Low concern       Low concern         Are there concerns that the included patients may enclude bias?       Low concern       Low concern         DOMAIN 2: Index Test (All tests)       Ves       Low concern       Low concern	Target condition and reference standard(s)	Target condition: pulmonary hypertension					
Mean pulmonary arterial pressure: mean 37.6 ± 14.9 mmHg         Flow and timing       The interval between the index test and reference standard: within 1 day Number of indeterminates for whom the results of reference standard was available: 0 (0%) Number of patients who were excluded from the analysis: 0 (0%)         Comparative       Image: standard was available: 0 (0%)         Notes       Image: standard was available: 0 (0%)         Methodological quality       Image: standard was available: 0 (0%)         DOMAIN 1: Patient Selection       Kisk of bias       Applicability concerns         Vas a consecutive or random sample of patients enrolled?       Yes       Image: standard was available: 0 (0%)         Did the study avoid inappropriate exclu- sions?       Yes       Image: standard was available: 0 		<b>Description of reference standard:</b> Haemodynamic measurements were performed using a 7F Swan-Ganz catheter (Edwards Lifesciences GmbH, Austria) via a femoral access. Pressures were documented as average of eight measurements over eight consecutive heart cycles using CathCorLX (Siemens AG, Berlin and Munich, Germany).					
Flow and timing       The interval between the index test and reference standard: within 1 day         Number of indeterminates for whom the results of reference standard was available: 0 (0%)         Number of patients who were excluded from the analysis: 0 (0%)         Comparative         Notes         Methodological quality         Item       Authors' judgement       Risk of bias       Applicability concerns         DOMAIN 1: Patient Selection       Yes       Image: Selection Selection       Image: Selection Selection Selection         Did the study avoid inappropriate exclusions?       Yes       Image: Selection Selection Selection Selection Selection Selection Selection Selection of patients have introduced bias?       Low risk         Are there concerns that the included patients have introduced bias?       Low concern       Low concern         DOMAIN 2: Index Test (All tests)       Selection Select		Mean pulmonary arterial pressure: mean $37.6 \pm 14.9 \text{ mmHg}$					
Number of indeterminates for whom the results of reference standard was available: 0         Number of patients who were excluded from the analysis: 0 (0%)         Comparative         Notes         Methodological quality         Item       Authors' judgement       Risk of bias       Applicability concerns         DOMAIN 1: Patient Selection       Yes       Item       Yes         Did the study avoid inappropriate exclusions?       Yes       Item risk       Item risk         Could the selection of patients have introduced bias?       Low risk       Low concern         Are there concerns that the included patients and setting do not match the review question?       Low concern       Low concern	Flow and timing	The interval between the index test and reference standard: within 1 day					
Number of patients who were excluded from the analysis: 0 (0%)         Comparative         Notes         Methodological quality         Item       Authors' judgement       Risk of bias       Applicability concerns         DOMAIN 1: Patient Selection       Yes       Implicability concerns         Did the study avoid inappropriate exclu- sions?       Yes       Implicability concerns         Could the selection of patients have in- troduced bias?       Yes       Implicability concerns         Are there concerns that the included pa- tients and setting do not match the re- view question?       Implicability concern         DOMAIN 2: Index Test (All tests)       Implicability concerns		Number of indeterminates for whom the results of reference standard was available: 0 (0%)					
Comparative         Notes         Methodological quality         Item       Authors' judgement       Risk of bias       Applicability concerns         DOMAIN 1: Patient Selection       Yes       Implicability concerns       Implicability concerns         Was a consecutive or random sample of patients enrolled?       Yes       Implicability concerns       Implicability concerns         Did the study avoid inappropriate exclusions?       Yes       Implicability concerns       Implicability concerns         Could the selection of patients have introduced bias?       Yes       Implicability concern       Implicability concern         Are there concerns that the included patients and setting do not match the review question?       Implicability concern       Implicability concern         DOMAIN 2: Index Test (All tests)       Implicability concerns       Implicability concerns       Implicability concerns		Number of patients who were excluded from the analysis: 0 (0%)					
Notes         Methodological quality         Item       Authors' judgement       Risk of bias       Applicability concerns         DOMAIN 1: Patient Selection       Yes       Item       Yes         Was a consecutive or random sample of patients enrolled?       Yes       Item       Yes         Did the study avoid inappropriate exclusions?       Yes       Item       Low risk         Could the selection of patients have introduced bias?       Low risk       Low concern         Are there concerns that the included patients and setting do not match the review question?       Low concern       Low concern         DOMAIN 2: Index Test (All tests)       Item       Item       Item	Comparative						
Methodological quality         Item       Authors' judgement       Risk of bias       Applicability concerns         DOMAIN 1: Patient Selection       Yes       Image: Selection of patients and sample of patients enrolled?       Yes         Did the study avoid inappropriate exclusions?       Yes       Image: Selection of patients have introduced bias?       Low risk         Are there concerns that the included patients and setting do not match the review question?       Low concern       Low concern         DOMAIN 2: Index Test (All tests)       Image: Selection of patients test patients test patients test patients test patients test patients test patients patients and setting do not match the review question?       Image: Selection patients test patients test patients patient	Notes						
ItemAuthors' judgementRisk of biasApplicability concernsDOMAIN 1: Patient SelectionWas a consecutive or random sample of patients enrolled?YesDid the study avoid inappropriate exclusions?YesCould the selection of patients have in- troduced bias?Low riskAre there concerns that the included pa- tients and setting do not match the re- view question?Low concernDOMAIN 2: Index Test (All tests)Ves	Methodological quality						
DOMAIN 1: Patient Selection         Was a consecutive or random sample of patients enrolled?         Did the study avoid inappropriate exclusions?         Ves         Could the selection of patients have introduced bias?         Are there concerns that the included patients and setting do not match the review question?         DOMAIN 2: Index Test (All tests)	Item	Authors' judgement	Risk of bias	Applicability concerns			
Was a consecutive or random sample of patients enrolled?       Yes         Did the study avoid inappropriate exclusions?       Yes         Could the selection of patients have introduced bias?       Low risk         Are there concerns that the included patients and setting do not match the review question?       Low concern         DOMAIN 2: Index Test (All tests)       Ves	DOMAIN 1: Patient Selection						
Did the study avoid inappropriate exclusions?       Yes         Could the selection of patients have introduced bias?       Low risk         Are there concerns that the included patients and setting do not match the review question?       Low concern         DOMAIN 2: Index Test (All tests)       Ves	Was a consecutive or random sample of patients enrolled?	Yes					
Could the selection of patients have in- troduced bias?       Low risk         Are there concerns that the included pa- tients and setting do not match the re- view question?       Low concern         DOMAIN 2: Index Test (All tests)       Low concern	Did the study avoid inappropriate exclu- sions?	Yes					
Are there concerns that the included pa- tients and setting do not match the re- view question?       Low concern         DOMAIN 2: Index Test (All tests)       Low concern	Could the selection of patients have in- troduced bias?		Low risk				
DOMAIN 2: Index Test (All tests)	Are there concerns that the included pa- tients and setting do not match the re- view question?			Low concern			
	DOMAIN 2: Index Test (All tests)						


Schneider 2017 (Continued)			
Were the index test results interpreted without knowledge of the results of the ref- erence standard?	Unclear		
If a threshold was used, was it pre-speci- fied?	Yes		
Could the conduct or interpretation of the index test have introduced bias?		Unclear risk	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?			High
DOMAIN 3: Reference Standard			
Were the reference standard results inter- preted without knowledge of the results of the index tests?	Unclear		
Were the criteria of reference standard for target condition prespecified?	Yes		
Could the reference standard, its con- duct, or its interpretation have intro- duced bias?		Unclear risk	
Are there concerns that the target con- dition as defined by the reference stan- dard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			
Was the interval between the index test and reference standard less than one day?	Yes		
Did all patients receive the same reference standard?	Yes		
Were all patients included in the analysis?	Yes		
Could the patient flow have introduced bias?		Low risk	

#### Venkateshvaran 2021

Study characteristics	
Patient Sampling	Retrospective
Patient characteristics and setting	Study location: Sweden
	Study periods: between 2010 and 2018
	Care setting: Karolinska University Hospital and Norrlands University Hospital



Venkateshvaran 2021 (Continued)	Participants enrolled: 480
	Participants included in analysis: 419: 199 males and 220 females
	Age: not reported
	BMI: not reported
	Classification of PH defined by WHO (diagnosis from right-heart catheterisation): not re- ported
	Number of patients with asymptomatic or mild symptom: not reported
	Number of participants with COPD: not reported
	Number of intubated participants: not reported
	<b>Inclusion criteria:</b> patients with unexplained dyspnoea referred for right-heart catheterisa- tion to the pulmonary hypertension referral centres at Karolinska University Hospital (2014– 2018) and Norrlands University Hospital (2010–2015)
	<b>Exclusion criteria:</b> Subjects with absent or poor TR signal quality, in addition to those with a fail tricuspid valve, endocarditis or a coaptation defect resulting in massive, free-flowing jet
Index tests	<b>Description of index test:</b> TRVmax was measured with continuous wave Doppler, considering the most optimal signal obtained from multiple echocardiographic windows. RAP- mean was estimated by evaluating inferior vena cava (IVC) size and collapsibility with pa- tients in a supine position, taking care to maximise IVC diameter both during relaxed respira- tion and with rapid inspiration. All images were subsequently exported and analysed offline (EchoPACPC version 11.0.0.0 GE Ultrasound, Waukesha, Wisconsin).
	<b>Description of method to estimate right atrial pressure:</b> RAPmean was estimated as 3 mmHg if the IVC diameter was < 2.1 cm and collapsed > 50% during rapid inspiration and 15 mmHg if the IVC diameter was ≥ 2.1 cm and collapsed < 50%. In scenarios where IVC size and dynamics did not ft this paradigm (IVC diameter < 2.1 cm with < 50% collapse and IVC diameter ter ≥ 2.1 cm with > 50% collapse), RAPmean was estimated as 8 mmHg.
	Cut-off value to declare PH: 2.8 m/sec
	Estimated systolic pulmonary arterial pressure: not reported
	Sonographer qualification: credentialed echocardiographers with > 15 years' experience
	How to handle the uninterpretable results: excluded from analysis
Target condition and reference	Target condition: pulmonary hypertension
standard(s)	<b>Description of reference standard:</b> 6F Swan Ganz catheter employing jugular or femoral vein access. After suitable calibration with the zero-level set at the mid-thoracic line, pressure measurements were taken from the right atrium (RA), right ventricle (RV) and PA during end-expiration. Five to ten cardiac cycles were acquired and all pressure tracings were stored and analysed offline using a standard haemodynamic software package (WITT Series III, Witt Bio-medical Corp., Melbourne, FL).
	Mean pulmonary arterial pressure: median 32 (IQR: 23-41 mmHg)
Flow and timing	The interval between the index test and reference standard: within 3 hours
	Number of indeterminates for whom the results of reference standard was available: $0$
	Number of patients who were excluded from the analysis: 61

Comparative



#### Venkateshvaran 2021 (Continued)

Notes			
Methodological quality			
Item	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sam- ple of patients enrolled?	Yes		
Did the study avoid inappropriate exclusions?	No		
Could the selection of patients have introduced bias?		High risk	
Are there concerns that the in- cluded patients and setting do not match the review question?			Unclear
DOMAIN 2: Index Test (All tests)			
Were the index test results interpret- ed without knowledge of the results of the reference standard?	Yes		
If a threshold was used, was it pre- specified?	Unclear		
Could the conduct or interpreta- tion of the index test have intro- duced bias?		Unclear risk	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?			High
DOMAIN 3: Reference Standard			
Were the reference standard results interpreted without knowledge of the results of the index tests?	Yes		
Were the criteria of reference stan- dard for target condition prespeci- fied?	Yes		
Could the reference standard, its conduct, or its interpretation have introduced bias?		Low risk	
Are there concerns that the target condition as defined by the refer- ence standard does not match the question?			Low concern



### Venkateshvaran 2021 (Continued)

DOMAIN 4: Flow and Timing		
Was the interval between the in- dex test and reference standard less than one day?	Yes	
Did all patients receive the same ref- erence standard?	Yes	
Were all patients included in the analysis?	No	
Could the patient flow have intro- duced bias?		High risk

## Wainstein 2017

Study characteristics	
Patient Sampling	Retrospective
Patient characteristics and setting	Study location: Argentina
	Study periods: between June 2010 and June 2016
	Care setting: Transplant Center in Buenos Aires, Argentina
	Participants enrolled: 134: 63 males and 71 females
	Participants included in analysis: 134: 63 males and 71 females
	<b>Age:</b> mean age $47 \pm 14.7$ years
	BMI: not reported
	<b>Classification of PH defined by WHO (diagnosis from</b> right-heart catheterisation): Class I: 0, Class II: 0, Class III: 83, Class IV: 0, Class V: 0
	Number of patients with asymptomatic or mild symptom: not report- ed
	Number of participants with COPD: 65
	Number of intubated participants: 0
	<b>Inclusion criteria:</b> The population included all patients who had Doppler echocardiography and right-heart catheterisation performed within 3 days of each other.
	Exclusion criteria: not reported
Index tests	Description of index test: not reported
	Description of method to estimate right atrial pressure: not reported
	Cut-off value to declare PH: 36 mmHg
	Estimated systolic pulmonary arterial pressure: not reported
	Sonographer qualification: not reported

Wainstein 2017 (Continued)	How to handle the uni	nterpretable results:	not applicable
Target condition and reference standard(s)	Target condition: puln	nonary hypertension	
	Description of referen	<b>ce standard:</b> not repo	orted
	Mean pulmonary arter	rial pressure: not repo	orted
Flow and timing	The interval between th days	e index test and refere	ence standard: within 3
	Number of indetermina was available: 0 (0%)	tes for whom the resu	lts of reference standard
	Number of patients who	o were excluded from	the analysis: 0 (0%)
Comparative			
Notes			
Methodological quality			
Item	Authors' judgement	Risk of bias	Applicability con- cerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sample of patients en- rolled?	Yes		
Did the study avoid inappropriate exclusions?	Yes		
Could the selection of patients have introduced bias?		Low risk	
Are there concerns that the included patients and set- ting do not match the review question?			High
DOMAIN 2: Index Test (All tests)			
Were the index test results interpreted without knowl- edge of the results of the reference standard?	Unclear		
If a threshold was used, was it pre-specified?	Unclear		
Could the conduct or interpretation of the index test have introduced bias?		Unclear risk	
Are there concerns that the index test, its conduct, or interpretation differ from the review question?			Unclear
DOMAIN 3: Reference Standard			
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear		
Were the criteria of reference standard for target condi- tion prespecified?	Unclear		



Wainstein 2017 (Continued)			
Could the reference standard, its conduct, or its inter- pretation have introduced bias?		Unclear risk	
Are there concerns that the target condition as de- fined by the reference standard does not match the question?			Low concern
DOMAIN 4: Flow and Timing			
Was the interval between the index test and reference standard less than one day?	No		
Did all patients receive the same reference standard?	Yes		
Were all patients included in the analysis?	Yes		
Could the patient flow have introduced bias?		High risk	
BMI: body mass index COPD: chronic obstructive pulmonary disease HIV: human immunodeficiency virus IQR: interquartile range IPH: idiopathic pulmonary hypertension IVC: inferior vena cava PA: pulmonary artery PCW: pulmonary capillary wedge PH: pulmonary typertension PP: pulmonary pressure PVR: pulmonary vascular resistance RA: right atrium RAPmean: mean right atrial pressure RVSP: right ventricular systolic pressure RV: right ventricle TR: tricuspid regurgitation TRVmax: tricuspid regurgitation velocity maximum UERD: University echocardiographic regional diploma v: velocity WHO: World Health Organization			

# Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Aashish 2020	Insufficient diagnostic test accuracy data
Abaci 1998	Insufficient diagnostic test accuracy data
Abbas 2003	Insufficient diagnostic test accuracy data
Abreu 1990	Insufficient diagnostic test accuracy data
Adrian 2016	Case series
Aduen 2009	Insufficient diagnostic test accuracy data
Aduen 2011	Insufficient diagnostic test accuracy data



Study	Reason for exclusion
Agrawal 2019	Insufficient diagnostic test accuracy data
Ahmed 2016	The index test and reference standard were not performed within one week.
Albani 2020	Insufficient diagnostic test accuracy data
Ali 1987	Not a diagnostic test accuracy study
Ali 1988	Not a diagnostic test accuracy study
Alonso 1988	Insufficient diagnostic test accuracy data
Althammer 1994	Inappropriate target condition
Antoun 2009	Insufficient diagnostic test accuracy data
Arcasoy 2003	Insufficient diagnostic test accuracy data
Arellano 2017	Insufficient diagnostic test accuracy data
Artaud-Macari 2010	Insufficient diagnostic test accuracy data
Ashrith 2015	Case series
Attaran 2009	Insufficient diagnostic test accuracy data
Barbier 2020	Insufficient diagnostic test accuracy data
Bech-Hanssen 2009	Insufficient diagnostic test accuracy data
Bech-Hanssen 2013	Insufficient diagnostic test accuracy data
Belfort 1994	Not a diagnostic test accuracy study
Bloch 1989	Not a diagnostic test accuracy study
Boley 2013	Insufficient diagnostic test accuracy data
Bournia 2020	Insufficient diagnostic test accuracy data
Calvin 2011	The index test and reference standard were not performed within one week.
Caravita 2019	Insufficient diagnostic test accuracy data
Castria 2012	Insufficient diagnostic test accuracy data
Cebrian 2010	Insufficient diagnostic test accuracy data
Chan 1987	Insufficient diagnostic test accuracy data
ChiCtr65129	Inappropriate index test
Correale 2019	Insufficient diagnostic test accuracy data
Cottini 2017	Insufficient diagnostic test accuracy data



Study	Reason for exclusion
Cotton 2002	Insufficient diagnostic test accuracy data
D'Alto 2013	Insufficient diagnostic test accuracy data
D'Alto 2018	Not a diagnostic test accuracy study
De Scordilli 2019	Inappropriate reference standard
Denton 1997	The index test and reference standard were not performed within one week.
Dina 2020	Insufficient diagnostic test accuracy data
Doutreleau 2016	Insufficient diagnostic test accuracy data
Etxebeste 1989	Insufficient diagnostic test accuracy data
Fauvel 2020	Inappropriate reference standard
Fei 2017	Insufficient diagnostic test accuracy data
Finkelhor 2014	The index test and reference standard were not performed within one week.
Fisher 2004	Insufficient diagnostic test accuracy data
Fisher 2007	The index test and reference standard were not performed within one week.
Fisher 2009	Insufficient diagnostic test accuracy data
Fitzgerald 2012	Case series
Fontana 2013	Insufficient diagnostic test accuracy data
Gallet 1989	Insufficient diagnostic test accuracy data
Ge 1993	Inappropriate population
Gelape 2011	Insufficient diagnostic test accuracy data
Glinel 2015	Not a diagnostic test accuracy study
Gopal 2014	Insufficient diagnostic test accuracy data
Granstam 2013	Insufficient diagnostic test accuracy data
Guvenc 2020	Inappropriate population
Habash 2017	Case-control study
Habash 2018	The index test and reference standard were not performed within one week.
Hachulla 2004	Not a diagnostic test accuracy study
Hachulla 2005	Insufficient diagnostic test accuracy data
Held 2014	Insufficient diagnostic test accuracy data



Study	Reason for exclusion
Hilde 2012	Insufficient diagnostic test accuracy data
Hsu 2004	Insufficient diagnostic test accuracy data
Hua 2009	Inappropriate target condition
Jiang 2017	Insufficient diagnostic test accuracy data
Julien 2015	Case series
Junsirimongkol 2019	Insufficient diagnostic test accuracy data
Khanduja 2012	Insufficient diagnostic test accuracy data.
Kim 2000	Insufficient diagnostic test accuracy data
Kim 2013	Insufficient diagnostic test accuracy data
Kooranifar 2021	Insufficient diagnostic test accuracy data
Kovacs 2014	Inappropriate index test
Krowka 1999	Insufficient diagnostic test accuracy data
Laaban 1989	Inappropriate index test
Laaban 1989a	Insufficient diagnostic test accuracy data
Lamia 2014	Insufficient diagnostic test accuracy data
Lange 2013	The index test and reference standard were not performed within one week.
Lanzarini 2005	Insufficient diagnostic test accuracy data
Li 1988	Insufficient diagnostic test accuracy data
Lindgren 2009	Insufficient diagnostic test accuracy data
Lindqvist 2011	Inappropriate population
Lindqvist 2012	Insufficient diagnostic test accuracy data
Lindqvist 2013	Insufficient diagnostic test accuracy data
Maeder 2010	Insufficient diagnostic test accuracy data
Maeder 2011	Insufficient diagnostic test accuracy data
Marangoni 1988	Insufficient diagnostic test accuracy data
Matos 1988	Insufficient diagnostic test accuracy data
McClanahan 2011	Insufficient diagnostic test accuracy data
Mercado 2019	Insufficient diagnostic test accuracy data



Study	Reason for exclusion
Metz 1987	Insufficient diagnostic test accuracy data
Metz 1991	Insufficient diagnostic test accuracy data
Minai 2010	Insufficient diagnostic test accuracy data
Miyamoto 1993	Not a diagnostic test accuracy study
Mo 2015b	Inappropriate target condition
Modrykamien 2010	The index test and reference standard were not performed within one week.
Mogollon 2008	Inappropriate reference standard
Mukerjee 2004	The index test and reference standard were not performed within one week.
Naeije 1995	Not a diagnostic test accuracy study
Nathan 2008	The index test and reference standard were not performed within one week.
Niederle 1988	Insufficient diagnostic test accuracy data
Niederle 1990	Insufficient diagnostic test accuracy data
Nishimaki 1991	Insufficient diagnostic test accuracy data
Nogami 2009	Insufficient diagnostic test accuracy data
O'Leary 2018	Insufficient diagnostic test accuracy data
Okubo 1988	Insufficient diagnostic test accuracy data
Okubo 1989	Insufficient diagnostic test accuracy data
Oudiz 2003	Not a diagnostic test accuracy study
Pande 2014	Inappropriate population
Parsaee 2016	Insufficient diagnostic test accuracy data
Pasierski 1993	Not a diagnostic test accuracy study
Penning 2001	Inappropriate reference standard
Phetcharat 2019	Index test and reference standard were not performed within one week
Philip 2013	The index test and reference standard were not performed within one week.
Polak-Slaboszewska 1989	Insufficient diagnostic test accuracy data
Prasanna 2009	Insufficient diagnostic test accuracy data
Raevens 2013	Insufficient diagnostic test accuracy data
Raevens 2013a	Insufficient diagnostic test accuracy data



Study	Reason for exclusion
Rajagopalan 2009	Inappropriate target condition
Rallidis 2020	Inappropriate reference standard
Rallidis 2021	Inappropriate reference standard
Refini 2021	Insufficient diagnostic test accuracy data
Rich 2010	Insufficient diagnostic test accuracy data
Rich 2011	Insufficient diagnostic test accuracy data
Roodpeyma 2015	Insufficient diagnostic test accuracy data
Saner 2006	Insufficient diagnostic test accuracy data
Schewel 2020	Insufficient diagnostic test accuracy data
Schiopu 2010	The index test and reference standard were not performed within one week.
Seidova 2020	Insufficient diagnostic test accuracy data
Selby 2012	Insufficient diagnostic test accuracy data
Shen 1989	Insufficient diagnostic test accuracy data
Shim 2018	Not a diagnostic test accuracy study
Skjaerpe 1986	Insufficient diagnostic test accuracy data
Slegg 2021	Insufficient diagnostic test accuracy data
Sohrabi 2016	Insufficient diagnostic test accuracy data
Solik 2013	Insufficient diagnostic test accuracy data
Sonaglioni 2021	Inappropriate population
Torbicki 1987	Insufficient diagnostic test accuracy data
Torbicki 1989	Insufficient diagnostic test accuracy data
Torregrosa 2001	The index test and reference standard were not performed within one week.
Tramarin 1991	Inappropriate reference standard
Wahi 2015	Insufficient diagnostic test accuracy data
Wang 2016	Inappropriate population
Wilansky 1998	Not a diagnostic test accuracy study
Wurtemberger 1992	Insufficient diagnostic test accuracy data
Wylie 2007	Insufficient diagnostic test accuracy data



Study	Reason for exclusion
Yagi 1988	Insufficient diagnostic test accuracy data.
Yamamoto 2013	Insufficient diagnostic test accuracy data
Yamamoto 2013a	Insufficient diagnostic test accuracy data
Yock 1984	Insufficient diagnostic test accuracy data
Zenker 1987	Insufficient diagnostic test accuracy data
Zhuravlev 2004	Not a diagnostic test accuracy study
Zompatori 1993	Insufficient diagnostic test accuracy data

# DATA

Presented below are all the data for all of the tests entered into the review.

## Table Tests. Data tables by test

Test	No. of studies	No. of participants
1 Doppler trans-thoracic echocardiography	17	3656
2 Sensitivity analysis 1	4	254

# Test 1. Doppler trans-thoracic echocardiography

#### Doppler trans-thoracic echocardiography

Study	ТР	FP	FN	TN	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)Specificity (95% CI)
Amsallem 2016	140	5	13	41	0.92 [0.86, 0.95]	0.89 [0.76, 0.96]	• -•
Balci 2016	50	15	9	29	0.85 [0.73, 0.93]	0.66 [0.50, 0.80]	
Colle 2003	13	8	4	140	0.76 [0.50, 0.93]	0.95 [0.90, 0.98]	
Er 2010	42	0	1	7	0.98 [0.88, 1.00]	1.00 [0.59, 1.00]	
Greiner 2014	86	334	13	1262	0.87 [0.79, 0.93]	0.79 [0.77, 0.81]	
Hellenkamp 2018	55	10	13	12	0.81 [0.70, 0.89]	0.55 [0.32, 0.76]	
Hsu 2008	12	3	4	30	0.75 [0.48, 0.93]	0.91 [0.76, 0.98]	
Kyranis 2018	60	4	5	27	0.92 [0.83, 0.97]	0.87 [0.70, 0.96]	
Lafitte 2013	91	9	12	43	0.88 [0.81, 0.94]	0.83 [0.70, 0.92]	
Mazhar 2011	38	- 7	19	35	0.67 [0.53, 0.79]	0.83 [0.69, 0.93]	
Mo 2015	20	2	1	1	0.95 [0.76, 1.00]	0.33 [0.01, 0.91]	
Mo 2015a	48	4	11	24	0.81 [0.69, 0.90]	0.86 [0.67, 0.96]	
Nowak 2018	24	2	2	9	0.92 [0.75, 0.99]	0.82 [0.48, 0.98]	
Sawada 2019	45	13	4	127	0.92 [0.80, 0.98]	0.91 [0.85, 0.95]	-+ +
Schneider 2017	47	1	- 7	10	0.87 [0.75, 0.95]	0.91 [0.59, 1.00]	
Venkateshvaran 2021	364	4	45	6	0.89 [0.86, 0.92]	0.60 [0.26, 0.88]	••
Wainstein 2017	33	6	50	45	0.40 [0.29, 0.51]	0.88 [0.76, 0.96]	



# Test 2. Sensitivity analysis 1

## Sensitivity analysis 1

Study	ΤР	FP	FN	τN	Sensitivity (95% CI)	Specificity (95% Cl)	Sensitivity (95% CI)Specificity (95% CI)
Er 2010	42	0	1	7	0.98 [0.88, 1.00]	1.00 [0.59, 1.00]	
Hellenkamp 2018	55	10	13	12	0.81 [0.70, 0.89]	0.55 [0.32, 0.76]	
Hsu 2008	12	3	4	30	0.75 [0.48, 0.93]	0.91 [0.76, 0.98]	
Schneider 2017	47	1	7	10	0.87 [0.75, 0.95]	0.91 [0.59, 1.00]	0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1

# Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults (Review) Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ADDITIONAL TABLES

Table 1. Summary of characteristics of included studies

Study ID	Number of partici- pants (in- cluded in analy- sis/in- cluded in study)	Preva- lence of PH (%)	Age	Sex, male (%)	Classifi- cation of PH defined by WHO	Thresh- old of index test (mmHg)	RAP estimation	The in- terval be- tween the index test and refer- ence stan- dard	How to han- dle the uninter- pretable results of the index test	Sensi- tivity	Speci- ficity
Amsallem 2016	199/307	77	50 ± (13)*	46	NR	40	using the diameter of IVC	2 days	excluded from analysis	92%	89%
Balci 2016	103/103	57	48 (18 to 70)***	65	Group 3	35	NR	3 days	NA	85%	66%
Colle 2003	165/165	10	48 ± (8)*	70	Group 1	30	using the diameter of IVC	7 days	NA	76%	95%
Er 2010	50/50	86	66.9 ± (14.5)*	28	NR	38	using the diameter of IVC	2 hours	NA	98%	100%
Greiner 2014	1695/3920	72	63 ± (15)*	67	NR	36	using the diameter of IVC	5 days	excluded from analysis	87%	79%
Hellenkamp 2018	90/90	76	64.8 [55 to 79]****	48	NR	31	using the diameter of IVC	1 days	NA	81%	55%
Hsu 2008	49/55	33	55 (20 to 80)**	18	Group 1	47	not using the diam- eter of IVC	4 hours	excluded from analysis	75%	91%
Kyranis 2018	96/100	68	58 ± (14)*	43	NR	31	using the diameter of IVC	1 days	excluded from analysis	92%	87%
Lafitte 2013	155/310	67	64.8 ± (15.9)*	52	NR	38	using the diameter of IVC	5 days	excluded from analysis	88%	83%
Mazhar 2011	99/159	58	NR	NR	NR	31	NR	3 days	excluded from analysis	67%	83%
Mo 2015	24/30	88	NR	NR	NR	35	NR	7 days	excluded from analysis	95%	33%

Cochrane Library

84

nmary of ch	aracteris	tics of include	d studies	<b>5</b> (Continued)						
87/87	68	NR	NR	NR	45	NR	7 days	excluded from analysis	81%	86%
37/65	70	53.3 ± (9.5)*	75	NR	43	NR	5 days	excluded from analysis	92%	82%
189 /189	26	58 ± (17)*	56	NR	41	using the diameter of IVC	1 days	NA	92%	91%
65/65	83	67.2 (19 to 89)**	43	mixture of Group 1, 2, 3, and 4	34	not using the diam- eter of IVC	1 days	NA	87%	91%
419/480	62	NR	NR	NR	31	using the diameter of IVC	3 hours	excluded from analysis	40%	88%
134/134	62	47 ± (14.7)*	47	Group 3	36	NR	3 days	NA	89%	60%
	nmary of ch 87/87 37/65 189 /189 65/65 419/480 134/134	arry of characteris         87/87       68         37/65       70         189 /189       26         65/65       83         419/480       62         134/134       62	arry of characteristics of includes $87/87$ $68$ NR $37/65$ $70$ $53.3 \pm (9.5)^*$ $189/189$ $26$ $58 \pm (17)^*$ $65/65$ $83$ $67.2 (19 \text{ to } 89)^{**}$ $419/480$ $62$ NR $134/134$ $62$ $47 \pm (14.7)^*$	mary of characteristics of included studies $87/87$ $68$ NRNR $37/65$ $70$ $53.3 \pm (9.5)^*$ $75$ $189/189$ $26$ $58 \pm (17)^*$ $56$ $65/65$ $83$ $67.2 (19 \text{ to } 43 89)^{**}$ $43$ $419/480$ $62$ NRNR $134/134$ $62$ $47 \pm (14.7)^*$ $47$	arry of characteristics of included studies (Continued) $87/87$ $68$ NRNRNR $37/65$ $70$ $53.3 \pm (9.5)^*$ $75$ NR $189/189$ $26$ $58 \pm (17)^*$ $56$ NR $65/65$ $83$ $67.2 (19 \text{ to} 89)^{**}$ $43$ mixture of Group 1, 2, 3, and 4 $419/480$ $62$ NRNRNR $134/134$ $62$ $47 \pm (14.7)^*$ $47$ Group 3	mary of characteristics of included studies (Continued) $87/87$ $68$ NRNRNR45 $37/65$ $70$ $53.3 \pm (9.5)^{\star}$ $75$ NR43 $189/189$ $26$ $58 \pm (17)^{\star}$ $56$ NR41 $65/65$ $83$ $67.2 (19 \text{ to } 89)^{\star \star}$ $43$ mixture of Group 1, 2, 3, and 4 $419/480$ $62$ NRNRNR31 $134/134$ $62$ $47 \pm (14.7)^{\star}$ $47$ Group 3 $36$	mary of characteristics of included studies (Continued) $87/87$ $68$ NR       NR       NR $45$ NR $37/65$ $70$ $53.3 \pm (9.5)^*$ $75$ NR $43$ NR $189/189$ $26$ $58 \pm (17)^*$ $56$ NR $41$ using the diameter of IVC $65/65$ $83$ $67.2 (19 \text{ to } 89)^{**}$ $43$ mixture of Group $1, 2, 3, and 4$ $34$ not using the diameter of IVC $419/480$ $62$ NR       NR       NR $31$ using the diameter of IVC $134/134$ $62$ $47 \pm (14.7)^*$ $47$ Group $3$ $36$ NR	mary of characteristics of included studies (continued) $87/87$ $68$ NRNRNR $45$ NR7 days $37/65$ $70$ $53.3 \pm (9.5)^{\star}$ $75$ NR $43$ NR $5$ days $189/189$ $26$ $58 \pm (17)^{\star}$ $56$ NR $41$ using the diameter of IVC $1$ days $65/65$ $83$ $67.2 (19 \text{ to } 89)^{\star \star}$ $43$ mixture of Group $1, 2, 3, and 4$ $34$ not using the diameter of IVC $1$ days $419/480$ $62$ NRNRNR $31$ using the diameter of IVC $3$ hours $134/134$ $62$ $47 \pm (14.7)^{\star}$ $47$ Group $3$ $36$ NR $3$ days	mary of characteristics of included studies (continued) $87/87$ $68$ NRNRNR $45$ NR $7 \text{ days}$ excluded from analysis $37/65$ $70$ $53.3 \pm$ (9.5)* $75$ NR $43$ NR $5 \text{ days}$ excluded from analysis $189/189$ $26$ $58 \pm (17)^*$ $56$ NR $41$ using the diameter of IVC $1 \text{ days}$ NA $65/65$ $83$ $67.2 (19 \text{ to})$ $89)**43mixtureof Group1, 2, 3,and 434not using the diameterof IVC1 \text{ days}NA419/48062NRNRNR31using the diameterof IVC3 \text{ hours}excluded fromanalysis134/1346247 \pm(14.7)*47Group 336NR3 \text{ days}NA$	Barry of characteristics of included studies (continued)         87/87       68       NR       NR       NR       45       NR       7 days       excluded from analysis       81%         37/65       70       53.3 ± (9.5)*       75       NR       43       NR       5 days       excluded from analysis       92%         189 /189       26       58 ± (17)*       56       NR       41       using the diameter of IVC       1 days       NA       92%         65/65       83       67.2 (19 to 89)**       43       mixture of Group 1, 2, 3, and 4       not using the diameter of IVC       1 days       NA       87%         419/480       62       NR       NR       31       using the diameter of IVC       3 hours       excluded from analysis       40%         134/134       62       47 ± (14.7)*       47       Group 3       36       NR       3 days       NA       89%

\* mean ± (SD), \*\* mean (range), \*\*\* median (range), \*\*\*\* mean [interquartile]

Abbreviations: IVC: inferior vena cava

NA: not applicable

NR: not reported

PH: pulmonary hypertension

RAP, right atrial pressure

WHO: World Health Organization

85

Cochrane Library

\_\_\_\_

\_\_\_\_

Covariate	Subgroup	Number of studies	Number of partici- pants	Number of cases	Sensitivity	Specificity
Overall		17	3656	1342	Median (range): 87% (40% to 98%)	Median (range): 86% (33% to 100%)
WHO Clas- sification of	Not Group 3	3	279	87	Median (range): 76% (75% to 87%)	Median (range): 91% (91% to 95%)
	Group 3	2	237	142	Median (range): 63% (40% to 85%)	Median (range): 77% (66% to 88%)
	Not report- ed	12	3141	1113	Median (range): 92% (67% to 98%)	Median (range): 85% (33% to 100%)
The meth- ods used to estimating RAP	Using the diameter of IVC	9	3057	967	Median (range): 92% (76% to 98%)	Median (range): 89% (55% to 100%)
	Not using the diame- ter of IVC	2	114	70	Median (range): 81% (75% to 87%)	Median (range): 91% (91% to 91%)
	Not report- ed	6	485	305	Median (range): 83% (40% to 95%)	Median (range): 83% (33% to 88%)
Threshold groups	< 36 mmHg	8	1061	711	Pooled sensitivity (95% CI): 89% (79% to 94%)	Pooled specificity (95% Cl): 83% (70% to 91%)
	≥ 36 mmHg and < 40 mmHg	4	2034	328	Pooled sensitivity* (95% CI): 85% (57% to 96%)	Pooled specificity* (95% CI): 80% (76% to 84%)
	≥ 40 mmHg	5	561	303	Pooled sensitivity* (95% Cl): 88% (83% to 92%)	Pooled specificity* (95% CI): 89% (85% to 93%)

# Table 2. Summary of investigations for heterogeneity

\* Pooled sensitivity and specificity estimated by the bivariate random effects model

Abbreviations: CI: confidence interval IVC: inferior vena cava PH: pulmonary hypertension RAP: right atrial pressure WHO: World Health Organization

-

# Table 3. Summary of the results from sensitivity analyses

Types of sensitivity analysis	Subgroup	Number of studies	Number of participants	Number of cases	Pooled sensitivity (95% CI) under		
					fixed specificity of 86%*		

## Table 3. Summary of the results from sensitivity analyses (Continued)

Overall		17	3,656	1,342	87% (81% to 92%)
Excluding studies at high risk of bias in domains 1 or 4	Not high risk of bias in domains 1 or 4	4	254	181	83% (11% to 100%)
of the QUADAS-2 assess- ment					
Prevalence category	1st quartile	4	2098	181	84% (67% to 100%)
	2nd quartile	4	491	302	70% (8% to 100%)
	3rd quartile	4	310	218	79% (28% to 100%)
	4th quartile	5	757	641	84% (6% to 100%)

\* Pooled sensitivity and its 95% confidence interval using fixed specificity of 86% (median of the included studies).

Abbreviations:

CI: confidence interval

QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies

## APPENDICES

# Appendix 1. World Health Organization (WHO) functional classification for pulmonary hypertension

Class	WHO functional classification for pulmonary hypertension	
Ι	Patients with pulmonary hypertension but without resulting limitations of physical activity. Ordi- nary physical activity does not cause undue fatigue or dyspnoea, chest pain, or heart syncope.	
II	Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in undue fatigue or dyspnoea, chest pain, or heart syncope.	
111	Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less-than-ordinary physical activity causes undue fatigue or dyspnoea, chest pain, or heart syncope.	
IV	Patients with pulmonary hypertension resulting in inability to carry on any physical activity with- out symptoms. These patients manifest signs of right-heart failure. Dyspnoea or fatigue, or both, may be present even at rest. Discomfort is increased by physical activity.	

## Appendix 2. MEDLINE (Ovid) search strategy

- 1. exp Hypertension, Pulmonary/
- 2. Pulmonary Heart Disease/
- 3. (pulmonary adj3 hypertens\$).tw.
- 4. pulmonary vascular disease.tw.
- 5. or/1-4
- 6. exp Echocardiography/
- 7. (echocardiogra\$ or echo-cardiogra\$).tw.

<sup>8.</sup> doppler.tw.



9. or/6-8 10. 5 and 9 11. Animals/ not (Animals/ and Humans/) 12. 10 not 11

# Appendix 3. Embase (Ovid) search strategy

- 1. exp pulmonary hypertension/
- 2. pulmonary vascular disease/
- 3. (pulmonary adj3 hypertens\$).tw.
- 4. or/1-3
- 5. exp Doppler echocardiography/
- 6. doppler.tw.
- 7.5 or 6
- 8.4 and 7

9. (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/) not ((human/ or normal human/ or human cell/) and (exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/))

10. 8 not 9

#### Appendix 4. Web of Science search strategy

#1 TS=(pulmonary NEAR hypertension) OR TS=pulmonary heart disease #2 TS=(doppler\* NEAR echocardiograph\*) #3 #2 AND #1

## Appendix 5. ClinicalTrials.gov and WHO ICTRP search strategy

Field	Search term	
condition	pulmonary hypertension	
intervention	doppler	

#### Appendix 6. Study quality assessment details

#### **Domain 1: Patient selection**

#### Risk of bias: Could the selection of patients have introduced bias?

Signaling question 1: Was a consecutive or random sample of patients enrolled? Signaling question 2: Did the study avoid inappropriate exclusions?

Studies that make inappropriate exclusions, for example, excluding 'difficult to diagnose' patients, whose image of echocardiography is difficult to detect due to obesity or overinflated lungs, may result in overoptimistic estimates of diagnostic accuracy. We will classify the studies as 'yes' if all patients were included in the study regardless of clinical suspicion following index test, 'no' if they conduct any inappropriate exclusions, for example, excluding patients with low clinical suspicion based on the index test, and 'unclear' if this information is not clear.

#### Applicability: Are there concerns that the included patients and the setting do not match the review question?

If studies include only a clinically relevant population that would have undergone the index test in real practice and includes a representative form of target condition, we will assess as 'low' concern. If the study population differed from the population defined in the review question in terms of demographic features (e.g. studies include mainly younger patients or specific group of WHO classification), we will assess as 'high' concern. If this information is unclear (e.g. WHO classification was not reported), we will assess as 'unclear'.

#### Domain 2: Index test

#### Risk of bias: Could the conduct or interpretation of the index test have introduced bias?

Signaling question 1: Were the index test results interpreted without knowledge of the results of the reference standard? Signaling question 2: If a threshold was used, was it prespecified?

We will classify the study as 'yes' if echocardiography results were interpreted without knowledge of the reference standard, 'no' if the echocardiography tests were interpreted with knowledge of the reference standard results, and 'unclear' if this information is not clear. We will classify the study as 'yes' if a threshold was prespecified, 'no' if authors selected a cut-off value based on the analysis of data collected, and 'unclear' if insufficient information is provided.

#### Applicability: Are there concerns that the index test, its conduct, or its interpretation differ from the review question?

We will include studies where systolic pulmonary artery pressure calculated from the maximum tricuspid regurgitation jet velocity by using the modified Bernoulli equation and adding right atrial pressure evaluation of pulmonary artery pressure by echocardiography is an index test regardless of threshold, and we will include index tests using various right atrial pressure estimation methods. However, the most common method is using the diameter and collapse of the inferior vena cava during spontaneous respiration. We will therefore judge studies where the right atrial pressure was estimated by using the diameter and collapse of the inferior vena cava during spontaneous respiration as 'low' concern, those where right atrial pressure was estimated by using any other method as 'high' concern, and 'unclear' concern if this information is not clear.

#### **Domain 3: Reference standard**

#### Risk of bias: Could the reference standard, its conduct, or its interpretation have introduced bias?

Signaling question 1: Were the reference standard results interpreted without knowledge of the results of the index test? Signaling question 2: Were the criteria of reference standard for the target condition prespecified?

We will classify the study as 'yes' if right-heart catheterisation results were interpreted without knowledge of the index test, 'no' if rightheart catheterisation was interpreted with knowledge of the index test results, and 'unclear' if this information is not clear. We will classify the study as 'yes' if the criteria of the reference standard for the target condition were prespecified, 'no' if the criteria of the reference standard for the target condition were not prespecified, and 'unclear' if this information is not clear.

#### Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question?

The target condition is pulmonary hypertension defined as mean pulmonary artery pressure assessed by right-heart catheterisation of 25 mmHg or higher (Hoeper 2013). Use of right-heart catheterisation for the reference standard and the threshold of 25 mmHg are inclusion criteria for this review, so we anticipate that all studies will be classified as 'low' concern.

#### **Domain 4: Flow and timing**

#### Risk of bias: Could the patient flow have introduced bias?

Signaling question 1: Was the interval between the index test and reference standard less than one day? Signaling question 2: Did all patients receive the same reference standard? Signaling question 3: Were all patients included in the analysis?

Both echocardiography and right-heart catheterisation are subject to disagreement when performed at different times (e.g. days or weeks apart), which is a major limitation of the studies that compare their accuracy in the diagnosis of pulmonary hypertension (Lewis 2016). We will classify the study as 'yes' if there is a delay of less than a day, 'no' if there is a delay of more than or equal to a day, and 'unclear' if the information is not clear. We will classify the study as 'yes' if all patients had the same reference standard, 'no' if some included patients did not undergo the same reference standard, and 'unclear' if this information is not clear. Uninterpretable results may be present (e.g. unclear echocardiography or failure to insert right-heart catheterisation). Additionally, withdrawals from the study may be present. We anticipate that uninterpretable results would occur associated with the severity of pulmonary hypertension (e.g. difficulty in detecting Doppler echocardiography among severe chronic obstructive pulmonary disease patients due to overinflated lung) and not at random. If uninterpretable results are withdrawn from analysis, diagnostic accuracy will be overestimated. We will classify the study as 'yes' if uninterpretable results were not reported or there were withdrawals or the withdrawals were unlikely to affect the results; 'no' if uninterpretable results were not reported or there were withdrawals that were likely to affect the results, or both; and 'unclear' if this information is not clear.

#### WHAT'S NEW

Date	Event	Description
25 May 2022	Amended	Amended to rectify display of figures.

#### HISTORY

Protocol first published: Issue 9, 2017



Review first published: Issue 5, 2022

# CONTRIBUTIONS OF AUTHORS

JK drafted the protocol and review with contributions from SS, YN, YK, HT, YT, MK, SO, HI and TM. JK and YT devised the study selection criteria. JK, SS, YN, YK, HT, YT, and Elizabeth Stovold undertook the search strategy. JK, SS, YN, and HT developed the study design and research question. JK, HT, YK, and YT developed the statistical analysis/synthesis of the data plan. JK, YN, YK, YT, MK, SO, HI and TM screened search results. JK, YN, YK, YT, MK, SO, HI and TM extracted the data and assessed the methodological quality. All authors contributed to revising the manuscript, reviewed all drafts, and agreed on the final version.

### **Contributions of editorial team**

Chris Cates (Coordinating Editor): checked the data entry prior to the full write-up of the review, edited the review, advised on methodology, interpretation and content; approved the final review prior to publication.

Mia Schmidt-Hansen (Contact Editor, Diagnostic Test Accuracy Reviews Group): commented on the review and arranged peer review from DTA specialists; approved the peer reviewed draft prior to publication.

Emma Dennett (Deputy Coordinating Editor): coordinated the editorial process; advised on interpretation and content; edited the review; co-ordinated sign-off of the review and completed final checks.

Emma Jackson (Assistant Managing Editor): conducted peer review; obtained translations; edited the plain language summary and reference sections of the protocol and the review.

Elizabeth Stovold (Information Specialist): designed the search strategy; ran the searches; edited the search methods section.

# DECLARATIONS OF INTEREST

- JK: none known.
- SS: none known.
- YN: none known.

YK: employed by Kyoto Min-Iren Asukai Hospital

HT: none known.

YT: employed by Kyoritsu Hospital

MK: none known.

SO: none known.

HI: none known.

TM: none known.

# SOURCES OF SUPPORT

#### **Internal sources**

- Sakai City Medical Center, Japan
- Kyoto University, Japan
- Hyogo Prefectural Amagasaki General Medical Center, Japan

#### External sources

• The authors declare that no such funding was received for this systematic review., Japan

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

- We planned to use the HSROC model to perform the prespecified subgroup analyses. However, due to the limited data, we only presented the descriptive statistics as shown in Table 2.
- We planned subgroup analysis of the WHO classification to compare group 3 with other group classifications. However, most studies did not report the classification of PH, and we changed the subgroup analysis into: group 3, not group 3, or classification not reported.



- We performed the post hoc subgroup analysis using the bivariate model stratified by the threshold of index test (< 36 mmHg, ≥ 36 and < 40 mmHg, and ≥ 40 mmHg).We planned the sensitivity analysis using median-splitting of the prevalence of PH in each study. However, as the prevalence varied greatly, we split the prevalence into quartiles.</li>
- We planned a sensitivity analysis on uninterpretable results, however, we could not perform it because the data on whether the patients with uninterpretable data had PH or not were not available.
- For the Summary of Findings table and additional Table 3, we presented the pooled sensitivity under the fixed specificity of 86% (median of the included studies) using the estimated parameters from the HSROC model.

# INDEX TERMS

## **Medical Subject Headings (MeSH)**

Echocardiography; Echocardiography, Doppler; \*Hypertension, Pulmonary [diagnostic imaging]; Physical Examination [methods]; Sensitivity and Specificity

## **MeSH check words**

Adult; Humans